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Global, regional, and national incidence, prevalence, and 
years lived with disability for 310 diseases and injuries, 
1990–2015: a systematic analysis for the Global Burden of 
Disease Study 2015
GBD 2015 Disease and Injury Incidence and Prevalence Collaborators*
Background Non-fatal outcomes of disease and injury increasingly detract from the ability of the world’s population to 
live in full health, a trend largely attributable to an epidemiological transition in many countries from causes aﬀ ecting 
children, to non-communicable diseases (NCDs) more common in adults. For the Global Burden of Diseases, 
Injuries, and Risk Factors Study 2015 (GBD 2015), we estimated the incidence, prevalence, and years lived with 
disability for diseases and injuries at the global, regional, and national scale over the period of 1990 to 2015.
Methods We estimated incidence and prevalence by age, sex, cause, year, and geography with a wide range of updated 
and standardised analytical procedures. Improvements from GBD 2013 included the addition of new data sources, 
updates to literature reviews for 85 causes, and the identiﬁ cation and inclusion of additional studies published up to 
November, 2015, to expand the database used for estimation of non-fatal outcomes to 60 900 unique data sources. 
Prevalence and incidence by cause and sequelae were determined with DisMod-MR 2.1, an improved version of the 
DisMod-MR Bayesian meta-regression tool ﬁ rst developed for GBD 2010 and GBD 2013. For some causes, we used 
alternative modelling strategies where the complexity of the disease was not suited to DisMod-MR 2.1 or where incidence 
and prevalence needed to be determined from other data. For GBD 2015 we created a summary indicator that combines 
measures of income per capita, educational attainment, and fertility (the Socio-demographic Index [SDI]) and used it to 
compare observed patterns of health loss to the expected pattern for countries or locations with similar SDI scores.
Findings We generated 9·3 billion estimates from the various combinations of prevalence, incidence, and YLDs for 
causes, sequelae, and impairments by age, sex, geography, and year. In 2015, two causes had acute incidences in excess 
of 1 billion: upper respiratory infections (17·2 billion, 95% uncertainty interval [UI] 15·4–19·2 billion) and diarrhoeal 
diseases (2·39 billion, 2·30–2·50 billion). Eight causes of chronic disease and injury each aﬀ ected more than 10% of the 
world’s population in 2015: permanent caries, tension-type headache, iron-deﬁ ciency anaemia, age-related and other 
hearing loss, migraine, genital herpes, refraction and accommodation disorders, and ascariasis. The impairment that 
aﬀ ected the greatest number of people in 2015 was anaemia, with 2·36 billion (2·35–2·37 billion) individuals aﬀ ected. 
The second and third leading impairments by number of individuals aﬀ ected were hearing loss and vision loss, 
respectively. Between 2005 and 2015, there was little change in the leading causes of years lived with disability (YLDs) on 
a global basis. NCDs accounted for 18 of the leading 20 causes of age-standardised YLDs on a global scale. Where rates 
were decreasing, the rate of decrease for YLDs was slower than that of years of life lost (YLLs) for nearly every cause 
included in our analysis. For low SDI geographies, Group 1 causes typically accounted for 20–30% of total disability, 
largely attributable to nutritional deﬁ ciencies, malaria, neglected tropical diseases, HIV/AIDS, and tuberculosis. Lower 
back and neck pain was the leading global cause of disability in 2015 in most countries. The leading cause was sense 
organ disorders in 22 countries in Asia and Africa and one in central Latin America; diabetes in four countries in 
Oceania; HIV/AIDS in three southern sub-Saharan African countries; collective violence and legal intervention in two 
north African and Middle Eastern countries; iron-deﬁ ciency anaemia in Somalia and Venezuela; depression in Uganda; 
onchoceriasis in Liberia; and other neglected tropical diseases in the Democratic Republic of the Congo.
Interpretation Ageing of the world’s population is increasing the number of people living with sequelae of diseases 
and injuries. Shifts in the epidemiological proﬁ le driven by socioeconomic change also contribute to the continued 
increase in years lived with disability (YLDs) as well as the rate of increase in YLDs. Despite limitations imposed by 
gaps in data availability and the variable quality of the data available, the standardised and comprehensive approach 
of the GBD study provides opportunities to examine broad trends, compare those trends between countries or 
subnational geographies, benchmark against locations at similar stages of development, and gauge the strength or 
weakness of the estimates available.
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Introduction
Although substantial progress has been made toward 
reducing mortality and extending life expectancy 
throughout the world over the past few decades, the 
epidemiological transition is manifest in the growing 
importance of non-fatal diseases, outcomes, and injuries 
which pose, partly as a consequence of decreasing death 
rates, a rising challenge to the ability of the world’s 
population to live in full health. Complementing 
information on deaths by age, sex, cause, geography, and 
time with equally detailed information on disease 
incidence, prevalence, and severity is key to a balanced 
debate in health policy. For this reason, the Global 
Burden of Disease (GBD) Study uses the disability-
adjusted life-year (DALY), combining years of life lost 
(YLLs) due to mortality and years lived with disability 
(YLDs) in a single metric. One DALY can be thought of 
as one lost year of healthy life. The sum of DALYs in a 
population can be thought of as the gap between the 
population’s present health status and an ideal situation 
where the entire population lives to an advanced age, 
free of disease. Assessments of how diﬀ erent diseases 
lead to multimorbidity and reductions in functional 
health status are important for both health system 
planning1 and a broader range of social policy issues 
such as the appropriate age for retirement in some 
countries.2,3 Many challenges in making standardised 
estimates of non-fatal health outcomes are similar to 
those aﬀ ecting mortality estimates (including variations 
in case deﬁ nitions, data collection methods, variable 
quality of data collection, conﬂ icting data, and missing 
data) but are compounded by more sparse and varied 
data sources, the need to characterise each disease by its 
disabling sequelae or consequence(s), and the need to 
quantify the severity of these consequences. The 
standardised approach of the annual GBD updates 
addresses these measurement problems to enhance 
comparability between causes by geography and 
over time.
The estimates from GBD 2013 drew attention to large 
increases in the number of YLDs over the previous 
decade, whereas rates of YLDs for most causes remained 
stable or showed only small decreases.4 The GBD 2013 
assessment largely attributed increases in the number 
of YLDs to musculoskeletal disorders, mental and 
substance use disorders, neurological disorders, and 
chronic respiratory diseases, as well as population growth 
and ageing. GBD 2013 also brought attention to increased 
diﬀ erences in trends between mortality and morbidity 
for many causes. YLDs as a proportion of DALYs 
increased globally, a manifestation of the continuing 
epidemiological transition in low-income and middle-
income countries. Decreases in mortality from diseases 
such as pneumonia, diarrhoea, maternal and neonatal 
disorders, and an absence of progress in reducing YLD 
rates continued to drive a transition toward a greater 
global number of YLDs.
Along with broad recognition that data from some 
regions were sparse and that more and higher quality data 
in general would probably improve estimation, useful 
debates on the GBD results have been published. These 
debates have focused on the analysis or presentation of 
individual diseases, such as changes over time in GBD 
estimates of dementia,5 the accuracy of HIV incidence 
estimates,6,7 the absence of sepsis as a disease,8,9 the quality 
of some cancer registry data,10 and the absence of mental 
disorders as sequelae of neglected tropical diseases.11 The 
GBD empirical approach to measuring the public’s view of 
health state severity has generated substantial interest with 
questions about the relative importance of diﬀ erent 
dimensions of health,12,13 the quantiﬁ cation of health loss,14,15 
and discussions of the transferability of judgments about 
relative health to conventional notions of disability and 
dependence.5 In each cycle of the GBD, we seek to improve 
the estimates, reﬂ ecting published and unpublished 
critique through the acquisition of new data, expansion of 
the network of collaborators, changes in how data are 
corrected for bias, advances in modelling techniques, and 
the targeted expansion of the GBD cause list.
The primary objective of this component of the GBD 
was to use all available data of suﬃ  cient quality to 
generate reliable and valid assessments of disease and 
injury sequelae incidence, prevalence, and YLDs for all 
310 causes in the GBD cause hierarchy for 591 locations 
in the GBD study during 1990–2015. We describe the 
change over time and between populations in relation to 
where countries fall on the development continuum.16 
Continuing eﬀ orts to improve data and code transparency 
are an important part of the GBD cycle. These results 
thus supersede any previous publications about the GBD 
on disease incidence, prevalence, and YLDs.
Methods
Overall approach
We estimated incidence and prevalence by age, sex, cause, 
year, and geography using a wide range of updated and 
standardised analytical procedures. The overall logic of 
our analytical approach is shown for the entire non-fatal 
estimation process in ﬁ gure 1. The appendix provides a 
single source for detail of inputs, analytical processes, 
and outputs and methods speciﬁ c to each cause. This 
study complies with the Guidelines for Accurate and 
Transparent Health Estimates Reporting (GATHER) 
recommendations (methods appendix pp 1, 608–10).17
Geographies in GBD 2015
The geographies included in GBD 2015 have been 
arranged into a set of hierarchical categories composed of 
seven super-regions and a further nested set of 21 regions 
containing 195 countries and territories. Eight additional 
subnational assessments were done for Brazil, China, 
India, Japan, Kenya, Saudi Arabia, South Africa, Sweden, 
and the USA (methods appendix pp 611–24). For this 
study we present data at the national and territory level.
See Online for appendix
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List of causes and sequelae
The GBD cause and sequelae list is organised 
hierarchically (methods appendix 625–53). At Level 1 
there are three cause groups: communicable, maternal, 
neonatal, and nutritional diseases (Group 1 diseases); 
non-communicable diseases; and injuries. These Level 1 
aggregates are subdivided at Level 2 of the hierarchy into 
21 cause groupings. The disaggregation into Levels 3 
and 4 contains the ﬁ nest level of detail for causes 
captured in GBD 2015. Sequelae of diseases and injuries 
are organised at Levels 5 and 6 of the hierarchy. The 
ﬁ nest detail for all sequelae estimated in GBD is at 
Level 6 and is aggregated into summary sequelae 
categories (Level 5) for causes with large numbers of 
sequelae. Sequelae in GBD are mutually exclusive and 
collectively exhaustive, and thus our YLD estimates at 
each level of the hierarchy sum to the total of the level 
above. Prevalence aggregations are estimated at the level 
of individuals who might have more than one sequela or 
disease and therefore are not additive.
The cause and sequelae list was expanded based upon 
feedback after the release of GBD 2013 and input from 
GBD 2015 collaborators. Nine causes for which 
non-fatal outcomes are estimated were added: Ebola 
virus disease, motor-neuron disease, environmental 
heat and cold exposure, four subtypes of leukaemia, 
and two subtypes of non-melanoma skin cancer 
(methods appendix pp 625–53). The incorporation of 
these changes expanded the cause list from the 
301 causes with non-fatal estimates examined in 
GBD 2013, to 310 causes with non-fatal estimates and 
from 2337 to 2619 unique sequelae at Level 6 of the 
hierarchy. At the newly created Level 5 of the hierarchy 
there were 154 summary sequela categories. The 
methods appendix (pp 654–61) provides a list of 
International Classiﬁ cation of Diseases version 9 
(ICD-9) and version 10 (ICD-10) codes used in the 
extraction of hospital and claims data, mapped to GBD 
2015 non-fatal causes, impairments, and nature of 
injury categories.
Input data
Process
Results
Database
Non-fatal estimation process
Raw data source
Data adjustment
Database
Alternative disease modelling
Impairment and underlying cause
Post DisMod-MR
DisMod-MR
Injury modelling 
Disability weights
Final burden estimates
Colours of non-fatal estimation
Case notiﬁcations
1 Data sources 2 Data adjustment 3b Alternative disease modelling strategies (details figure 1B)
3c Injury modelling strategy
5 Severity distribution
6 Disability weights
7 Comorbidity
8 YLDs
3a DisMod-MR 
      2.1 estimation
4 Impairment and underlying cause estimation
Expansion factors for
case notiﬁcations
Population-at-risk
data
Seroprevalence data
Disease registries
Birth registries
Active screening
Intervention coverage
Vital registration
Surveillance
Community surveys
National surveys
Outpatient hospital
data
Claims data:
outpatient visits
Inpatient hospital
data
SMR data from
cohort studies
Cohort study
MEPS
Expert estimates
duration untreated
injuries
Sequelae mapped
to health states
Household surveys
Open access web-
based survey
GBD collaborator
advice
Surveys with
diagnostic information
and SF-12
Opportunistic surveys
by IHME to ﬁll SF-12
for 60 lay descriptions
Cohort follow-up
studies
Claims data:
inpatient visits
Adjustment for
under-reporting
HIV/AIDS and
TB
Malaria
Seroprevalence
to incidence
models
Case fatality
proportion and
cause of death
rate models
Apply aetiology or
severity proportions to
disease or impairment
morbidity estimates
Scale impairment
prevalence by
underlying cause or
severity to envelope
Neonatal
disorders
Cancer
Age–sex
splitting
Add study-level
covariaties
Pre DisMod bias
correction
Adjustment for
multiple outpatient
visits per prevalent or
incident case based
on claims data
Adjustment from
primary code to all
code based on claims
data for causes
with long duration
Adjustment for
multiple admissions
in same individual
Generate cause–nature
of injury matrices
with negative
binomial models
Determine most
severe nature of
injury category in
any individual
Compute excess
mortality before
from available
incidence or
prevalence and
CSMR data
Adjusted
input
data
Non-fatal database:
prevalence, incidence, excess
mortality rate, RR, SMR,
duration, remission,
severity proportions, and
intermediary modelling
variables
CSMR from
CoDCorrect
Study
covariates
Disability weights for
235 health states
Country
covariates
Apply cause–nature
injury of matrices
Regression to estimate
disability weight by
cause in survey
respondents controlling
for comorbidity
YLD to YLL ratio for
12 residual
causes without
primary data
Analysis of paired
comparison and
population health
equivalence responses
Incidence by cause
of injury code
Prevalence and
incidence by disease
or impairment
Proportion of
disease or impairment
sequelae or causes
Scaled proportion of
disease or impairment
sequelae or underlying
causes
Proportion by
sequelae
Prevalence and
incidence of
sequelae from
alternative models
Prevalence and
incidence of
sequelae
Unadjusted YLD
by sequelae
Probability of
long-term
disability
Estimate duration
of short-term
disability
DisMod-MR 2.1
Meta-analysisShort-term incidenceby cause–nature
and inpatient
or outpatient
     Short-term prevalence
by cause–nature and
inpatient or outpatient   
Lay descriptions for
235 health states
Long-term incidence
by cause–nature
combination
Long-term prevalence
by cause–nature 
and inpatient or   
outpatient    
Map EQ5D
to SF-12
DisMod-MR
2.1
Scale to
100%
Scale to
100%
Map SF-12 to
GBD disability
weights
Meta-analysis
proportion by
severity level
DisMod analysis
proportion by
severity level
Comorbidity
correction
(COMO)
      Prevalence and incidence
   of sequelae of impairment
or diseases (by severity 
or underlying cause)  
YLLs residual
causes without
primary data
YLDs for each disease
and injury by age, sex,
year, and country
Figure 1: Analytical ﬂ ow chart for the estimation of cause-speciﬁ c YLDs by location, age, sex, and year for GBD 2015
Ovals represent data inputs, square boxes represent analytical steps, cylinders represent databases, and parallelograms represent intermediate and ﬁ nal results. The ﬂ ow chart is colour-coded by major 
estimation component: raw data sources, in pink; data adjustments, in yellow; DisMod-MR 2.1 estimation, in purple; alternative modelling strategies, in light green; injury modelling strategy, in dark 
green; estimation of impairments and underlying causes, in brown; post-DisMod-MR and comorbidity correction, in blue; disability weights, in orange; and cause of death and demographic inputs, in 
grey. GBD=Global Burden of Disease. TB=tuberculosis. SF-12=Short Form 12 questions. MEPS=Medical Expenditure Panel Surveys. CSMR=cause-speciﬁ c mortality rate. SMR=standardised mortality 
ratio. YLDs=years lived with disability. YLLs=years of life lost. IHME=Institute for Health Metrics and Evaluation.
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Period of analysis
A complete set of age-speciﬁ c, sex-speciﬁ c, cause-
speciﬁ c, and geography-speciﬁ c incidence and prevalence 
numbers and rates were computed for the years 1990, 
1995, 2000, 2005, 2010, and 2015. In this study we focus 
on trends for main and national results over the past 
decade, from 2005 to 2015, together with more detailed 
results for 2015. Online data visualisations at vizhub 
provide access to results for all GBD metrics.
Non-fatal modelling strategies vary substantially 
between causes. Figure 1 outlines the general process of 
non-fatal outcome estimation from data inputs to 
ﬁ nalisation of YLD burden results; step 3b of that process 
identiﬁ es alternative modelling approaches used for 
speciﬁ c causes (methods appendix pp 603, 604). The 
starting point for non-fatal estimation is the compilation 
of data sources identiﬁ ed through systematic analysis 
and extractions based on predetermined inclusion and 
exclusion criteria (methods appendix p 603). As part of 
the inclusion criteria, we deﬁ ned disease-speciﬁ c or 
injury-speciﬁ c reference case deﬁ nitions and study 
methods, as well as alternative allowable case deﬁ nitions 
and study methods which were adjusted for if we detected 
a systematic bias. We used 15 types of primary data 
sources representing disease prevalence, incidence, 
mortality risk, duration, remission, or severity in the 
estimation process (oval shapes in ﬁ gure 1).
Data sources
For this iteration of the study, we updated data searches 
through systematic data and literature reviews for 
85 causes published up to Oct 31, 2015. For other 
causes, input from GBD collaborators resulted in 
the identiﬁ cation and inclusion of a small number of 
additional studies published after January, 2013. Data were 
systematically screened from household surveys archived 
in the Global Health Data Exchange, sources suggested 
to us by in-country experts, and surveys identiﬁ ed in 
major multinational survey data catalogues and Ministry 
of Health and Central Statistical Oﬃ  ce websites. Case 
notiﬁ cations reported to WHO were updated up to and 
including 2015. Citations for all data sources used for non-
fatal estimation in GBD 2015 are provided in searchable 
form through a new web tool. A description of the 
search terms used for cause-speciﬁ c systematic reviews, 
inclusion and exclusion criteria, and the preferred and 
alternative case deﬁ nitions and study methods are detailed 
by cause in the methods appendix (pp 26–601).
Hospital inpatient data were extracted from 
284 country-year and 976 subnational-year combinations 
from 27 countries in North America, Latin America, 
Europe, and New Zealand. Outpatient encounter data 
were available from the USA, Norway, Sweden, and 
Canada for 48 country-years. For GBD 2015, we also 
accessed aggregate data derived from claims information 
in a database of US private and public insurance schemes 
for the years 2000, 2010, and 2012. From the linked 
claims data, we generated several correction factors to 
account for bias in health service encounter data from 
elsewhere, which were largely available to us aggregated 
by ICD code and by primary diagnosis only. First, for 
chronic disorders, we estimated the ratio between 
prevalence from primary diagnoses and prevalence from 
all diagnoses associated with a claim. Second, we used 
the claims data to generate the average number of 
outpatient visits per disorder. Similarly, we generated per 
person discharge rates from hospital inpatient data in the 
USA and New Zealand, the only sources with unique 
patient identiﬁ ers available for GBD 2015.
In GBD 2013, we calculated a geographical and temporal 
data representativeness index (DRI) of non-fatal data 
sources for each cause or impairment. The DRI represents 
the fraction of countries for which any incidence, 
prevalence, remission, or mortality risk data were available 
for a cause. This metric quantiﬁ es data availability, not 
data quality. The overall DRI and period-speciﬁ c DRI 
measures for each cause and impairment are presented in 
the methods appendix (pp 662–68). DRI ranged from 90% 
for nine causes, including tuberculosis and measles, to 
less than 5% for acute hepatitis C and the category of 
other exposures to mechanical forces. Required case 
reporting resulted in high DRI values for notiﬁ able 
infectious diseases; the network of population-based 
registries for cancers resulted in a DRI of above 50%. 
DRI values ranged from 6·1% in North Korea to 91·3% 
in the USA. Many high-income countries, as well as 
Brazil, India, and China, had DRI values above 63%; data 
availability was low in several countries, including 
Equatorial Guinea, Djibouti, and South Sudan.
Non-fatal disease models
In addition to the corrections applied to claims and 
hospital data, a number of other adjustments were applied 
including age–sex splitting, bias correction, adjustments 
for under-reporting of notiﬁ cation data, and computing 
expected values of excess mortality. In GBD 2013, we 
estimated expected values of excess mortality from 
prevalence or incidence and cause-speciﬁ c mortality 
rate data for a few causes only, including tuberculosis 
and chronic obstructive pulmonary disease. In order to 
achieve greater consistency between our cause of death 
and non-fatal data, we adopted this strategy systematically 
for GBD 2015. We matched every prevalence data point 
(or incidence datapoint for short duration disorders) with 
the cause-speciﬁ c mortality rate value corresponding to 
the age range, sex, year, and location of the datapoint. 
The ratio of cause-speciﬁ c mortality rate to prevalence is 
conceptually equivalent to an excess mortality rate.
To estimate non-fatal health outcomes in previous 
iterations of GBD, most diseases and impairments were 
modelled in DisMod-MR, a Bayesian meta-regression tool 
originally developed for GBD 2010 (step 3a in ﬁ gure 1).18 
DisMod-MR was designed to address statistical challenges 
in estimation of non-fatal health outcomes, and for 
For Global Health Data Exchange 
see http://ghdx.healthdata.org
For data in GBD 2015 see http://
ghdx.healthdata.org/global-
burden-disease-study-2015 
For data visualisations at 
vizhub see http://vizhub.
healthdata.org/gbd-compare
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synthesis of often sparse and heterogeneous epidemio-
logical data. For GBD 2015, the computational engine of 
DisMod-MR 2.1 remained unchanged, but we substantially 
rewrote the code that organises the ﬂ ow of data and 
settings at each level of the analytical cascade. The 
sequence of estimation occurs at ﬁ ve levels: global, super-
region, region, country, and where applicable, subnational 
locations (appendix pp 611–24). At each level of the cascade, 
the DisMod-MR 2.1 computational engine enforces 
consistency between all disease parameters. For GBD 2015, 
we generated ﬁ ts for the years 1990, 1995, 2000, 2005, 2010, 
and 2015. We log-linearly interpolated estimates for the 
intervening years in each 5-year period. Greater detail on 
DisMod-MR 2.1 is available at Global Health Data 
Exchange and the methods appendix (pp 7–11).
In previous iterations of GBD, custom models were 
created for a short list of causes for which the compartment 
model underpinning DisMod (susceptible, diseased, and 
dead) was insuﬃ  cient to capture the complexity of the 
disease or for which incidence and prevalence needed to 
be derived from other data. Step 3b of ﬁ gure 1 describes 
the development of custom models with greater detail 
shown in the methods appendix ﬁ gure 1B (p 604, and 
for associated write-ups pp 26–601) for HIV/AIDS, 
tuberculosis, malaria, cancer, neonatal disorders, 
infectious diseases for which we derived incidence from 
seroprevalence data, and infectious diseases for which we 
derived incidence from cause of death rates and pooled 
estimates of the case fatality proportion.
In GBD 2013, we estimated the country–age–sex–year 
prevalence of nine impairments (step 4 of ﬁ gure 1). 
Impairments in GBD are disorders or speciﬁ c domains of 
functional health loss that are spread across many GBD 
causes as sequelae and for which there are better data to 
estimate the occurrence of the overall impairment than for 
each sequela based on the underlying cause. Overall 
impairment prevalence was estimated with DisMod-MR 2.1 
except for anaemia, for which spatiotemporal Gaussian 
Process regression methods were applied. We constrained 
cause-speciﬁ c estimates of impairments, such as in the 
19 causes of blindness, to sum to the total prevalence 
estimated for that impairment. Anaemia, epilepsy, hearing 
loss, heart failure, and intellectual disability were estimated 
at diﬀ erent levels of severity.
Severity distributions
In step 5, sequelae were further deﬁned in terms 
of severity for 194 causes at Level 4 of the hierarchy 
(ﬁ gure 1A). We generally followed the same approach for 
estimating the distribution of severity as in GBD 2013. 
For Ebola virus disease, we created a health state for the 
infectious disease episode with duration derived from 
average hospital admission times, and a health state for 
ongoing postinfection malaise and joint problems based 
on four follow-up studies19–22 from which we derived an 
average duration. The health states for the subtypes of 
leukaemia and non-melanoma skin cancer were the 
same as the general cancer health states. For motor-
neuron disease we accessed the Pooled Resource Open-
Access ALS Clinical Trials (PROACT) database containing 
detailed information on symptoms and impairments for 
more than 8500 patients who took part in the trials.23
Disability weights  
We used the same disability weights as in GBD 2013 (see 
methods appendix pp 669–94 for a complete listing of 
the lay descriptions and values for the 235 health states 
used in GBD 2015).
Comorbidity
In step 7, we estimated the co-occurrence of diﬀ erent 
diseases by simulating 40 000 individuals in each 
geography–age–sex–year combination as exposed to the 
independent probability of having any of the sequelae 
included in GBD 2015 based on disease prevalence. We 
tested the contribution of dependent and independent 
comorbidity in the US Medical Expenditure Panel Surveys 
(MEPS) data, and found that independent comorbidity 
was the dominant factor even though there are well 
known examples of dependent comorbidity. Age was 
the main predictor of comorbidity such that age-speciﬁ c 
microsimulations accommodated most of the required 
comorbidity correction. Taking dependent comorbidity 
into account changed the overall YLDs estimated in the 
MEPS data by only 2·5% (and ranging from 0·6% to 
3·4% depending on age) in comparison to assuming 
independent comorbidity (methods appendix pp 18–20).24
YLD computation
We report 95% uncertainty intervals (95% UI) for each 
quantity in this analysis using 1000 samples from the 
posterior distribution of prevalence and 1000 samples of 
the disability weight to generate 1000 samples of the YLD 
distribution. The 95% UI is reported as the 25th and 975th 
values of the distribution. We report signiﬁ cant changes 
in disease estimates between countries or over time if the 
change was noted in more than 950 of the 1000 samples 
computed for each result. For GBD 2015, we computed 
age-standardised prevalence YLD rates from the updated 
world population age standard developed for GBD 2013.25 
Less common diseases and their sequelae were included 
in 35 residual categories (methods appendix pp 695–97). 
For 22 of these residual categories, estimates were made 
from epidemiological data for incidence or prevalence. 
For 13 residual categories, we estimated YLDs by 
multiplying the residual YLL estimates by the ratio of 
YLDs to YLLs from the estimates for explicitly modelled 
Level 3 causes in the same disease category.
Socio-demographic Index
In GBD 2013, a sociodemographic status variable 
was computed based on a principal components 
analysis of income per capita, educational attainment, 
average age of the population, and the total fertility 
For DisMod-MR 2.1 engine and 
the code see http://ghdx.
healthdata.org/global-burden-
disease-study-2015
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rate.26 For GBD 2015, we excluded mean age of the 
population because it is directly aﬀ ected by death 
rates. To improve interpretability for GBD 2015, we 
computed a Socio-demographic Index (SDI) similar to 
the computation of the human development index.27 
In the SDI, each component was weighted equally and 
rescaled from zero (for the lowest value observed during 
1980–2015) to one (for the highest value observed) for 
income per capita and average years of schooling, and 
the reverse for the total fertility rate. The ﬁ nal SDI score 
was computed as the geometric mean of each of the 
components. SDI ranged from 0·060 in Mozambique in 
1987 to 0·978 in District of Columbia, USA, in 2015.
Role of the funding source
The funder of the study had no role in study design, 
data collection, data analysis, data interpretation, 
or writing of the report. The corresponding author 
had full access to all the data in the study and had 
ﬁ nal responsibility for the decision to submit for 
publication.
Results
Global incidence and prevalence
We generated over 9·3 billion outcomes of incidence, 
prevalence, and YLDs for 310 diseases, injuries, and 
aggregate categories; 2619 unique and aggregate 
sequelae; nine impairments; 63 age–sex groups; 
591 geographies; and 26 individual years from 1990 
to 2015. Each of these 9·3 billion estimates was 
calculated 1000 times to determine uncertainty 
intervals. Here, we present key summary ﬁ ndings 
on global incidence of short duration diseases, global 
prevalence of long-term disorders, global prevalence 
of impairments, global numbers and rates of YLDs 
and changes from 2005 to 2015, global YLL and YLD 
rates of change, patterns of comorbidity, the expected 
changes in the composition of YLDs with SDI, and 
country ﬁ ndings of leading causes of YLDs.
Disorders of less than 3 months duration and injuries 
with incidence of more than 1 million cases per year in 
2015 are listed in table 1. There were two disorders with 
incidence greater than 1 billion per year: upper respiratory 
infections (17·2 billion [95% UI 15·4–19·2 billion]), and 
diarrhoeal diseases (2·39 billion [2·30–2·50 billion]). 
A further 13 diseases and injuries caused between 
100 million and 1 billion incident cases a year 
and 16 diseases and injuries had incident cases of 
between 10 million and 100 million per year (table 1).
The disease and injury sequelae with a duration of 
more than 3 months and a global prevalence of more 
than 1% in 2015 are presented in table 2, aggregated to 
the cause level. Prevalence for impairments is presented 
at the bottom of table 3. Eight out of 56 high-prevalence 
causes aﬀ ected more than 10% of the world’s population 
in 2015. A further 48 causes aﬀ ected between 1% and 
10% of the world’s population (table 2). Although many of 
Incidence (thousands) Percentage change 
(%)
2005 2015
Upper respiratory infections 15 624 257
(13 851 237–17 411 199)
17 230 659
(15 351 516–19 172 439)
10·3
(9·0 to 11·6)*
Diarrhoeal diseases 2 235 739
(2 139 050–2 348 407)
2 392 517
(2 301 101––2 503 094)
7·0
(6·0 to 8·0)*
Permanent caries 426 963
(371 216–484 332)
487 629
(423 507–552 895)
14·2
(13·1 to 15·4)*
Otitis media 429 820
(353 915–525 059)
471 027
(386 606–577 286)
9·6
(7·9 to 11·2)*
Lower respiratory infections 273 131
(257 286–288 078)
291 759
(276 244–307 004)
6·8
(5·6 to 8·1)*
Malaria 339 275
(261 417–447 605)
286 859
(219 712–377 332)
–15·4
(–23·0 to –8·1)*
Gastritis and duodenitis 185 250
(167 471–204 974)
213 729
(192 486–236 339)
15·4
(10·8 to 17·2%)*
Pyoderma 178 382
(172 199–184 147)
207 452
(200 498–213 936)
16·3
(15·6% to 17·0)*
Gonococcal infection 138 220
(107 106–184 385)
172 676
(129 731–235 737)
24·9
(17·9 to 31·0)*
Interstitial nephritis and 
urinary tract infections
127 380
(124 308–130 683)
152 295
(148 748–156 177)
19·6
(19·2 to 19·9)*
Varicella and herpes zoster 128 678
(124 298–133 090)
142 413
(137 804–147 181)
10·7
(10·0 to 11·4)*
Trichomoniasis 121 948
(104 825–141 284)
140 781
(121 207–163 163)
15·4
(14·5 to 16·5)*
Acute hepatitis A 109 609
(101 813–117 648)
114 212
(103 349–124 776)
4·2
(–7·2 to 17·0)
Hepatitis B 98 277
(86 507–112 527)
111 212
(97 410–126 251)
13·2
(–4·3 to 35·2)
Gallbladder and biliary 
diseases
88 215
(79 276–96 495)
104 322
(93 074–114 430)
18·3
(16·0 to 20·7)*
Peptic ulcer disease 83 388
(77 760–89 435)
87 410
(80 343–94 506)
4·8
(2·6 to 7·0)*
Dengue 32 749
(18 879–68 335)
79 609
(53 784–169 704)
143·1
(–0·3 to 564·7)
Other sense organ diseases 60 659
(58 721–62 579)
69 945
(67 856–72 080)
15·3
(14·6 to 16·0)*
Chlamydial infection 56 976
(45 489–70 839)
61 173
(48 871–76 698)
7·4
(5·5 to 9·4)*
Maternal abortion, 
miscarriage, and ectopic 
pregnancy
53 942
(43 630–67 168)
53 958
(43 224–67 417)
0·0
(–3·8 to 4·0)
Syphilis 43 515
(37 479–51 054)
45 413
(37 787–54 921)
4·4
(–0·3 to 8·1)
Deciduous caries 41 353
(28 723–58 131)
43 688
(29 630–62 543)
5·6
(2·1 to 8·1)*
Genital herpes 29 112
(25 131–33 432)
39 791
(35 569–44 572)
36·7
(32·4 to 41·6)*
Urolithiasis 17 875
(16 320–19 728)
22 080
(20 183–24 295)
23·5
(21·2 to 25·6)*
Cellulitis 17 312
(15 988–18 739)
21 211
(19 582–22 985)
22·5
(21·0 to 24·1)*
Maternal hypertensive 
disorders
20 416
(17 593–23 417)
20 731
(17 355–24 379)
1·5
(–3·0 to 6·3)
Acute hepatitis E 18 869
(17 340–20 580)
19 525
(18 011–21 273)
3·5
(2·2% to 4·7)*
Whooping cough 22 457
(17 322–28 268)
16 298
(12 599–20 445)
–27·4
(–29·5 to –25·2)*
(Table 1 continues on next page)
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these causes are not among the dominant causes of YLDs 
because of comparatively low average disability weights, 
some causes, such as headaches, gynaecological diseases, 
oral disorders, and skin diseases, put great demands on 
health system resources by their sheer numbers.
Anaemia was the most common of our nine 
impairments, aﬀ ecting 2·36 billion (2·35–2·37 billion) 
people in 2015. The next most common impairments 
were hearing loss of greater than 20 dB (1·33 billion 
[1·26–1·40 billion]), vision loss (940 million 
[905–974 million]), developmental intellectual disability 
(153 million [114–191 million]), infertility (113 million 
[93·4–136 million]), heart failure (40·0 million 
[38·6–41·4 million]), and epilepsy (39·2 million 
[34·3–43·7 million]; table 3; see results appendix 
(pp 740–48) for the prevalence estimates of the underlying 
causes of these impairments). Iron deﬁ ciency was the 
cause of anaemia in more than half of all cases. Over 
90% of hearing loss was classiﬁ ed as age-related or other 
hearing loss. The largest number of people with vision 
loss had uncorrected refraction error. Idiopathic 
developmental intellectual disability, idiopathic female 
infertility, and idiopathic epilepsy were the most common 
causes of their impairments. Ischaemic heart disease 
was the most common cause of heart failure.
Global causes of disability 
Global trends in YLDs 2005 to 2015
GBD 2015 included the assessment of 2619 sequelae at 
Level 6 of the GBD cause hierarchy, including 1316 sequelae 
from injuries that contributed to the global burden of 
disability. Causes at Level 4 of the hierarchy that resulted in 
30 million or more YLDs in 2015 included lower back pain, 
major depressive disorder, age-related and other hearing 
loss, and neck pain. Figure 2 compares the leading causes 
of global YLDs in 2005 and 2015, using the cause 
breakdowns at Level 3 of the GBD cause hierarchy. Among 
the ten leading causes of YLDs, iron-deﬁ ciency anaemia 
and depressive disorders switched ranks to positions three 
and four respectively, diabetes rose from the eighth to the 
sixth position, migraine dropped from position six to 
seven, and other musculoskeletal disorders dropped from 
rank seven to eight (ﬁ gure 2).
Estimates of prevalence and YLDs at the global level for 
2005 and 2015 for each cause are presented in table 3 (see 
results appendix pp 717–40 for full detail at the sequelae 
level). Prevalence and age-standardised YLDs for 
21 Group 1 diseases decreased signiﬁ cantly and by more 
than 10%, including measles, African trypanosomiasis, 
diphtheria, lymphatic ﬁ lariasis, and rabies.
Age-standardised YLD rates for all maternal causes and 
sequelae combined decreased between 2005 and 2015, 
whereas overall age-standardised YLDs for neonatal 
disorders increased by 3·11% (–0·32–6·79%) since 2005 to 
144 YLDs per 100 000 (109–185 YLDs per 100 000) in 2015, 
and age-standardised YLD rates decreased and absolute 
numbers of cases increased for nutritional deﬁ ciencies. 
Age-standardised YLD rates attributable to hepatitis A, B, 
and C increased, and decreased for hepatitis E. The number 
of individuals with chronic hepatitis C infection increased 
from 121 million (108–133 million) in 2005 to 142 million 
(127–157 million) in 2015.
Changes in age-standardised YLDs and YLLs over time
In 2005, non-communicable diseases (NCDs) accounted 
for 23 of the leading 25 causes of age-standardised YLDs 
worldwide and 23 of the 25 leading causes in 2015 
(ﬁ gure 2). Although diabetes rose only two ranks in the 
list of leading cause of YLDs, from position eight to six 
between 2005 and 2015, the increase in age-standardised 
rate was 5·4% (3·2–7·5%). Musculoskeletal disorders 
occupied three of the leading 25 causes of disability in 
both 2005 and 2015; lower back and neck pain were the 
single largest cause with little change in their rates. 
Incidence (thousands) Percentage change 
(%) 
2005 2015
(Continued from previous page)
Typhoid fever 15 341
(13 454–17 417)
12 538
(10 887–14 283)
–18·3
(–20·8 to –15·6)*
Maternal sepsis and other 
maternal infections
11 938
(9457–15 125)
11 817
(9300–15 009)
–1·0
(–4·6 to 2·8)
Appendicitis 10 159
(9549 to 10 840)
11 619
(10 918 to 12 407)
14·4
(13·5 to 15·2)*
Pancreatitis 7160
(6 660–7 694)
8 902
(8 212–9 643)
24·3
(21·9 to 26·6)*
Maternal haemorrhage 8438
(6614–10 620)
8740
(6774–11 061)
3·6
(–0·3 to 7·6)
Other sexually transmitted 
diseases
7569
(6511–8741)
7656
(6583–8853)
1·2
(–0·1 to 2·4)
Ischaemic heart disease 6308
(5918–6716)
7287
(6798–7808)
15·5
(14·3 to 16·8)*
Maternal obstructed labour 
and uterine rupture
6830
(5202–8933)
6521
(4977–8588)
–4·5
(–9·1 to –0·3)*
Hepatitis C 4609
(4316 to 4918)
5394
(5032 to 5778)
17·0
(15·7 to 18·4)*
Ischaemic stroke 4651
(4397 to 4912)
5385
(5017 to 5726)
15·8
(13·4 to 18·4)*
Measles 15 610
(6699–31 357)
4652
(2072–9206)
–70·2
(–73·6 to –66·0)*
Paratyphoid fever 5580
(4498–6896)
4587
(3738–5601)
–17·8
(–22·6 to –12·7)*
Haemorrhagic stroke 3144
(2973–3307)
3583
(3336–3822)
14·0
(11·4 to 16·2)*
Paralytic ileus and intestinal 
obstruction
2664
(2494–2855)
3167
(2946–3406)
18·9
(16·9 to 20·7)*
Encephalitis 1489
(1380–1608)
1603
(1472–1750)
7·7
(5·9 to 9·5)*
Acute glomerulonephritis 1528
(1395–1672)
1534
(1394–1685)
0·4
(–2·6 to 3·1)
Data in parentheses are 95% UIs. *Percentage changes that are statistically signiﬁ cant.
Table 1: Global incidence of short duration (less than 3 months) sequelae in 2005 and 2015 for all ages 
and both sexes combined, with percentage change between 2005 and 2015 for level 4 causes with 
incidence greater than 1 million cases per year
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However, age-standardised rates of YLDs increased for 
osteoarthritis 3·90% (3·00–4·83%) by 2015. Depressive 
disorders were the fourth leading cause of disability in 
2005 and the third leading cause of disability in 2015, 
and age-standardised YLD rates associated with the 
disorder increased marginally (1·0% [0·5–1·5%]). 
Age-standardised rates of YLDs from alcohol use disorders 
decreased after 2005 (4·5% [2·3–6·4%]) whereas disability 
due to drug use disorders increased by 8·2% (6·2–10·2%).
In contrast with global trends for NCDs, both relative 
ranks and age-standardised YLD rates decreased for 
most injuries. Falls, which were the 13th leading cause 
of disability in 2005, dropped to the 15th rank, 
and age-standardised YLD rates decreased (8·58% 
[5·23–12·2%]). Other unintentional injuries decreased 
in global rank from 27th in 2005 to 34th in 2015, 
and age-standardiSed YLD rates decreased by 16·7% 
(15·7–17·9%).
The leading causes of disability varied considerably with 
age (ﬁ gure 3). The leading cause in children younger than 
5 years was iron-deﬁ ciency anaemia followed by skin 
diseases, protein-energy malnutrition, and diarrhoea. In 
older children, iron-deﬁ ciency anaemia, skin diseases, 
asthma, and mental health disorders such as conduct, 
autistic spectrum, and anxiety disorders were top ten 
causes of disability. In adolescents and young adults (aged 
between 15 and 39 years), iron-deﬁ ciency anaemia, skin 
diseases, depression, lower back and neck pain, and 
migraine led the rankings. Other mental health disorders 
such as anxiety disorders and schizophrenia were in the 
top ten causes in this age group. In middle-aged adults, 
musculoskeletal disorders dominated the top rankings 
followed by mental health disorders, especially depression. 
Diabetes and sense organ disorders were more prominent 
causes of disability in middle-age. In older adults (older 
than 65 years), sense organ disorders were the top-ranked 
cause of disability. Musculoskeletal disorders remained a 
dominant source of disability, and chronic obstructive 
pulmonary disease entered the top ten. In the oldest age 
groups, ischaemic heart disease and Alzheimer’s and 
other dementias made their ﬁ rst appearance in the top ten.
We examined the trends in YLDs and YLLs in a 
scatterplot (ﬁ gure 4). YLLs decreased for the majority of 
causes. For Group 1 causes and injuries, the decrease in 
YLLs was accompanied by a decrease in YLDs, albeit at a 
slower pace. The exceptions were neonatal encephalopathy, 
haemolytic disease and other neonatal jaundice, 
leishmaniasis, meningitis, hepatitis, and sexually trans-
mitted diseases with increasing YLD rates between 1990 
and 2015. A few Group 1 disorders and injuries had a 
faster decrease in YLDs than in YLLs: intestinal infections, 
obstructed labour, and neonatal sepsis. The only NCDs 
with a faster decrease in YLDs compared with YLLs were 
epilepsy and cervical cancer. Another small number of 
NCDs saw an increase in YLDs and YLLs, including drug 
use disorders, diabetes, and Parkinson’s disease. NCDs 
with decreasing YLLs but increasing YLDs included 
Prevalence (thousands) Percentage change 
(%)
2005 2015
Permanent caries 2 045 859
(1 909 845–2 170 355)
2 344 628
(2 193 751–2 488 741)
14·6
(13·7 to 15·5)*
Tension-type headache 1 306 390
(1 160 423–1 463 889)
1 505 892
(1 337 310–1 681 575)
15·3
(14·0 to 16·6)*
Iron-deﬁ ciency anaemia 1 456 387
(1 449 846–1 462 782)
1 477 531
(1 470 902–1 485 322)
1·5
(0·9 to 2·1)*
Age-related and other 
hearing loss
943 504
(886 325–995 403)
1 210 055
(1 140 224–1 274 665)
28·3
(27·4 to 29·2)*
Migraine 831 726
(755 991–918 968)
958 789
(872 109–1 055 631)
15·3
(14·0 to 16·6)*
Genital herpes 716 115
(626 987–817 387)
845 826
(736 724–968 066)
18·1
(16·4 to 19·9)*
Refraction and 
accommodation disorders
672 165
(649 969–694 024)
819 307
(789 917–848 059)
21·9
(20·5 to 23·2)*
Ascariasis 854 489
(790 000–924 895)
761 894
(682 558–861 031)
–10·8
(–22·5 to 2·5)
G6PD trait 663 704
(625 032–703 799)
728 549
(676 735–781 534)
9·8
(7·9 to 11·4)*
Acne vulgaris 605 008
(568 577–642 061)
632 741
(595 242–671 249)
4·6
(3·5 to 5·6)*
Other skin and 
subcutaneous diseases
492 883
(480 852–505 426)
605 036
(589 500–619 676)
22·8
(22·1 to 23·4)*
Deciduous caries 534 122
(449 525–635 866)
558 028
(462 649–669 027)
4·5
(2·3 to 6·1)*
Low back pain 460 164
(444 680–477 119)
539 907
(521 449–559 556)
17·3
(16·5 to 18·2)*
Periodontal diseases 428 784
(372 953–498 682)
537 506
(465 114–625 889)
25·4
(24·1 to 26·5)*
Fungal skin diseases 434 604
(395 512–475 904)
492 373
(448 951–538 232)
13·3
(12·5 to 14·1)*
Trichuriasis 473 399
(443 689–505 928)
463 652
(426 621–502 939)
–2·1
(–12·0 to 9·0)
Diabetes 333 325
(310 773–355 510)
435 328
(404 736–468 562)
30·6
(28·0 to 33·0)*
Premenstrual syndrome 391 207
(375 009–407 896)
430 697
(410 841–450 494)
10·1
(7·9 to 11·8)*
Hookworm disease 462 111
(430 885–495 596)
428 246
(394 486–468 292)
–7·3
(–16·9 to 3·5)
Sickle-cell trait 338 756
(318 736–378 582)
404 566
(381 223–448 155)
19·4
(18·3 to 20·3)*
Asthma 327 097
(296 406–358 060)
358 198
(323 134–393 466)
9·5
(7·6 to 11·6)*
Neck pain 295 532
(258 878–338 138)
358 007
(313 408–409 411)
21·1
(19·0 to 23·3)*
Hepatitis B 293 745
(284 478–303 036)
343 251
(330 541–357 195)
16·9
(15·3 to 18·4)*
Other musculoskeletal 
disorders
283 317
(254 135–315 519)
342 068
(305 431–385 147)
20·7
(17·5 to 24·0)*
Urolithiasis 259 567
(238 100–281 892)
318 763
(290 695 349 154)
22·8
(20·8 to 24·9)*
Thalassaemias trait 252 798
(247 008–259 972)
279 451
(272 819–287 357)
10·5
(10·1 to 11·0)*
Malaria 207 773
(186 530–230 942)
278 961
(240 158–320 921)
34·3
(26·8 to 42·3)*
Edentulism and severe 
tooth loss
216 473
(207 563–226 331)
275 619
(264 201–288 252)
27·3
(26·9 to 27·7)*
Anxiety disorders 232 597
(204 165–264 445)
267 202
(234 064–306 318)
14·9
(13·0 to 16·8)*
(Table 2 continues on next page)
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cancers of the prostate, testis, uterus, kidney, colorectum, 
and pancreas, melanoma, and congenital disorders. Some 
cancers (stomach and Hodgkin’s lymphoma), rheumatic 
heart disease, asthma, chronic obstructive pulmonary 
disease, acute glomerulonephritis, peptic ulcer disease, 
gastritis, hernia, and gallbladder disease had decreasing 
YLLs and YLDs, but with a faster decrease in YLLs than in 
YLDs. The rate of change in YLDs for the main drivers of 
non-fatal health loss, musculoskeletal disorders, and 
mental and substance use disorders was small.
Global distribution of disability weights across individuals
Figure 5 shows the global distribution of individuals from 
our comorbidity microsimulation by six categories of 
disability, age, and sex for the highest and lowest SDI 
quintile. The six categories of disability are no disability, 
very mild disability (disability weight less than or equal to 
0·01), mild disability (from 0·01 to 0·05 inclusive), 
moderate (from 0·05 to 0·1 inclusive), severe (from 0·1 to 
0·3 inclusive), and profound (greater than 0·3). In 2015, 
most of the world’s population experienced mild or 
greater disability. Having no disability at all was most 
common in children. After age 25 years, the proportion of 
the population having no disability became progressively 
smaller, and by age 55 years in low SDI countries and age 
75 years in high SDI countries, nearly everyone had some 
form of disability. Very mild to moderate disability (ie, 
individuals with a disability weight of 0·1 or less) was 
common in childhood and young adults, but was replaced 
by more severe disability with increasing age. The 
patterns were similar for both sexes, apart from a much 
larger amount of disability in women older than 80 years 
in the top SDI quintiles, reﬂ ecting the much higher 
average age of women in this age category. For policy 
considerations around the age of retirement in ageing 
populations, it is noteworthy that from age 60 years 
onwards more than half of the population had severe or 
worse disability. The extent to which this loss of health 
limits or precludes the ability to work depends on the 
nature of the impairments and the type of employment in 
older workers with that level of disability.
Expected changes in disease proﬁ le with higher 
Socio-demographic Index
Figure 6 depicts changes in patterns of disability by level of 
SDI for age-standardised and all-age YLD rates per 100 000. 
Age-standardised YLD rates gradually decreased with 
increasing SDI in both sexes (ﬁ gure 6A). The cause 
composition of YLDs somewhat varied across levels of 
SDI; these diﬀ erences were largely derived from absolute 
levels of disability due to communicable causes and 
nutritional deﬁ ciencies, and to a lesser extent, maternal 
and neonatal disorders. Age-standardised YLD rates due to 
NCDs and injuries were similar at all SDI levels.
Across levels of SDI, mental and substance use 
disorders, musculoskeletal disorders, and other NCDs 
were consistently among the leading causes of 
Prevalence (thousands) Percentage change  
(%)
2005 2015
(Continued from previous page)
Other sense organ diseases 214 761
(207 401–222 622)
266 346
(257 047–276 383)
24·0
(23·1 to 24·9)*
Schistosomiasis 329 773
(297 093–367 878)
252 340
(211 032–321 081)
–23·5
(–32·5 to –4·4)*
G6PD deﬁ ciency 231 109
(205 067–259 769)
247 074
(209 307–286 713)
6·9
(1·4 to 11·9)*
Dermatitis 215 260
(199 590–230 536)
245 291
(227 283–262 752)
14·0
(13·2 to 14·8)*
Osteoarthritis 178 665
(173 558–184 053)
237 369
(230 336–244 648)
32·9
(31·9 to 33·8)*
Major depressive disorder 183 434
(163 947–206 420)
216 047
(192 863–243 319)
17·8
(16·6 to 19·0)*
Scabies 191 482
(166 101–223 739)
204 152
(177 534–237 466)
6·6
(4·0 to 9·5)*
Viral skin diseases 161 167
(152 218–170 651)
174 843
(165 156–185 072)
8·5
(8·0 to 9·0)*
Chronic obstructive 
pulmonary disease
149 115
(137 380–160 739)
174 483
(160 205–188 952)
17·0
(15·1 to 19·0)*
Genital prolapse 137 383
(121 623–154 875)
161 679
(142 335–182 566)
17·7
(15·2 to 20·0)*
Gastritis and duodenitis 135 993
(134 420–137 351)
157 060
(154 055–160 141)
15·5
(12·9 to 17·9)*
Peripheral vascular disease 115 109
(101 439–131 405)
154 651
(136 318–176 211)
34·4
(33·4 to 35·2)*
Uterine ﬁ broids 126 797
(120 900–133 050)
151 115
(144 147–158 477)
19·2
(18·8 to 19·5)*
Hepatitis C 120 457
(108 080–133 129)
142 123
(126 978–157 045)
18·0
(16·7 to 19·2)*
Other mental and 
substance use disorders
107 895
(107 213–108 449)
128 178
(127 512–128 877)
18·8
(17·9 to 19·7)*
Iodine deﬁ ciency 103 701
(93 441–116 438)
110 920
(100 337–125 253)
7·0
(4·7 to 9·4)*
Ischaemic heart disease 87 511
(80 133–96 170)
110 193
(100 332–121 427)
25·9
(24·6 to 27·2)*
Benign prostatic 
hyperplasia
80 684
(70 338–90 853)
104 625
(90 730–118 244)
29·7
(27·5 to 32·0)*
Dysthymia 86 812
(74 974–99 103)
104 106
(90 398–118 969)
19·9
(18·4 to 21·5)*
Chronic kidney disease due 
to diabetes 
79 184
(68 481–90 737)
100 824
(86 923–115 652)
27·3
(24·9 to 29·9)*
Chronic kidney disease due 
to other causes
74 917
(64 012–86 576)
94 553
(81 142–109 371)
26·2
(24·2 to 28·3)*
Idiopathic developmental 
intellectual disability
82 996
(47 588–117 109)
92 074
(52 280–130 411)
10·9
(9·5 to 11·9)*
Other cardiovascular and 
circulatory diseases
72 772
(68 090–77 763)
90 348
(84 711–96 659)
24·2
(22·7 to 25·5)*
Otitis media 83 022
(73 657–93 266)
86 393
(76 374–97 104)
4·1
(2·7% to 5·5)*
Psoriasis 67 753
(65 107–70 298)
79 700
(76 691–82 804)
17·6
(17·0 to 18·3)*
Other 
haemoglobinopathies and 
haemolytic anaemias
73 045
(72 600–73 470)
74 385
(73 898–74 862)
1·8
(0·9 to 2·7%)
Data in parentheses are 95% UIs. *Percentage changes that are statistically signiﬁ cant. 
Table 2: Global prevalence of longer duration (more than 3 months) sequelae in 2005 and 2015 for all 
ages and both sexes combined, with percentage change between 2005 and 2015 for Level 4 causes with 
prevalence greater than 1%
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age-standardised YLD rates. Anaemia led to generally 
higher rates of age-standardised YLDs in women than in 
men across levels of SDI, but the largest imbalance 
occurred at SDI levels between 0·10 and 0·50. Disability 
from injuries exacted a larger burden for men than for 
women, particularly at lower levels of SDI.
Without adjustments for population age structure 
(ﬁ gure 6B), the eﬀ ect of ageing populations and causes 
of disability that disproportionately aﬀ ect older 
individuals become prominent. At all levels of SDI, 
total YLDs per 100 000 did not notably diﬀ er by sex; 
instead, the cause composition of disability showed 
greater diﬀ erences. Below an SDI score of 0·25, 
communicable causes accounted for 30–45% of total 
disability, primarily due to nutritional deﬁ ciencies, 
malaria, and neglected tropical diseases. YLDs 
per 100 000 due to musculoskeletal disorders, 
particularly lower back and neck pain and other mus-
culo skeletal disorders, increased substantially from low 
to high SDI, with a more pronounced increase 
beginning at an SDI score of 0·6. This rise was 
particularly evident in women.
Trends in age-standardised YLDs per capita 
Globally, age-standardised YLDs per capita (an indicator 
of overall disability experienced per person in a given 
place) moderately decreased for both sexes between 1990 
and 2015 (results appendix pp 714–16). Age-standardised 
YLDs per capita were consistently higher for women 
than for men at the global level. For both sexes, YLDs 
per capita were generally higher for lower levels of SDI. 
YLDs per capita were noticeably larger for low SDI and 
low-middle SDI groups than for other SDI levels (ie, 
high SDI, high-middle SDI, and middle SDI), which 
were more similar to each other. 
Leading causes of YLDs and deviations from expected levels 
based on Socio-demographic Index
Clear, though varied, patterns emerged across and within 
GBD regions in comparison of observed levels of YLDs 
due to leading causes of disability with levels expected on 
the basis of SDI. Figure 7 displays ratios of observed and 
expected YLDs for the leading ten causes at level 3 of the 
GBD hierarchy in 2015, colour coded by the magnitude 
of diﬀ erences between observed and expected YLDs.
Globally, lower back and neck pain was the leading 
cause of disability in 2015. Two mental disorders, major 
depressive and anxiety disorders, were the third and 
ninth leading causes of global disability, and diabetes was 
the sixth leading driver of disability. Iron-deﬁ ciency 
anaemia was the only Group 1 cause among the leading 
ten causes for global YLDs (ranked fourth). Sensory 
disorders ranked second and skin diseases ranked ﬁ fth. 
Lower back and neck pain was the leading global cause of 
disability in 2015 in most countries. The leading cause of 
disability in 2015 was iron-deﬁ ciency anaemia in 
27 countries; HIV/AIDS in all six southern sub-Saharan 
African countries; depression in ﬁ ve eastern sub-Saharan 
Africa countries; other neglected tropical diseases in 
Angola, Democratic Republic of the Congo, and Gabon; 
sense organ disorders in Comoros and Myanmar; 
diabetes in Fiji and Marshall Islands; war in Lebanon and 
Syria; and onchocerciasis in Liberia.
Regional, country, territory, and selected subnational results
Lower back and neck pain was the leading cause of 
disability in all high-income countries in 2015. However, 
ratios of observed to expected YLDs from lower back and 
neck pain ranged from 0·60 for Singapore to more than 
1·59 in Norway. Most high-income countries experienced 
higher than expected levels of disability due to depressive 
disorders. The USA and Australia were the only two high-
income countries where drug use disorders were a top ten 
cause of disability, and observed levels of YLDs were much 
higher than expected. South Korea’s ratio of observed-to-
expected levels of YLDs due to diabetes exceeded 1·30, 
whereas Japan’s diabetes-related disability was lower than 
expected on the basis of SDI. In the UK, observed disability 
due to asthma was well above expected levels.
In 2015, lower back and neck pain was the leading 
cause of YLDs for all but two countries in Latin America 
and the Caribbean; Haiti and Venezuela were the 
exceptions, with iron-deﬁ ciency anaemia as the leading 
causes of disability for both countries. Disability due to 
diabetes surpassed expected levels by at least a factor of 
two for six countries and territories: Antigua, Barbados, 
Dominica, Puerto Rico, Trinidad and Tobago, and the 
Virgin Islands. Peru, however, had a ratio of less than 0·6 
for observed and expected YLDs for diabetes. 
In 2015, lower back and neck pain was the leading 
cause of YLDs for 24 out of 28 countries and territories of 
southeast Asia, east Asia, and Oceania. Other leading 
causes of disability were sensory disorders in Myanmar, 
diabetes in Fiji and the Marshall Islands, and 
iron-deﬁ ciency anaemia in Papua New Guinea. Although 
lower back and neck pain was the primary cause of 
disability, many countries had far lower levels of this 
than expected given their SDI, including Thailand (0·73), 
Indonesia (0·76), and Malaysia (0·75). Observed YLDs 
due to depressive disorders were often lower than 
expected, with 22 countries recording ratios below 0·80. 
Conversely, numerous geographies recorded YLD ratios 
exceeding 2·00 for diabetes (eg, 2·29 in Taiwan). 
Beyond lower back and neck pain, which was the leading 
cause of YLDs for three of ﬁ ve countries in south Asia  in 
2015 (with India and Pakistan being the exception), a 
mixture of causes accounted for the region’s main causes 
of disability; this heterogeneity probably reﬂ ects the 
diversity of countries in the region and their places along 
the development spectrum. Iron-deﬁ ciency anaemia was 
the ﬁ rst leading cause and lower back and neck pain was 
the second leading cause of YLDs in both India and 
Pakistan, whereas sensory disorders, other musculoskeletal 
disorders, and iron-deﬁ ciency anaemia ranked second for 
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Prevalence (thousands) YLDs (thousands)
2015 Percentage change in 
counts between 2005 
and 2015
Percentage change in 
ASR between 2005 and 
2015
2015 Percentage change in 
counts between 2005 
and 2015
Percentage change in 
ASR between 2005 
and 2015
All causes ·· ·· ·· 792 004·7
(588 538·7–1 019 955·2)
15·1
(14·5 to 15·6)*
–2·1
(–2·5 to –1·7)*
Communicable, maternal, 
neonatal, and nutritional 
diseases
4 133 822·3
(4 108 132·5 to 
4 161 262·6)
8·0
(7·3 to 8·7)*
–4·2
(–4·8 to –3·6)*
112 501·9
(80 347·4–156 270·9)
–0·5
(–2·4 to 2·5)
–9·7
(–11·4 to –7·0)*
HIV/AIDS and tuberculosis 46 005·2
(44 985·8 to 47 146·6)
18·6
(15·2 to 22·1)*
2·9
(–0·0 to 5·9)
6702·3
(4798·6–8863·5)
2·1
(–3·5 to 7·2)
–12·2
(–17·0 to –7·8)*
Tuberculosis 8861·2
(8076·3 to 9707·2)
9·2
(6·3 to 12·2)*
–7·2
(–9·5 to –4·7)*
2712·4
(1829·9–3744·0)
9·4
(6·4 to 12·5)*
–6·8
(–9·2 to –4·2)*
HIV/AIDS 37 277·5
(36 279·9 to 38 339·1)
21·1
(16·9 to 25·5)*
5·6
(2·0 to 9·6)*
3989·9
(2891·2–5159·5)
–2·4
(–10·5 to 5·5)
–15·6
(–23·0 to –8·5)*
HIV/AIDS—tuberculosis 1258·0
(1142·5 to 1386·9)
–17·9
(–20·7 to –14·9)*
–28·3
(–30·7 to –25·7)*
471·9
(316·0–645·6)
–17·8
(–20·7 to –14·7)*
–28·1
(–30·6 to –25·5)*
HIV/AIDS resulting in 
other diseases
37 543·3
(36 350·0 to 39 028·4)
23·6
(20·5 to 26·7)*
7·9
(5·1 to 10·6)*
3518·0
(2 555·4–4 558·9)
0·2
(–9·3 to 9·3)
–13·6
(–22·1 to –5·2)*
HIV aggregate 21 149·0
(20 260·3 to 22 292·3)
–19·5
(–22·5 to –16·3)*
–29·7
(–32·3 to –26·9)*
1543·6
(1 107·2–2 025·2)
–20·4
(–23·4 to –17·2)*
–30·4
(–33·1 to –27·6)*
AIDS aggregate 16 394·3
(15 747·0 to 17 154·2)
299·5
(251·4 to 355·5)*
232·9
(193·5 to 279·0)*
1974·4
(1432·0–2559·9)
25·5
(0·9 to 56·1)*
6·1
(–14·6 to 32·4)
Diarrhoea, lower respiratory 
infections, and other 
common infectious diseases
402 320·4
(393 746·5 to 
408 994·2)
8·0
(7·2 to 8·8)*
–2·9
(–3·7 to –2·3)*
14 865·0
(10 397·0–20 283·4)
6·2
(5·4 to 7·1)*
–4·0
(–4·7 to –3·3)*
Diarrhoeal diseases 35 820·6
(34 342·1 to 37 537·8)
6·4
(5·5 to 7·3)*
–3·3
(–4·1 to –2·5)*
5731·7
(3 943·3–7 890·5)
6·4
(5·4 to 7·5)*
–3·1
(–4·0 to –2·2)*
Diarrhoea episodes 
aggregate
35 816·3
(34 337·5 to 37 534·1)
6·4
(5·5 to 7·3)*
–3·3
(–4·1 to –2·5)*
5730·4
(3 942·2–7 889·0)
6·4
(5·4 to 7·5)*
–3·1
(–4·0 to –2·2)*
Guillain-Barré syndrome 
due to diarrhoeal diseases
4·2
(3·2 to 5·5)
16·9
(14·7 to 19·5)*
–0·2
(–0·9 to 0·4)
1·3
(0·8–1·9)
16·9
(14·7 to 19·5)*
–0·2
(–0·9 to 0·4) 
Intestinal infectious diseases 1666·8
(1594·4 to 1 732·8)
–23·3
(–25·6 to –20·6)*
–28·2
(–30·4 to –25·8)*
220·3
(149·3–306·5)
–18·6
(–22·8 to –13·8)*
–24·2
(–28·1 to –19·8)*
Typhoid fever 1446·7
(1256·2 to 1 648·1)
–18·3
(–20·8 to –15·6)*
–23·9
(–26·3 to –21·3)*
191·0
(129·5–267·8)
–17·7
(–22·1 to –12·6)*
–23·2
(–27·4 to –18·5)*
Typhoid fever episodes 
aggregate
1197·9
(1041·3 to 1366·6)
–18·3
(–21·7 to –14·8)*
–23·9
(–27·1 to –20·5)*
113·3
(75·8–162·5)
–18·1
(–22·6 to –13·4)*
–23·7
(–27·8 to –19·2)*
Complications of 
typhoid fever aggregate
248·8
(210·8 to 292·2)
–18·2
(–28·6 to –5·4)*
–23·8
(–33·5 to –12·1)*
77·8
(51·6–110·8)
–17·0
(–28·5 to –3·0)*
–22·6
(–33·1 to –9·9)*
Paratyphoid fever 529·3
(431·3 to 646·3)
–17·8
(–22·6 to –12·7)*
–23·8
(–28·2 to –19·2)*
27·5
(17·5–40·7)
–17·5
(–24·7 to –9·2)*
–23·5
(–30·1 to –16·1)*
Paratyphoid fever 
episodes aggregate
502·2
(409·6 to 612·7)
–17·8
(–22·6 to –12·4)*
–23·8
(–28·2 to –19·0)*
24·4
(15·5–36·4)
–17·5
(–24·9 to –8·7)*
–23·5
(–30·7 to –15·5)*
Intestinal perforation 
due to paratyphoid
27·1
(20·9 to 34·5)
–17·6
(–33·0 to 1·4)
–23·7
(–37·8 to –6·1)*
3·1
(1·9–4·6)
–17·5
(–32·8 to 1·6)
–23·6
(–37·7 to –5·9)*
Other intestinal infectious 
diseases
·· ·· ·· 1·8
(0·6–4·1)
–67·0
(–78·8 to –45·8)*
–69·3
(–80·2 to –50·1)*
Lower respiratory infections 8986·6
(8545·2 to 9393·7)
5·1
(4·0 to 6·2)*
–8·2
(–9·1 to –7·3)*
540·4
(365·3–760·3)
4·9
(3·5 to 6·3)*
–8·1
(–9·2 to –7·0)*
Lower respiratory 
infection episodes 
aggregate
8982·2
(8539·8 to 9387·9)
5·1
(4·0 to 6·2)*
–8·2
(–9·1 to –7·3)*
539·1
(364·5–759·5)
4·9
(3·5 to 6·3)*
–8·1
(–9·2 to –7·0)*
Guillain-Barré syndrome 
due to lower respiratory 
infections
4·4
(2·5 to 6·9)
16·9
(14·7 to 19·5)*
–0·2
(–0·9 to 0·4)
1·3
(0·7–2·2)
16·9
(14·7 to 19·5)*
–0·2
(–0·9 to 0·4)
Upper respiratory infections 233 470·3
(208 009·7 to 259 076·8)
10·2
(8·9 to 11·5)*
–1·4
(–2·0 to –0·8)*
2738·4
(1538·6–4644·3)
10·1
(8·9 to 11·5)*
–1·3
(–1·9 to –0·6)*
Upper respiratory infection 
episodes aggregate
233 458·2
(207 997·9 to 259 065·2)
10·2
(8·9 to 11·5)*
–1·4
(–2·0 to –0·8)*
2734·8
(1 533·9–4 641·4)
10·1
(8·9 to 11·5)*
–1·3
(–1·9 to –0·6)*
Guillain-Barré syndrome 
due to upper respiratory 
infections
12·1
(9·6 to 15·2)
16·9
(14·7 to 19·5)*
–0·2
(–0·9 to 0·4)
3·6
(2·2–5·4)
17·0
(14·7 to 19·5)*
–0·2
(–0·9 to 0·4)
(Table 3 continues on next page)
Articles
1556 www.thelancet.com   Vol 388   October 8, 2016
Prevalence (thousands) YLDs (thousands)
2015 Percentage change in 
counts between 2005 
and 2015
Percentage change in 
ASR between 2005 and 
2015
2015 Percentage change in 
counts between 2005 
and 2015
Percentage change in 
ASR between 2005 
and 2015
(Continued from previous page)
Otitis media 112 089·1
(100 504·6 to 123 655·6)
5·2
(4·1 to 6·5)*
–4·4
(–5·5 to –3·4)*
3321·5
(2 114·2–4 906·3)
3·3
(0·6 to 6·0)*
–5·6
(–8·0 to –3·1)*
Acute otitis media 25 630·8
(21 044·2 to 31 570·6)
9·4
(7·5 to 11·2)*
1·3
(–0·4 to 3·0)
334·9
(169·4–623·7)
9·4
(7·5 to 11·4)*
1·4
(–0·3 to 3·1)
Chronic otitis media 
aggregate
86 458·3
(76 403·0 to 97 133·7)
4·1
(2·7 to 5·5)*
–6·0
(–7·2 to –4·8)*
2986·6
(1904·2–4 371·1)
2·7
(–0·2 to 5·6)
–6·3
(–8·9 to –3·6)*
Meningitis 8733·5
(8320·6 to 9107·1)
16·9
(13·4 to 20·0)*
2·5
(–0·6 to 5·1)
1516·9
(1076·1–1986·0)
15·0
(13·7 to 16·5)*
1·9
(0·7 to 3·0)*
Pneumococcal meningitis 7297·2
(6228·5 to 8635·3)
22·2
(19·7 to 25·1)*
6·9
(4·7 to 9·6)*
728·8
(513·1–959·9)
17·6
(15·5 to 19·7)*
3·9
(2·0 to 5·6)*
Acute pneumococcal 
meningitis
40·3
(33·5 to 48·4)
25·3
(17·4 to 33·8)*
12·1
(5·2 to 19·5)*
5·3
(3·4–7·8)
25·1
(15·1 to 37·1)*
11·9
(3·2 to 22·3)*
Complications of 
pneumococcal 
meningitis aggregate
7256·9
(6191·3 to 8591·7)
22·2
(19·7 to 25·1)*
6·9
(4·7 to 9·6)*
723·5
(509·2–952·4)
17·6
(15·4 to 19·6)*
3·8
(2·0 to 5·6)*
H inﬂ uenzae type b 
meningitis
2455·6
(1966·7 to 3032·6)
–8·3
(–12·2 to –3·9)*
–18·0
(–21·5 to –13·9)*
302·1
(209·4–407·1)
6·9
(3·4 to 10·6)*
–3·3
(–6·6 to 0·0)
Acute H inﬂ uenzae type 
b meningitis
22·0
(17·2 to 28·7)
–19·2
(–25·3 to –11·9)*
–26·0
(–31·8 to –19·2)*
2·9
(1·8–4·5)
–18·7
(–26·1 to –10·8)*
–25·6
(–32·4 to –18·1)*
Complications of H 
inﬂ uenzae type b 
meningitis aggregate
2433·5
(1947·4 to 3010·8)
–8·2
(–12·1 to –3·7)*
–17·9
(–21·5 to –13·7)*
299·1
(207·9–402·7)
7·3
(3·7 to 11·0)*
–3·0
(–6·3 to 0·3)
Meningococcal meningitis 1720·8
(1327·7 to 2 180·5)
22·0
(17·9 to 26·2)*
7·5
(3·8 to 11·3)*
161·6
(111·7–215·6)
19·7
(17·5 to 22·1)*
5·1
(3·2 to 7·4)*
Acute meningococcal 
meningitis
22·8
(18·9 to 27·7)
24·4
(14·4 to 34·9)*
12·7
(3·7 to 22·4)*
3·0
(1·8–4·5)
24·7
(10·9 to 39·4)*
12·9
(0·5 to 25·9)*
Complications of 
meningococcal 
meningitis aggregate
1698·0
(1305·2 to 2155·2)
22·0
(17·9 to 26·2)*
7·4
(3·8 to 11·2)*
158·6
(109·4–211·9)
19·6
(17·4 to 22·0)*
5·0
(3·1 to 7·3)*
Other meningitis 3015·2
(2438·5 to 3618·0)
19·0
(16·6 to 21·6)*
3·5
(1·4 to 5·9)*
324·5
(225·1–428·1)
15·3
(13·3 to 17·4)*
0·9
(–0·8 to 2·7)
Other meningitis 
episodes aggregate
134·5
(120·0 to 151·7)
16·3
(10·2 to 22·5)*
5·7
(0·1 to 11·4)*
17·8
(11·5–25·3)
16·6
(8·6 to 24·0)*
5·9
(–1·1 to 12·5)
Complications of other 
meningitis aggregate
2880·4
(2300·7 to 3474·9)
19·1
(16·5 to 21·9)*
3·4
(1·2 to 5·8)*
306·7
(213·3–406·6)
15·2
(13·2 to 17·5)*
0·6
(–1·1 to 2·6)
Encephalitis 4315·8
(3145·8 to 5875·6)
4·8
(2·8 to 7·4)*
–9·3
(–11·3 to –6·7)*
457·0
(326·7–594·9)
6·7
(4·6 to 9·0)*
–6·3
(–8·2 to –4·3)*
Acute encephalitis 81·8
(74·8 to 89·5)
7·1
(5·2 to 9·0)*
–4·1
(–5·7 to –2·4)*
10·8
(7·1–15·5)
7·5
(3·8 to 11·1)*
–3·7
(–6·9 to –0·5)*
Complications of 
encephalitis aggregate
4233·6
(3069·6 to 5787·5)
4·8
(2·7 to 7·3)*
–9·4
(–11·4 to –6·8)*
446·2
(318·8–581·4)
6·7
(4·6 to 9·0)*
–6·4
(–8·3 to –4·4)*
Diphtheria 0·6
(0·3 to 1·2)
–59·6
(–81·7 to –12·7)*
–62·8
(–83·1 to –19·5)*
0·0
(0·0–0·1)
–59·7
(–81·7 to –12·7)*
–62·8
(–83·1 to –19·5)*
Whooping cough 2232·6
(1725·9 to 2800·7)
–27·4
(–29·5 to –25·2)*
–32·4
(–34·3 to –30·3)*
110·3
(65·6–167·0)
–27·3
(–29·6 to –24·8)*
–32·3
(–34·5 to –30·0)*
Tetanus 209·3
(204·8 to 214·7)
8·4
(6·1 to 9·8)*
–2·7
(–5·0 to –1·4)*
9·1
(6·7–12·2)
–8·9
(–14·5 to –3·7)*
–18·1
(–23·3 to –13·3)*
Severe tetanus 8·6
(6·5 to 13·0)
–46·3
(–54·0 to –36·0)*
–52·1
(–59·1 to –42·9)*
1·1
(0·7–1·9)
–45·9
(–53·8 to –35·7)*
–51·8
(–58·9 to –42·6)*
Complications of tetanus 
aggregate
200·7
(196·7 to 204·5)
13·3
(12·8 to 13·9)*
1·8
(1·4 to 2·3)*
8·0
(5·8–10·6)
1·0
(–3·7 to 5·4)
–8·8
(–13·0 to –4·9)*
Measles 127·4
(56·8 to 252·2)
–70·2
(–73·6 to –66·0)*
–72·3
(–75·4 to –68·4)*
11·5
(4·3–25·3)
–70·0
(–73·6 to –65·4)*
–72·0
(–75·4 to –67·7)*
Varicella and herpes zoster 5907·7
(5489·4 to 6344·6)
15·2
(14·1 to 16·5)*
–0·4
(–0·8 to –0·0)*
207·8
(127·9–316·5)
18·5
(16·5 to 20·8)*
–0·4
(–1·4 to 0·7)
(Table 3 continues on next page)
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Prevalence (thousands) YLDs (thousands)
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ASR between 2005 and 
2015
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and 2015
(Continued from previous page)
Neglected tropical diseases 
and malaria
1 900 062·6
(1 863 148·8 to 
1 940 058·5)
–0·4
(–2·5 to 1·9)
–10·7
(–12·7 to –8·7)*
20 763·1
(13 382·4–32 174·5)
–4·7
(–13·2 to 8·9)
–14·5
(–22·2 to –2·4)*
Malaria 295 717·3
(257 568·4 to 338 449·0)
29·9
(22·5 to 37·2)*
20·0
(12·9 to 27·2)*
3358·2
(2356·9–4703·9)
16·1
(12·8 to 19·3)*
8·5
(5·4 to 11·4)*
Asymptomatic malaria 
parasitaemia
(PfPR)
206 147·2
(168 670·7 to 246 888·7)
37·3
(27·0 to 48·1)*
26·4
(16·6 to 36·8)*
0·0
(0·0–0·0)
0·0
(0·0 to 0·0)
0·0
(0·0 to 0·0)
Malaria episodes 
aggregate
16 756·8
(10 341·8 to 25 965·5)
–15·9
(–23·6 to –8·4)*
–21·1
(–28·4 to –14·1)*
346·6
(174·4–598·4)
–15·8
(–23·6 to –8·2)*
–20·9
(–28·2 to –13·7)*
Complications of malaria 
aggregate
876·9
(798·1 to 957·9)
28·4
(26·5 to 30·5)*
18·4
(16·5 to 20·3)*
274·9
(209·7–344·8)
24·7
(20·5 to 29·1)*
15·0
(11·2 to 18·9)*
Anaemia due to malaria 
parasitaemia
(PfPR) aggregate
71 936·4
(70 137·5 to 73 504·2)
26·3
(24·4 to 28·0)*
17·0
(15·3 to 18·6)*
2736·7
(1848·0–3918·8)
21·1
(18·1 to 24·3)*
13·1
(10·5 to 16·1)*
Chagas disease 6653·6
(5750·5 to 7575·6)
–7·1
(–9·7 to –4·1)*
–22·1
(–24·2 to –19·7)*
63·1
(42·1–90·8)
–1·8
(–5·1 to 1·7)
–21·0
(–23·6 to –18·3)*
Chagas disease episodes 
aggregate
5634·7
(4850·5 to 6414·1)
–7·8
(–10·3 to –4·9)*
–22·2
(–24·3 to –19·8)*
0·0
(0·0–0·1)
–18·7
(–22·9 to –14·4)*
–27·6
(–31·1 to –24·1)*
Complications of Chagas 
disease aggregate
666·0
(525·5 to 820·6)
–5·2
(–7·9 to –1·9)*
–22·0
(–24·3 to –19·6)*
44·8
(30·0–62·8)
–2·5
(–6·0 to 1·2)
–21·0
(–23·6 to –18·3)*
Heart failure due to 
Chagas disease aggregate
353·0
(221·5 to 503·5)
0·3
(–2·9 to 4·0)
–20·9
(–23·4 to –18·2)*
18·2
(9·7–29·4)
0·2
(–3·6 to 4·4)
–20·9
(–23·8 to –17·8)*
Leishmaniasis 3859·3
(3438·4 to 4570·4)
27·3
(5·9 to 55·0)*
11·4
(–7·0 to 35·1)
45·8
(22·8–86·7)
25·5
(21·9 to 28·9)*
10·5
(7·5 to 13·5)*
Visceral leishmaniasis 60·8
(57·5 to 64·7)
10·6
(9·7 to 11·4)*
2·3
(1·6 to 3·0)*
4·3
(2·9–6·1)
10·8
(2·1 to 20·7)*
2·6
(–5·4 to 11·5)
Cutaneous and 
mucocutaneous 
leishmaniasis
3895·9
(3 324·6 to 4 767·5)
27·0
(23·7 to 30·1)*
11·0
(8·3 to 13·8)*
41·5
(19·4–80·8)
27·3
(23·6 to 30·5)*
11·4
(8·3 to 14·5)*
African trypanosomiasis 10·7
(6·0 to 17·0)
–68·7
(–70·4 to –67·3)*
–72·3
(–73·8 to –71·0)*
3·0
(1·4–5·3)
–67·4
(–72·6 to –62·1)*
–71·0
(–75·5 to –66·6)*
Schistosomiasis 252 339·5
(211 032·5 to 321 081·3)
–23·5
(–32·5 to –4·4)*
–30·9
(–39·0 to –13·7)*
2472·6
(1275·0–4521·2)
–21·8
(–29·3 to –4·0)*
–29·1
(–36·0 to –13·1)*
Schistosomiasis episodes 
aggregate
130 285·7
(114 433·9 to 156 900·0)
–26·3
(–34·5 to –13·6)*
–33·1
(–40·5 to –21·3)*
740·7
(292·3–1584·0)
–27·3
(–35·2 to –14·1)*
–34·0
(–41·0 to –22·0)*
Complications of 
schistosomiasis aggregate
105 621·9
(76 641·0 to 160 339·4)
–19·6
(–32·6 to 14·1)
–27·7
(–39·4 to 3·0)
1188·8
(535·9–2 463·3)
–18·0
(–30·5 to 15·6)
–26·3
(–37·5 to 4·3)
Anaemia due to 
schistosomiasis aggregate
16 331·3
(16 075·8 to 16 655·1)
–19·6
(–21·1 to –17·7)*
–27·0
(–28·3 to –25·3)*
543·1
(365·1–781·5)
–21·5
(–24·0 to –18·6)*
–27·8
(–30·0 to –25·1)*
Cysticercosis 1931·0
(1597·8 to 2312·0)
–6·2
(–10·2 to –2·5)*
–20·8
(–24·3 to –17·6)*
286·7
(194·2–392·8)
–16·3
(–21·3 to –11·8)*
–29·2
(–33·3 to –25·3)*
Cystic echinococcosis 1383·0
(1265·9 to 1498·6)
24·7
(22·6 to 27·0)*
6·7
(5·0 to 8·5)*
126·8
(86·7–174·6)
24·3
(21·1 to 27·5)*
6·6
(4·1 to 9·2)*
Lymphatic ﬁ lariasis 38 464·1
(31 328·2 to 46 783·0)
–44·9
(–49·9 to –39·9)*
–51·6
(–56·0 to –47·2)*
2075·0
(1120·6–3311·2)
–16·2
(–32·1 to –3·9)*
–27·7
(–41·5 to –17·1)*
Prevalence of detectable 
microﬁ liaria due to 
lymphatic ﬁ lariasis
19 707·9
(17 173·8 to 22 270·5)
–58·8
(–61·8 to –55·3)*
–63·5
(–66·1 to –60·3)*
0·0
(0·0–0·0)
0·0
(0·0 to 0·0)
0·0
(0·0 to 0·0)
Complications of 
lymphatic ﬁ lariasis 
aggregate
18 756·3
(12 420·1 to 26 397·1)
–14·8
(–29·9 to –3·5)*
–26·7
(–40·1 to –16·7)*
2075·0
(1120·6–3311·2)
–16·2
(–32·1 to –3·9)*
–27·7
(–41·5 to –17·1)*
Onchocerciasis 15 531·5
(11 963·5 to 19 993·8)
–29·1
(–39·5 to –18·8)*
–36·8
(–46·0 to –27·5)*
1135·7
(546·2–2005·4)
–21·2
(–38·5 to –4·8)*
–31·2
(–46·7 to –16·2)*
Asymptomatic 
onchocerciasis
2280·4
(1525·0 to 3173·2)
–62·4
(–66·1 to –59·6)*
–66·2
(–69·5 to –63·7)*
0·0
(0·0–0·0)
0·0
(0·0 to 0·0)
0·0
(0·0 to 0·0)
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(Continued from previous page)
Skin disease due to 
onchocerciasis aggregate
12 223·9
(8 474·7 to 16 585·2)
–17·4
(–31·0 to –2·7)*
–26·5
(–38·6 to –13·1)*
1055·6
(467·4–1894·7)
–22·2
(–41·8 to –3·2)*
–31·6
(–49·0 to –14·8)*
Vision loss due to 
onchocerciasis aggregate
1025·4
(724·8 to 1452·1)
–2·3
(–15·0 to 11·8)
–22·3
(–32·3 to –11·0)*
80·1
(51·3–117·5)
–6·1
(–16·9 to 6·0)
–25·4
(–33·9 to –15·9)*
Trachoma 3557·1
(2940·5 to 4321·8)
4·6
(0·4 to 9·2)*
–19·3
(–22·9 to –15·2)*
279·2
(192·8–396·0)
–1·2
(–5·6 to 3·0)
–23·9
(–27·5 to –20·3)*
Dengue 4730·0
(2654·1 to 10 254·2)
143·6
(–0·3 to 564·7)
119·7
(–10·1 to 498·7)
764·1
(346·8–1 744·2)
140·8
(–0·1 to 558·4)
117·7
(–9·8 to 494·3)
Dengue episodes 
aggregate
1409·2
(937·6 to 2943·8)
134·1
(–3·8 to 521·2)
110·8
(–13·2 to 459·0)
82·1
(45·0–183·9)
141·4
(0·4 to 549·2)*
117·9
(–9·4 to 486·7)
Post-dengue chronic 
fatigue syndrome
3324·6
(1600·3 to 7347·9)
143·7
(–0·3 to 564·7)
119·8
(–10·1 to 498·7)
682·0
(295·2–1 608·9)
140·8
(–0·2 to 558·0)
117·6
(–9·8 to 494·1)
Yellow fever 2·8
(0·8 to 7·7)
–25·7
(–31·6 to –19·2)*
–31·6
(–36·9 to –25·8)*
0·1
(0·0–0·3)
–25·7
(–31·6 to –19·2)*
–31·6
(–36·9 to –25·8)*
Rabies 0·7
(0·6 to 0·8)
–43·4
(–51·5 to –33·8)*
–50·8
(–57·6 to –42·6)*
0·1
(0·1–0·1)
–43·4
(–51·5 to –33·8)*
–50·8
(–57·6 to –42·6)*
Intestinal nematode 
infections
1 447 209·3
(1 414 995·0 to 
1 481 332·3)
–2·5
(–5·1 to 0·2)
–12·8
(–15·2 to –10·4)*
3173·8
(1861·3–5090·8)
–22·8
(–27·3 to –17·3)*
–30·4
(–34·5 to –25·4)*
Ascariasis 761 893·8
(682 557·5 to 861 031·5)
–10·8
(–22·5 to 2·5)
–20·3
(–30·7 to –8·2)*
871·0
(482·5–1 464·3)
–37·7
(–45·3 to –29·4)*
–43·9
(–50·8 to –36·4)*
Complications of 
ascariasis aggregate
47 626·4
(44 087·5 to 51 711·9)
–35·6
(–41·9 to –28·4)*
–42·1
(–47·8 to –35·6)*
871·0
(482·5–1 464·3)
–37·7
(–45·3 to –29·4)*
–43·9
(–50·8 to –36·4)*
Asymptomatic ascariasis 714 230·7
(634 201·9 to 814 009·5)
–8·5
(–20·9 to 6·4)
–18·2
(–29·3 to –4·9)*
0·0
(0·0–0·0)
0·0
(0·0 to 0·0)
0·0
(0·0 to 0·0)
Trichuriasis 463 652·1
(426 621·2 to 502 939·4)
–2·1
(–12·0 to 9·0)
–12·2
(–21·1 to –2·1)*
544·1
(290·7–946·0)
–16·7
(–30·6 to 3·6)
–24·9
(–37·5 to –6·8)*
Complications of 
trichuriasis aggregate
27 129·6
(24 188·7 to 31 890·8)
–15·6
(–27·8 to 2·1)
–24·1
(–35·0 to –8·2)*
544·1
(290·7–946·0)
–16·7
(–30·6 to 3·6)
–24·9
(–37·5 to –6·8)*
Asymptomatic 
trichuriasis
436 525·4
(400 013·3 to 475 985·5)
–1·1
(–11·8 to 11·0)
–11·3
(–21·0 to –0·3)*
0·0
(0·0–0·0)
0·0
(0·0 to 0·0)
0·0
(0·0 to 0·0)
Hookworm disease 428 245·9
(394 486·0 to 468 292·4)
–7·3
(–16·9 to 3·5)
–17·2
(–25·8 to –7·5)*
1758·8
(1088·5–2754·9)
–14·6
(–19·9 to –9·4)*
–22·9
(–27·7 to –18·2)*
Complications of 
hookworm disease 
aggregate
51 012·9
(48 151·1 to 54 346·2)
–14·0
(–21·0 to –6·2)*
–23·2
(–29·5 to –16·3)*
1046·7
(572·8–1732·1)
–15·5
(–24·0 to –6·3)*
–24·4
(–32·1 to –16·3)*
Anaemia due to 
hookworm disease 
aggregate
24 220·2
(24 078·2 to 24 365·2)
–6·2
(–7·3 to –5·1)
–15·5
(–16·5 to –14·6)*
712·1
(476·3–1031·1)
–13·2
(–15·6 to –11·1)*
–20·5
(–22·6 to –18·7)*
Asymptomatic 
hookworm disease
352 948·6
(319 143·2 to 392 574·4)
–6·4
(–18·3 to 7·5)
–16·4
(–27·2 to –3·9)*
0·0
(0·0–0·0)
0·0
(0·0 to 0·0)
0·0
(0·0 to 0·0)
Food-borne trematodiases 71 095·4
(67 365·5 to 75 246·9)
4·0
(1·5 to 6·6)*
–9·3
(–11·4 to –7·1)*
1686·5
(857·1–3066·8)
3·7
(–0·4 to 10·1)*
–10·0
(–13·4 to –5·2)*
Asymptomatic food-
borne trematodiases 
aggregate
56 131·7
(45 765·9 to 63 620·3)
3·8
(1·2 to 6·6)*
–9·3
(–11·6 to –6·9)*
0·0
(0·0–0·0)
0·0
(0·0–0·0)
0·0
(0·0–0·0)
Symptomatic food-borne 
trematodiases aggregate
14 963·7
(8 632·7 to 25 256·6)
4·8
(0·5 to 11·4)*
–9·3
(–12·8 to –4·2)*
1686·5
(857·1–3066·8)
3·7
(–0·4 to 10·1)
–10·0
(–13·4 to –5·2)*
Leprosy 514·2
(487·0 to 545·7)
–0·1
(–0·5 to 0·3)
–19·7
(–20·2 to –19·3)*
31·0
(20·9–43·5)
0·6
(–1·5 to 2·9)
–19·2
(–20·8 to –17·4)*
Ebola 2·8
(1·2 to 5·2)
54 521·3
(46 386·2 to 
68 346·9)*
49 817·9
(41 865·6 to 
62 764·9)*
0·6
(0·2–1·1)
51 908·8
(42 739·0 to 66 884·3)*
47 453·0
(38 609·5 to 
61 730·3)*
Other neglected tropical 
diseases
61 452·6
(60 842·8 to 62 054·9)
0·1
(–1·0 to 1·3)
–7·7
(–8·8 to –6·6)*
5261·1
(2558·5–12 199·0)
7·4
(–18·9 to 50·6)
–1·2
(–25·5 to 38·0)
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Anaemia due to other 
neglected tropical diseases 
aggregate
61 452·6
(60 842·8 to 62 054·9)
0·1
(–1·0 to 1·3)
–7·7
(–8·8 to –6·6)*
2158·2
(1 446·3–3 073·1)
–6·0
(–8·2 to –3·8)*
–12·4
(–14·5 to –10·4)*
Maternal disorders 11 372·9
(10 686·6 to 11 894·1)
2·1
(–4·2 to 9·2)
–7·9
(–13·6 to –1·8)*
898·8
(642·8–1222·9)
–5·1
(–18·7 to 11·2)
–15·1
(–27·0 to –0·3)*
Maternal haemorrhage 2304·8
(2231·6 to 2 393·5)
1·6
(–3·0 to 6·5)
–7·8
(–12·0 to –3·4)*
84·7
(57·3–119·5)
0·1
(–13·5 to 17·2)
–9·1
(–21·3 to 6·6)
Maternal hemorrhage 
episodes aggregate
191·7
(127·8 to 277·5)
2·9
(–36·5 to 66·2)
–6·4
(–42·1 to 49·9)
31·3
(18·1–49·0)
3·3
(–30·6 to 54·9)
–6·0
(–36·3 to 41·1)*
Anaemia due to 
maternal haemorrhage 
aggregate
2113·4
(2082·8 to 2141·5)
1·5
(–0·9 to 3·9)
–7·9
(–10·1 to –5·8)*
53·5
(35·0–78·6)
–1·8
(–5·9 to 2·6)
–10·8
(–14·5 to –6·9)*
Maternal sepsis and other 
maternal infections
3140·8
(2658·0 to 3727·7)
3·7
(–15·2 to 27·8)
–7·8
(–24·2 to 13·1)
56·5
(29·5–102·4)
–1·0
(–42·3 to 70·4)
–9·7
(–47·1 to 55·2)
Maternal sepsis and 
other maternal 
infections aggregate
900·0
(486·7 to 1462·3)
–2·4
(–50·3 to 93·7)
–10·2
(–54·4 to 78·1)
45·3
(22·2–82·7)
–2·7
(–49·0 to 91·0)
–10·5
(–53·2 to 73·6)
Infertility due to 
puerperal sepsis
2242·1
(2 030·5 to 2483·0)
6·4
(4·4 to 8·9)*
–6·8
(–8·6 to –4·7)*
11·2
(4·2–24·3)
6·7
(4·0 to 9·5)*
–6·6
(–8·9 to –4·1)*
Maternal hypertensive 
disorders
4624·4
(3030·8 to 6592·4)
2·7
(–37·9 to 69·8)*
–5·8
(–43·0 to 55·4)*
222·4
(118·4–365·4)
2·6
(–37·3 to 68·5)
–5·9
(–42·4 to 54·4)
Maternal hypertensive 
disorders episodes 
aggregate
4629·2
(3031·5 to 6602·4)
2·8
(–37·8 to 70·0)
–5·7
(–42·9 to 55·7)
219·1
(115·4–363·3)
2·7
(–37·0 to 68·8)
–5·8
(–42·4 to 55·2)
Eclampsia 5·4
(2·2 to 10·5)
–5·8
(–69·0 to 182·2)
–12·9
(–71·6 to 158·3)
3·3
(1·2–6·3)
–5·7
(–69·0 to 182·2)
–12·8
(–71·6 to 158·3)
Maternal obstructed 
labour and uterine rupture
1077·2
(933·3 to 1255·2)
–13·1
(–17·5 to –7·9)*
–23·9
(–27·7 to –19·7)*
352·0
(234·6–499·9)
–12·6
(–17·3 to –7·3)*
–23·4
(–27·4 to –18·9)*
Obstructed labour, acute 
event
89·6
(53·0 to 142·9)
–3·6
(–45·9 to 74·7)
–11·4
(–49·7 to 60·1)
27·7
(14·8–47·0)
–3·1
(–44·9 to 72·1)
–10·9
(–49·0 to 58·2)
Fistula due to maternal 
obstructed labour and 
uterine rupture 
aggregate
987·6
(850·6 to 1156·0)
–13·9
(–16·3 to –11·4)*
–24·9
(–27·0 to –22·8)*
324·3
(216·2–457·4)
–13·3
(–16·6 to –10·1)*
–24·3
(–27·1 to –21·7)*
Maternal abortion, 
miscarriage, and ectopic 
pregnancy
441·3
(285·5 to 630·6)
–0·4
(–37·2 to 58·1)
–9·4
(–42·4 to 44·2)
48·2
(27·2–78·5)
–0·4
(–36·9 to 60·5)
–9·3
(–42·4 to 45·6)
Other maternal disorders ·· ·· ·· 135·0
(90·6–190·2)
–2·2
(–19·6 to 17·5)
–12·2
(–27·7 to 5·5)
Neonatal disorders 52 961·9
(50 435·8 to 54 978·4)*
14·7
(11·9 to 17·8)*
3·9
(1·3 to 6·7)*
10 710·5
(8113·9–13 786·1)
13·3
(9·5 to 17·4)*
3·1
(–0·3 to 6·8)
Neonatal preterm birth 
complications
41 855·4
(36 843·4 to 47 188·1)*
10·6
(6·2 to 15·2)*
–0·4
(–4·3 to 3·8)*
5090·9
(3864·5–6555·6)*
4·4
(–1·1 to 10·1)
–5·2
(–10·1 to 0·2)
Vision loss due to 
retinopathy of 
prematurity aggregate
4245·1
(3386·2 to  5265·3)
11·1
(7·2 to 15·1)*
–2·3
(–5·8 to 1·3)
135·5
(83·0–208·8)
13·9
(9·5 to 18·4)
–0·8
(–4·5 to 3·2)
Complications of 
preterm birth 
complications 
aggregate
37 609·0
(33 086·7 to 42 697·0)
10·5
(5·6 to 15·7)*
–0·1
(–4·6 to 4·5)
4955·4
(3756·9–6394·8)
4·1
(–1·4 to 10·0)
–5·3
(–10·4 to 0·2)
Neonatal encephalopathy 
due to birth asphyxia and 
trauma
13 681·5
(9 797·3 to 19 759·3)
27·3
(24·6 to 30·0)*
16·2
(13·7 to 18·5)*
3769·4
(2451·7–5809·3)
25·1
(22·0 to 28·3)*
14·2
(11·5 to 17·0)*
Neonatal sepsis and other 
neonatal infections
139·1
(79·9 to 216·0)
–1·6
(–3·0 to –0·0)*
–6·7
(–8·0 to –5·2)*
17·7
(9·2–31·0)
–1·8
(–3·5 to 0·1)
–6·9
(–8·5 to –5·1)*
Severe infection due to 
neonatal sepsis and 
other neonatal 
infections
130·1
(71·1 to 207·6)
–2·2
(–3·8 to –0·5)*
–7·3
(–8·8 to –5·6)*
16·6
(8·1–30·0)
–2·1
(–3·7 to –0·3)*
–7·1
(–8·7 to –5·4)*
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Complications of 
neonatal sepsis and 
other neonatal 
infections aggregate
8·9
(7·5 to 10·4)
8·0
(4·3 to 12·7)*
2·4
(–1·1 to 6·9)
1·1
(0·6–1·6)
2·6
(–9·4 to 14·4)
–2·7
(–14·1 to 8·5)
Haemolytic disease and 
other neonatal jaundice
2042·8
(1825·0 to 2309·0)
20·0
(18·8 to 21·4)*
9·2
(8·0 to 10·3)*
603·0
(451·9–770·8)
17·0
(14·8 to 19·4)*
6·5
(4·4 to 8·6)*
Other neonatal disorders ·· ·· ·· 1229·5
(836·5–1 647·2)
19·9
(0·8 to 41·1)*
8·5
(–8·5 to 27·6)
Nutritional deﬁ ciencies 1 482 655·3
(1 477 085·9 to 
2·7
(2·2–3·2)*
–7·1
(–7·5––6·7)*
54 632·4
(36 772·8–77 894·3)
–3·5
(–4·9––2·1)*
–11·4
(–12·7––10·3)*
Protein-energy 
malnutrition
22 834·3
(21 764·0 to 23 985·1)
–4·8
(–10·2 to 0·8)
–12·1
(–17·1 to –6·9)*
2823·3
(1820·3–3984·2)
–4·5
(–9·8 to 1·1)
–11·8
(–16·7 to –6·6)*
Iodine deﬁ ciency 110 919·5
(100 337·2 to 125 252·8)
7·0
(4·7 to 9·4)*
–6·0
(–8·0 to –3·8)*
2386·9
(1 508·3–3 564·2)
7·7
(5·7 to 9·8)*
–4·4
(–6·4 to –2·4)*
Visible goiter due to 
iodine deﬁ ciency 
aggregate
108 307·6
(97 705·7 to 122 260·0)
6·9
(4·5 to 9·4)*
–6·2
(–8·2 to –4·0)*
1927·5
(1192·0–3040·1)
6·9
(4·4 to 9·3)*
–6·0
(–8·2 to –3·9)*
Visible goiter with heart 
failure due to iodine 
deﬁ ciency aggregate
0·3
(0·3 to 0·4)
39·6
(38·3 to 41·0)*
4·2
(3·3 to 5·2)*
0·0
(0·0–0·1)
39·6
(38·3 to 41·0)*
4·2
(3·3 to 5·2)*
Intellectual disability due 
to iodine deﬁ ciency 
aggregate
2611·6
(1085·6 to 3621·3)
10·4
(6·1 to 12·6)*
2·0
(–2·0 to 4·3)
459·3
(163·4–752·8)
11·0
(6·4 to 13·6)*
2·8
(–1·6 to 5·2)
Vitamin A deﬁ ciency 4901·1
(3975·6 to 5921·7)
9·3
(6·2 to 12·5)*
0·1
(–2·7 to 2·7)
232·4
(143·5–345·9)
10·9
(7·5 to 14·6)*
0·2
(–2·7 to 3·3)
Iron-deﬁ ciency anaemia 1 477 530·5
(1 470 902·3 to 
1 485 322·2)
1·5
(0·9 to 2·1)*
–8·0
(–8·5 to –7·4)*
48 529·2
(32 560·8–69 725·2)
–3·8
(–5·1 to –2·4)*
–11·6
(–12·8 to –10·5)*
Iron-deﬁ ciency anaemia 
without heart failure 
aggregate
1 477 458·4
(1 470 824·4 to 
39·7
(38·1–41·3)*
6·1
(4·7–7·4)*
8·1
(5·5–11·4)
39·6
(35·2–44·3)*
6·0
(2·5–9·9)*
Iron-deﬁ ciency anaemia 
with heart failure aggregate
72·1
(64·6 to 80·7)
39·7
(38·1 to 41·3)*
6·1
(4·7 to 7·4)*
8·1
(5·5–11·4)
39·6
(35·2 to 44·3)*
6·0
(2·5 to 9·9)*
Other nutritional 
deﬁ ciencies
·· ·· ·· 660·7
(396·0–1026·9)
–16·7
(–36·8 to 5·8)
–22·9
(–41·5 to –2·1)*
Other communicable, 
maternal, neonatal, 
and nutritional 
diseases
1 604 919·9
(1 563 786·8 to 
1 636 531·0)
16·1
(15·3 to 17·0)*
–0·4
(–1·1 to 0·4)
3929·7
(2566·9–5786·6)
6·5
(3·9 to 9·2)*
–4·0
(–6·2 to –1·7)*
Sexually transmitted 
diseases excluding 
HIV
1 145 527·5
(1 100 971·2 to 
1 176 685·1)
16·9
(15·7 to 18·3)*
–1·0
(–2·1 to 0·1)
1573·7
(974·0–2501·8)
16·9
(14·5 to 19·1)*
1·3
(–0·6 to 3·4)
Syphilis 43 604·9
(37 160·3 to 50 658·3)
3·7
(–0·4 to 7·0)
–9·8
(–13·4 to –6·9)*
242·8
(166·1–333·7)
15·3
(12·2 to 18·5)*
–5·6
(–8·0 to –3·0)*
Early syphilis aggregate 42 350·9
(35 898·4 to 49 441·3)
3·3
(–0·9 to 6·8)
–9·9
(–13·6 to –6·9)*
10·3
(3·0–25·3)
3·4
(–1·1 to 7·4)
–9·9
(–13·7 to –6·3)*
Adult tertiary syphilis 1254·0
(1127·1 to 1385·8)
15·8
(13·2 to 18·3)*
–5·6
(–7·8 to –3·6)*
232·6
(155·4–322·8)
15·9
(12·6 to 19·1)*
–5·4
(–7·9 to –2·8)*
Chlamydial infection 82 822·4
(66 426·4 to 104 328·5)
8·3
(6·1 to 10·7)*
–2·9
(–4·8 to –0·9)*
364·6
(210·6–589·5)
10·1
(6·9 to 13·4)*
–1·8
(–4·5 to 0·8)
Chlamydial infection 
episodes aggregate
81 072·5
(64 735·8 to 102 635·8)
8·3
(6·0 to 10·7)*
–2·9
(–4·8 to –0·9)*
332·7
(185·2–546·0)
10·7
(7·1 to 14·4)*
–1·1
(–4·1 to 2·1)
Pelvic inﬂ ammatory 
diseases due to 
chlamydial infection 
aggregate
1·73
(147·8 to 202·0)
1·4
(–0·8 to 3·4)
–11·5
(–13·2 to –9·8)*
23·1
(15·5 to 32·5)
1·8
(–2·2 to 5·7)
–11·1
(–14.5 to 7·8)*
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Infertility due to 
chlamydial infection 
aggregate
1576·6
(1450·8 to 1703·9)
11·1
(10·0 to 12·2)*
–3·0
(–3·9 to –2·0)
8·8
(3·6 to 18·4)
11·1
(9·0 to 13·2)*
–2·9
(–4·8 to –1·1)*
Gonococcal infection 47 468·5
(35 848·1 to 62 099·7)
25·3
(18·3 to 31·2)*
12·2
(5·9 to 17·7)*
444·9
(260·8–691·8)
26·3
(20·0 to 31·4)*
12·6
(6·7 to 17·3)*
Gonococcal infection 
episodes aggregate
46 561·5
(34 928·2 to 61 227·4)
25·6
(18·5 to 31·6)*
12·5
(6·1 to 18·1)*
430·3
(250·5–671·5)
27·3
(20·7 to 32·5)*
13·5
(7·4 to 18·3)*
Pelvic inﬂ ammatory 
diseases due to 
gonococcal infection 
aggregate
907·0
(822·0 to 1 016·3)
10·0
(7·6 to 11·8)*
–3·8
(–6·0 to –2·2)*
14·6
(9·6–21·4)
3·5
(–0·8 to 7·1)
–8·7
(–12·4 to –5·7)*
Trichomoniasis 167 618·6
(144 744·1 to 193 444·0)
16·2
(15·3 to 17·2)*
0·9
(0·4 to 1·3)*
194·3
(78·0–408·3)
16·1
(15·0 to 17·2)*
1·0
(0·3 to 1·8)*
Genital herpes 885 169·4
(772 303·8 to 
1 008 588·1)
18·1
(16·4 to 19·9)*
–1·3
(–2·7 to 0·1)
236·4
(74·3–554·2)
19·5
(17·4 to 23·0)*
0·7
(–1·4 to 5·0)
Moderate infection 
due to initial genital 
herpes episode
389·0
(88·0 to 909·7)
38·1
(33·6 to 43·2)*
29·5
(25·4 to 34·3)*
19·0
(4·3–45·8)
37·6
(30·9 to 45·6)*
29·1
(22·9 to 36·7)*
Complications of 
genital herpes 
aggregate
884 780·3
(771 914·6 to 
1 008 400·6)
18·1
(16·4 to 19·9)*
–1·3
(–2·7 to 0·0)
217·3
(62·2–534·5)
18·1
(16·3 to 19·9)*
–1·2
(–2·7 to 0·3)
Other sexually 
transmitted diseases
4821·8
(4452·8 to 5174·6)
9·6
(8·1 to 11·0)*
–4·7
(–5·9 to –3·6)*
90·7
(61·5–129·7)
3·7
(1·1 to 6·2)*
–10·0
(–12·2 to –7·8)*
Pelvic inﬂ ammatory 
diseases due to other 
sexually transmitted 
diseases aggregate
507·2
(437·2 to 591·9)
1·2
(–0·1 to 2·6)
–12·2
(–13·1 to –11·2)*
66·8
(45·4–92·9)
1·3
(–1·2 to 4·2)
–12·0
(–14·3 to –9·8)*
Infertility due to other 
sexually transmitted 
diseases aggregate
4314·5
(3943·8 to 4657·1)
10·7
(9·1 to 12·2)*
–3·8
(–5·1 to –2·4)*
23·9
(9·7–48·8)
10·8
(9·0 to 12·7)*
–3·6
(–5·2 to –2·0)*
Other sexually 
transmitted diseases
·· ·· ·· 329·4
(200·1–504·2)
19·5
(14·4 to 24·6)*
6·7
(2·2 to 11·3)*
Hepatitis 497 901·2
(490 397·2 to 505 815·2)
16·7
(15·8 to 17·6)*
2·2
(1·4 to 2·9)*
406·4
(267·6–588·8)
12·6
(1·7 to 24·1)*
1·2
(–8·3 to 11·5)
Acute hepatitis A 8785·5
(7 950·0 to 9 598·2)
4·2
(–7·2 to 17·0)
–2·8
(–13·5 to 9·1)
172·5
(111·5–249·7)
9·5
(–0·1 to 20·4)
1·9
(–6·9 to 12·0)
Hepatitis B 356 083·4
(342 942·4 to 370 231·5)
16·7
(15·0 to 18·4)*
2·8
(1·3 to 4·3)*
190·2
(121·1–282·2)
16·9
(–4·5 to 40·2)
1·2
(–16·9 to 20·7)
Acute hepatitis B 
aggregate
12 832·2
(11 239·6 to 14 567·4)
13·2
(–4·3 to 35·2)
1·0
(–14·6 to 20·0)
190·2
(121·1–282·2)
16·9
(–4·5 to 40·2)
1·2
(–16·9 to 20·7)
Chronic hepatitis B 343 251·2
(330 541·3 to 357 194·6)
16·9
(15·3 to 18·4)*
2·8
(1·5 to 4·3)*
0·0
(0·0–0·0)
0·0
(0·0 to 0·0)
0·0
(0·0 to 0·0)
Hepatitis C 142 745·3
(127 559·8 to 157 704·1)
18·0
(16·7 to 19·2)*
1·2
(0·1 to 2·2)*
8·7
(4·3–16·5)
17·0
(12·2 to 21·7)*
3·3
(–0·5 to 7·3)
Acute hepatitis C 
aggregate
622·3
(580·4 to 666·6)
17·0
(15·7 to 18·4)*
3·4
(2·5 to 4·3)*
8·7
(4·3–16·5)
17·0
(12·2 to 21·7)*
3·3
(–0·5 to 7·3)
Chronic hepatitis C 142 122·9
(126 977·7 to 157 044·9)
18·0
(16·7 to 19·2)*
1·2
(0·1 to 2·2)*
0·0
(0·0–0·0)
0·0
(0·0 to 0·0)
0·0
(0·0 to 0·0)
Acute hepatitis E 1501·9
(1385·4 to 1636·4)
3·5
(2·2 to 4·7)*
–3·2
(–4·1 to –2·3)*
34·9
(22·4–51·7)
4·9
(–4·4 to 15·5)
–2·6
(–10·9 to 6·8)
Other infectious diseases 54 835·4
(54 385·8 to 55 273·8)
0·4
(–1·6 to 2·3)
–8·0
(–9·8 to –6·2)*
1949·6
(1307·1–2797·1)
–1·6
(–5·1 to 2·0)
–8·7
(–12·0 to –5·5)*
Non-communicable diseases 6 652 153·4
(6 633 099·8 to 
6 668 805·2)
13·7
(13·6 to 13·8)*
0·0
(–0·0 to 0·1)
638 480·8
(478 716·6–819 498·9)
18·8
(18·4 to 19·2)*
–0·1
(–0·4 to 0·2)
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Neoplasms 90 497·5
(89 215·7 to 91 896·1)
44·4
(42·1 to 46·7)*
12·4
(10·6 to 14·2)*
8569·3
(6265·5–11 079·2)
36·6
(31·8 to 41·2)*
6·4
(2·7 to 9·7)*
Lip and oral cavity cancer 2425·1
(2278·7 to 2582·3)
38·6
(30·3 to 47·1)*
7·9
(1·5 to 14·3)*
209·1
(150·2–271·4)
36·7
(28·6 to 45·3)*
6·2
(–0·1 to 12·7)
Nasopharynx cancer 732·7
(580·5 to 883·9)
18·0
(0·2 to 39·8)*
–5·5
(–19·2 to 11·1)
69·7
(47·2–95·8)
16·8
(0·8 to 36·0)*
–6·8
(–18·7 to 7·7)
Other pharynx cancer 945·5
(885·9 to 1015·0)
32·7
(23·8 to 41·5)*
2·2
(–4·5 to 9·0)
79·5
(57·8–104·3)
30·7
(21·9 to 39·2)*
0·6
(–6·2 to 7·2)
Oesophageal cancer 746·0
(641·5 to 925·7)
19·6
(2·5 to 39·9)*
–8·2
(–21·2 to 7·1)
128·6
(92·0–167·5)
9·5
(–3·1 to 24·1)
–16·1
(–25·4 to –5·2)*
Stomach cancer 3539·4
(3339·9 to 3776·2)
16·3
(8·9 to 24·4)*
–9·9
(–15·5 to –3·7)*
396·5
(292·4–504·2)
12·0
(4·8 to 20·2)*
–13·3
(–18·8 to –7·1)*
Colon and rectum cancer 9399·0
(9059·3 to 9758·3)
42·6
(38·1 to 47·2)*
8·7
(5·4 to 12·2)*
762·8
(564·2–979·6)
38·4
(33·7 to 43·3)*
5·3
(1·9 to 8·9)*
Colon and rectum 
cancer aggregate
9377·0
(9037·3 to 9736·4)
42·6
(38·1 to 47·3)*
8·7
(5·4 to 12·2)*
759·8
(561·9–975·3)
38·4
(33·7 to 43·3)*
5·4
(1·9 to 9·0)*
Stoma due to colon and 
rectum cancer
22·0
(21·3 to 22·8)
26·1
(25·0 to 27·2)*
–4·9
(–5·7 to –4·1)*
3·0
(2·0–4·1)*
26·0
(20·7 to 31·6)*
–4·7
(–9·4 to –0·0)*
Liver cancer 618·7
(550·7 to 688·0)
59·8
(38·2 to 82·2)*
23·6
(6·8 to 40·6)*
188·2
(130·4–245·6)
25·2
(9·9 to 45·0)*
–1·8
(–13·5 to 13·2)
Liver cancer due to 
hepatitis B
305·9
(235·8 to 418·9)
20·6
(–9·1 to 63·2)
–3·6
(–26·5 to 29·1)
59·9
(40·2–80·4)
9·5
(–8·3 to 34·1)
–12·5
(–26·5 to 6·1)
Liver cancer due to 
hepatitis C
268·7
(228·4 to 320·8)
80·1
(53·9 to 113·8)*
38·1
(17·1 to 65·1)*
44·3
(31·6–57·3)
47·7
(34·2 to 65·9)*
13·2
(2·7 to 27·7)*
Liver cancer due to 
alcohol use
273·6
(229·0 to 350·7)
58·8
(28·9 to 94·8)*
22·1
(–0·3 to 49·1)
53·5
(37·3–70·1)
39·3
(22·1 to 61·6)*
7·2
(–5·8 to 23·5)
Liver cancer due to other 
causes
151·0
(118·8 to 201·0)
24·9
(–5·6 to 63·5)
–2·0
(–26·3 to 29·5)
30·5
(20·7–40·6)
12·1
(–4·5 to 32·8)
–11·9
(–24·9 to 4·8)
Gallbladder and biliary 
tract cancer
149·4
(138·5 to 158·9)
22·0
(14·4 to 30·1)*
–7·4
(–13·2 to –1·3)*
39·5
(27·7–51·5)
19·0
(11·8 to 26·8)*
–9·5
(–15·1 to –3·7)*
Pancreatic cancer 393·8
(372·9 to 417·1)
46·2
(40·7 to 52·1)*
10·9
(6·7 to 15·4)*
86·6
(61·1–112·2)
38·4
(33·1 to 43·8)*
5·1
(1·1 to 9·3)*
Larynx cancer 1412·6
(1340·0 to 1499·9)
26·2
(20·1 to 33·0)*
–2·3
(–7·0 to 2·9)
147·3
(105·7–194·3)
24·0
(18·1 to 30·0)*
–3·9
(–8·4 to 0·7)
Larynx cancer aggregate 820·9
(749·1 to 911·1)
24·4
(14·2 to 35·8)*
–4·9
(–12·5 to 3·4)
93·6
(67·4–121·5)
21·5
(12·7 to 30·8)*
–6·8
(–13·1 to 0·2)
Laryngectomy due to 
larynx cancer
591·0
(576·5 to 605·4)
28·7
(28·0 to 29·3)*
1·8
(1·3 to 2·4)*
53·7
(35·8–77·6)
28·6
(25·8 to 31·4)*
1·9
(–0·2 to 4·1)
Tracheal, bronchus, and 
lung cancer
3299·7
(3095·1 to 3536·4)
37·7
(29·6 to 47·1)*
5·6
(–0·5 to 12·6)
513·6
(377·9–648·8)
31·1
(23·4 to 40·0)*
0·6
(–5·2 to 7·1)
Malignant skin melanoma 3082·3
(2475·8 to 3901·7)
59·0
(50·7 to 67·0)*
26·2
(19·5 to 32·6)*
180·5
(120·8–257·6)
56·3
(47·9 to 64·0)*
23·7
(16·9 to 29·9)*
Non-melanoma skin 
cancer
2558·2
(2494·8 to 2625·6)
76·8
(72·0 to 81·6)*
34·5
(30·8 to 38·2)*
148·0
(104·7–197·7)
82·9
(72·7 to 93·9)*
40·1
(31·9 to 48·7)*
Non-melanoma skin 
cancer (squamous-cell 
carcinoma)
2155·9
(2019·5 to 2312·2)
93·5
(82·2 to 105·8)*
49·6
(40·5 to 59·2)*
142·0
(100·7–187·1)
86·4
(75·6 to 98·2)*
42·8
(34·2 to 52·1)*
Non-melanoma skin 
cancer (basal-cell 
carcinoma)
578·1
(497·7 to 671·7)
27·0
(24·0 to 29·7)*
–3·9
(-6·0 to –1·8)*
6·0
(2·9–11·1)
26·9
(23·5 to 30·1)*
–3·8
(–6·4 to –1·2)*
Breast cancer 21 361·8
(20 249·5 to 22 266·3)
41·5
(33·4 to 49·6)*
9·9
(4·1 to 15·7)*
1796·5
(1270·7–2411·6)
36·1
(29·2 to 42·7)*
5·3
(0·4 to 10·1)*
Breast cancer aggregate 10 718·5
(9581·7 to 11 667·2)
62·7
(42·9 to 83·3)*
32·0
(16·2 to 48·1)*
989·8
(719·8–1271·0)
46·6
(32·7 to 61·5)*
15·8
(5·3 to 27·5)*
Mastectomy due to 
breast cancer
10 638·5
(10 404·8 to 10 894·5)
25·1
(24·1 to 26·1)*
–4·7
(–5·4 to –3·9)*
806·8
(520·3–1171·8)
25·1
(24·0 to 26·2)*
–4·6
(–5·5 to –3·8)*
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Cervical cancer 3442·4
(3129·9 to 3765·0)
–1·6
(–11·4 to 9·8)
–20·5
(–28·2 to –11·5)*
264·0
(187·9–342·6)
–1·4
(–10·9 to 9·8)
–20·5
(–28·0 to –11·6)*
Uterine cancer 3827·7
(3425·6 to 4285·2)
39·5
(22·9 to 55·9)*
8·2
(–4·0 to 20·0)
250·2
(172·4–341·0)
37·1
(21·1 to 52·9)*
6·1
(–5·4 to 17·6)
Ovarian cancer 1174·2
(1107·4 to 1250·1)
28·3
(20·8 to 36·3)*
0·3
(–5·1 to 6·3)
150·7
(110·5–192·3)
25·8
(17·8 to 33·9)*
–1·7
(–7·4 to 4·3)
Prostate cancer 14 434·4
(11 932·2 to 19 785·1)
70·6
(61·6 to 81·4)*
29·7
(22·5 to 38·4)*
1150·3
(804·9–1 643·3)
60·5
(51·7 to 70·6)*
21·5
(14·5 to 29·6)*
Prostate cancer 
aggregate
13 492·3
(10 984·7 to 18 837·5)
74·6
(64·7 to 86·3)*
32·5
(24·6 to 42·1)*
1069·7
(739·5–1 543·7)
63·5
(53·7 to 74·9)*
23·5
(15·8 to 32·6)*
Impotence and 
incontinence due to 
prostate cancer 
aggregate
942·0
(927·1 to 957·3)
29·0
(28·6 to 29·4)*
–0·9
(–1·2 to –0·5)*
80·6
(55·2–111·8)
28·9
(27·1 to 30·5)*
–1·0
(–2·4 to 0·2)
Testicular cancer 685·8
(634·7 to 732·4)
41·9
(30·8 to 52·4)*
23·4
(13·9 to 32·2)*
42·1
(28·4–58·3)
40·3
(29·3 to 50·6)*
21·5
(11·9 to 30·4)*
Kidney cancer 2870·3
(2728·0 to 3031·5)
57·9
(50·0 to 66·0)*
22·8
(16·8 to 29·1)*
202·7
(145·7–270·5)
54·4
(46·9 to 61·8)*
19·8
(14·0 to 25·6)*
Bladder cancer 3407·9
(3240·0 to 3603·3)
35·7
(28·6 to 43·3)*
3·3
(–2·0 to 9·0)
267·0
(193·7–349·4)
32·1
(25·8 to 38·8)*
0·7
(–4·0 to 5·6)
Bladder cancer episodes 
aggregate
3273·4
(3 105·3 to 3 470·7)
36·3
(28·9 to 44·3)*
3·7
(–1·8 to 9·6)
244·1
(176·2–317·4)
33·1
(26·1 to 40·4)*
1·2
(–3·9 to 6·7)
Urinary incontinence 
due to bladder cancer
134·3
(129·7 to 139·4)
22·8
(22·0 to 23·7)*
–5·7
(–6·2 to –5·1)*
22·9
(15·9–31·2)
23·0
(18·7 to 27·1)*
–5·3
(–8·6 to –2·2)*
Brain and nervous system 
cancer
1205·1
(1101·7 to 1322·9)
25·3
(14·9 to 37·6)*
4·2
(–3·9 to 13·8)
126·1
(90·3–164·5)
24·7
(15·0 to 36·3)*
2·8
(–4·7 to 12·0)
Thyroid cancer 3166·5
(2936·7 to 3340·6)
101·1
(86·4 to 112·9)*
60·8
(48·9 to 70·2)*
190·0
(132·5–259·3)
96·8
(81·6 to 109·2)*
56·5
(44·3 to 66·3)*
Mesothelioma 60·8
(58·1 to 63·6)
41·3
(35·1 to 47·7)*
9·5
(4·6 to 14·5)*
12·2
(8·7–15·8)
39·5
(32·1 to 46·8)*
7·9
(2·1 to 13·9)*
Hodgkin’s lymphoma 574·4
(519·0 to 672·9)
17·8
(10·5 to 25·3)*
0·0
(–6·1 to 6·4)
48·5
(33·7–65·8)
14·6
(7·4 to 21·7)*
–3·6
(–9·6 to 2·4)*
Non-Hodgkin lymphoma 4292·3
(3741·0 to 4593·6)
63·5
(47·5 to 74·3)*
30·5
(19·1 to 38·4)*
312·3
(221·8–414·2)
57·9
(43·8 to 67·8)*
25·6
(15·1 to 33·1)*
Multiple myeloma 488·2
(449·4 to 527·7)
54·6
(44·8 to 64·5)*
18·0
(10·7 to 25·4)*
104·0
(73·6–134·8)
49·0
(40·0 to 58·5)*
13·6
(6·9 to 21·0)*
Leukaemia 2303·6
(2216·1 to 2384·5)
35·8
(29·7 to 41·8)*
10·2
(5·7 to 14·8)*
379·4
(276·2–488·9)
28·6
(21·2 to 36·9)*
4·3
(–1·1 to 10·4)
Acute lymphoid 
leukaemia
875·5
(709·0 to 1072·3)
25·4
(7·3 to 46·4)*
10·2
(–5·0 to 27·8)
97·3
(68·0–129·8)
25·7
(11·5 to 40·8)*
8·1
(–3·1 to 20·0)
Chronic lymphoid 
leukaemia
904·0
(833·2 to 974·4)
31·7
(22·2 to 42·9)*
4·5
(–2·2 to 12·4)
119·8
(87·2–152·9)
27·6
(18·9 to 37·4)*
0·5
(–6·0 to 7·7)
Acute myeloid 
leukaemia
999·3
(882·5 to 1136·8)
38·4
(26·6 to 50·7)*
14·2
(5·7 to 23·5)*
120·9
(87·3–155·6)
36·5
(27·5 to 45·6)*
10·4
(3·7 to 17·4)*
Chronic myeloid 
leukaemia
297·7
(271·8 to 324·7)
22·2
(14·3 to 31·0)*
–3·4
(–9·3 to 3·4)
41·4
(29·5–53·6)
17·7
(10·2 to 26·0)*
–7·5
(–13·3 to –1·2)*
Other neoplasms 4577·5
(4145·5 to 4922·0)
36·1
(27·2 to 44·5)*
10·9
(4·1 to 17·6)*
323·2
(228·6–431·8)
34·4
(26·2 to 42·6)*
9·0
(2·4 to 15·4)*
Cardiovascular diseases 422 738·4
(415 534·5 to 
427 870·8)
24·8
(24·0 to 25·6)*
–1·8
(–2·5 to –1·2)*
25 620·1
(18 401·6–33 656·6)
23·5
(21·7 to 24·5)*
–2·2
(–3·2 to –1·7)*
Rheumatic heart disease 33 438·8
(29 725·7 to 43 119·8)
–4·7
(–11·0 to 0·1)
–16·3
(–22·5 to –12·1)*
1654·7
(1041·4–2530·9)
–3·4
(–9·9 to 1·4)
–15·4
(–21·5 to –11·1)*
Rheumatic heart 
disease, without heart 
failure
32 236·8
(28 520·8 to 41 912·7)
–5·6
(–11·9 to –0·8)*
–16·9
(–23·1 to –12·7)*
1518·6
(941·1–2356·4)
–5·5
(–11·7 to –0·6)*
–16·8
(–22·9 to –12·3)*
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Heart failure due to 
rheumatic heart disease 
aggregate
1202·0
(1138·2 to 1269·0)
29·8
(28·5 to 31·2)*
2·2
(1·3 to 3·2)*
136·1
(94·5–187·6)
29·6
(27·2 to 32·1)*
2·4
(0·6 to 4·2)*
Ischaemic heart disease 110 550·3
(100 675·9 to 121 798·7)
25·9
(24·6 to 27·2)*
–3·4
(–4·2 to –2·6)*
7274·7
(4958·6–9940·3)
30·2
(29·1 to 31·3)*
–0·3
(–1·0 to 0·3)
Myocardial infarction 
episodes aggregate
15 930·1
(14 106·5 to 17 764·0)
6·4
(1·9 to 10·6)*
–18·1
(–21·6 to –14·8)*
33·0
(23·0–44·9)
15·2
(12·6 to 17·9)*
–13·1
(–15·1 to –11·1)*
Angina due to ischaemic 
heart disease aggregate
72 344·6
(62 699·8 to 83 460·0)
29·3
(27·7 to 30·7)*
–0·3
(–1·2 to 0·5)
4794·5
(3100·7–6633·6)
29·5
(27·8 to 31·0)*
–0·0
(–1·0 to 0·8)
Heart failure due to 
ischaemic heart disease 
aggregate
22 275·7
(21 272·0 to 23 320·4)
31·9
(31·1 to 32·7)*
–0·6
(–1·2 to –0·1)*
2447·2
(1736·8–3342·6)
31·9
(31·0 to 32·8)*
–0·5
(–1·1 to 0·1)
Cerebrovascular disease 42 430·9
(42 068·2 to 42 767·1)
21·0
(20·4 to 21·5)*
–4·4
(–4·8 to –3·9)*
6455·2
(4487·0–8609·6)
20·7
(19·8 to 21·6)*
–4·2
(–4·9 to –3·5)*
Ischaemic stroke 24 929·0
(24 362·2 to 25 610·0)
21·8
(21·0 to 22·6)*
–5·2
(–5·8 to –4·6)*
3660·0
(2559·3–4874·9)
22·0
(21·0 to 23·0)*
–4·9
(–5·7 to –4·2)*
Chronic ischaemic 
stroke aggregate
24 663·2
(24 092·1 to 25 345·8)
21·9
(21·1 to 22·7)*
–5·1
(–5·8 to –4·5)*
3605·1
(2512·6–4815·3)
22·1
(21·1 to 23·1)*
–4·9
(–5·6 to –4·1)*
Ischaemic stroke 
episodes aggregate
265·8
(246·6 to 285·1)
16·8
(14·2 to 19·7)*
–10·6
(–12·7 to –8·5)*
54·9
(36·3–74·5)
17·5
(13·8 to 20·9)*
–10·0
(–12·9 to –7·2)*
 Haemorrhagic stroke 18 669·6
(18 258·7 to 19 124·5)
19·2
(18·5 to 19·9)*
–3·3
(–3·8 to –2·7)*
2795·2
(1945·8–3749·6)
19·1
(18·1 to 20·2)*
–3·1
(–3·9 to –2·3)*
Chronic haemorrhagic 
stroke aggregate
18 494·8
(18 088·5 to 18 959·5)
19·3
(18·6 to 19·9)*
–3·2
(–3·8 to –2·6)*
2757·3
(1918·2–3700·6)
19·2
(18·1 to 20·3)*
–3·0
(–3·8 to –2·2)*
Acute haemorrhagic 
stroke aggregate
174·8
(162·3 to 187·8)
14·3
(11·6 to 16·6)*
–9·1
(–11·1 to –7·3)*
37·9
(24·7–51·2)
14·6
(11·8 to 17·0)*
–8·8
(–11·0 to –6·9)*
Hypertensive heart disease 6086·2
(5732·7 to 6434·1)
37·1
(36·2 to 37·9)*
3·4
(2·9 to 3·9)*
670·0
(467·1–917·1)
37·2
(35·9 to 38·4)*
3·6
(2·8 to 4·4)*
Cardiomyopathy and 
myocarditis
2536·8
(2404·8 to 2661·4)
26·7
(25·6 to 27·7)*
–1·3
(–2·0 to –0·7)*
275·1
(190·3–377·9)
26·3
(24·6 to 28·1)*
–1·3
(–2·5 to –0·2)*
Acute myocarditis 156·3
(137·1 to 179·6)
21·4
(19·1 to 23·7)*
2·2
(1·3 to 3·1)*
7·8
(4·8–11·6)
21·1
(18·5 to 23·9)*
2·1
(0·3 to 3·8)*
Heart failure due to 
cardiomyopathy 
aggregate
2380·4
(2254·3 to 2502·2)
27·0
(25·9 to 28·1)*
–1·5
(–2·2 to –0·9)*
267·3
(185·9–367·9)
26·5
(24·7 to 28·3)*
–1·4
(-2·6 to -0·2)*
Atrial ﬁ brillation and 
ﬂ utter
33 294·3
(29 959·8 to 37 202·0)
28·2
(27·2 to 29·1)*
–2·5
(–3·1 to –1·9)*
2634·6
(1782·6–3637·3)
28·2
(27·1 to 29·3)*
–2·4
(–3·1 to –1·7)*
Peripheral vascular disease 154 650·6
(136 318·0 to 176 210·9)
34·4
(33·4 to 35·2)*
1·8
(1·3 to 2·3)*
572·8
(272·1–1056·2)
34·5
(32·4 to 36·8)*
2·0
(1·2 to 2·8)*
Endocarditis 115·7
(108·1 to 124·8)
22·7
(20·9 to 24·5)*
–5·4
(–6·7 to –4·1)*
12·3
(8·5–17·1)
22·9
(18·6 to 27·6)*
–5·2
(–8·8 to –1·2)*
Endocarditis episodes 
aggregate
16·9
(15·7 to 18·2)
22·8
(20·3 to 25·3)*
–0·7
(–2·7 to 1·2)
1·0
(0·6–1·4)
22·7
(20·0 to 25·3)*
–0·9
(–3·1 to 1·2)
Heart failure due to 
endocarditis aggregate
98·8
(91·1 to 107·6)
22·7
(20·7 to 24·7)*
–6·1
(–7·6 to –4·6)*
11·4
(7·9–15·9)
22·9
(18·3 to 28·0)*
–5·5
(–9·3 to –1·2)*
Heart failure due to 
other cardiovascular 
diseases aggregate
1126·5
(1045·9 to 1206·1)
34·4
(33·3 to 35·6)*
1·2
(0·4 to 2·0)*
123·7
(86·0–173·3)
34·4
(32·5 to 36·5)*
1·3
(–0·2 to 2·7)
Other cardiovascular 
diseases episodes 
aggregate
89 221·1
(83 635·8 to 95 470·4)
24·0
(22·6 to 25·4)*
0·4
(–0·2 to 1·0)*
5947·0
(4074·6–8105·9)
23·7
(22·2 to 25·2)*
0·5
(–0·2 to 1·1)
Chronic respiratory 
diseases
514 625·8
(503 322·3 to 527 617·0)
12·1
(11·1 to 13·1)*
–3·3
(–4·1 to –2·4)*
30 465·9
(23 341·4–38 294·2)
11·8
(10·2 to 13·6)*
–4·6
(–6·2 to –3·1)*
Chronic obstructive 
pulmonary disease
174 483·1
(160 204·9 to 188 951·7)
17·0
(15·1 to 19·0)*
–5·8
(–7·3 to –4·4)*
12 047·0
(10 206·8–13 725·4)
16·2
(13·4 to 18·8)*
–5·9
(–8·0 to –3·9)*
(Table 3 continues on next page)
Articles
www.thelancet.com   Vol 388   October 8, 2016 1565
Prevalence (thousands) YLDs (thousands)
2015 Percentage change in 
counts between 2005 
and 2015
Percentage change in 
ASR between 2005 and 
2015
2015 Percentage change in 
counts between 2005 
and 2015
Percentage change in 
ASR between 2005 
and 2015
(Continued from previous page)
Chronic obstructive 
pulmonary disease 
without heart failure 
aggregate
168 694·6
(154 443·1 to 182 957·1)
16·5
(14·5 to 18·5)*
–6·1
(–7·6 to –4·6)*
9671·6
(8183·6–11 080·9)
12·3
(9·2 to 15·3)*
–8·0
(–10·5 to –5·6)*
Severe chronic 
obstructive pulmonary 
disease with heart 
failure aggregate
5876·4
(5073·7 to 6548·3)
34·9
(31·1 to 37·8)*
2·4
(–0·3 to 4·2)
2375·5
(1890·3–2747·2)
35·1
(31·4 to 38·2)*
2·5
(–0·0 to 4·5)
Pneumoconiosis 2405·8
(2317·2 to 2486·3)
30·3
(27·8 to 32·9)*
8·2
(6·2 to 10·2)*
474·0
(305·6–682·6)
26·6
(23·6 to 29·3)*
6·0
(3·6 to 8·4)*
Silicosis 402·9
(364·9 to 442·2)
18·1
(15·7 to 20·3)*
–4·3
(–6·1 to –2·6)*
65·7
(41·7–95·4)
18·5
(14·5 to 22·4)*
–3·9
(–7·0 to –0·9)*
Silicosis without heart 
failure aggregate
389·0
(351·0 to 426·8)
17·6
(15·2 to 19·9)*
–4·6
(–6·4 to –2·8)*
59·2
(36·8–87·9)
17·1
(12·7 to 21·3)*
–4·7
(–8·0 to –1·5)*
Severe silicosis with 
heart failure 
aggregate
13·9
(12·0 to 15·6)
32·2
(29·1 to 34·8)*
1·5
(–0·5 to 3·3)
6·4
(4·5–8·5)
33·1
(26·9 to 40·5)*
2·3
(–2·7 to 7·9)
Asbestosis 157·3
(144·8 to 170·9)
30·6
(28·8 to 32·6)*
2·7
(1·3 to 4·1)*
24·8
(16·0–35·6)
30·2
(27·0 to 33·6)*
2·5
(–0·1 to 5·2)
Asbestosis without 
heart failure 
aggregate
154·5
(141·8 to 168·1)
30·6
(28·7 to 32·5)*
2·7
(1·3 to 4·1)*
23·5
(15·0–34·0)
29·9
(26·4 to 33·4)*
2·5
(–0·2 to 5·4)
Severe asbestosis with 
heart failure 
aggregate
2·8
(2·6 to 3·0)
35·6
(34·2 to 37·1)*
1·1
(0·1 to 2·1)*
1·3
(0·9–1·7)*
35·7
(31·3 to 40·0)*
1·3
(–2·2 to 4·7)
Coal workers 
pneumoconiosis
84·2
(76·7 to 93·6)
37·0
(34·1 to 39·9)*
7·6
(5·2 to 10·0)*
13·3
(8·4–19·1)*
36·3
(29·4 to 43·4)*
7·0
(1·3 to 12·9)*
Coal workers 
pneumoconiosis 
without heart failure 
aggregate
82·3
(74·9 to 91·7)
36·9
(34·0 to 39·8)*
7·5
(5·2 to 10·0)*
12·4
(7·8–17·9)*
36·0
(28·6 to 43·5)*
6·9
(0·9 to 13·2)*
Severe coal workers 
pneumoconiosis with 
heart failure 
aggregate
1·9
(1·6 to 2·1)
41·6
(37·8 to 45·1)*
8·2
(5·4 to 10·9)*
0·9
(0·6–1·2)*
41·6
(37·7 to 45·2)*
8·2
(5·2 to 10·9)*
Other pneumoconiosis 2388·6
(2164·7 to 2629·1)
27·9
(25·3 to 30·7)*
8·3
(6·0 to 10·5)*
370·2
(239·2–533·9)*
27·5
(23·9 to 31·0)*
8·3
(5·3 to 11·2)*
Other 
pneumoconiosis 
without heart failure 
aggregate
2374·2
(2150·3 to 2615·1)
27·8
(25·2 to 30·7)*
8·3
(6·0 to 10·6)*
363·6
(234·0–524·9)*
27·3
(23·6 to 30·8)*
8·4
(5·3 to 11·4)*
Severe other 
pneumoconiosis with 
heart failure 
aggregate
14·4
(13·1 to 15·6)
41·1
(39·0 to 43·0)*
4·5
(3·4 to 5·5)*
6·5
(4·6–8·5)
40·5
(35·1 to 45·7)*
4·3
(0·3 to 8·4)*
Asthma 358 197·9
(323 133·7 to 393 465·6)
9·5
(7·6 to 11·6)*
–2·5
(–4·3 to –0·5)*
15 898·9
(10 371·0–22 344·1)
9·4
(7·4 to 11·5)*
–2·3
(–4·3 to –0·3)*
Asymptomatic asthma 108 461·1
(92 842·5 to 126 250·5)
9·5
(7·6 to 11·6)*
–2·5
(–4·3 to –0·5)*
0·0
(0·0–0·0)
0·0
(0·0 to 0·0)
0·0
(0·0 to 0·0)
Symptomatic asthma 
aggregate
249 736·8
(220 469·6 to 278 419·7)
9·5
(7·6 to 11·6)*
–2·5
(–4·3 to –0·5)*
15 898·9
(10 371·0–22 344·1)
9·4
(7·4 to 11·5)*
–2·3
(–4·3 to –0·3)*
Interstitial lung disease 
and pulmonary sarcoidosis
1916·0
(1757·4 to 2075·5)
25·8
(23·8 to 27·7)*
0·6
(–0·9 to 2·1)
234·7
(147·5–334·2)
25·7
(23·5 to 28·1)*
0·7
(–1·1 to 2·6)
Interstitial lung disease 
and pulmonary 
sarcoidosis without 
heart failure aggregate
1718·7
(1565·7 to 1881·0)
25·2
(23·1 to 27·2)*
0·5
(–1·1 to 2·1)
148·5
(88·8–221·4)
22·7
(19·6 to 25·9)*
0·2
(–2·2 to 2·6)
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Severe interstitial lung 
disease and pulmonary 
sarcoidosis with heart 
failure aggregate
197·4
(144·1 to 242·7)
31·5
(29·7 to 33·2)*
1·3
(–0·1 to 2·9)
86·2
(54·8–117·6)
31·3
(28·6 to 34·1)*
1·3
(–1·0 to 3·7)
Other chronic respiratory 
diseases
·· ·· ·· 1811·3
(1483·7–2123·4)
1·7
(–7·3 to 12·2)
–15·8
(–23·5 to –6·9)*
Cirrhosis and other chronic 
liver diseases
2828·3
(2791·3 to 2862·3)*
34·0
(32·4 to 35·8)*
8·2
(7·0 to 9·5)*
501·0
(352·9–683·1)
31·3
(29·8 to 32·9)*
7·3
(6·1 to 8·4)*
Cirrhosis and other 
chronic liver diseases due 
to hepatitis B
796·5
(737·6 to 857·3)
30·5
(28·4 to 32·7)*
4·7
(3·2 to 6·2)*
130·6
(88·7–178·7)
30·5
(27·0 to 33·8)*
4·8
(2·2 to 7·3)*
Cirrhosis and other 
chronic liver diseases due 
to hepatitis C
680·8
(628·3 to 734·2)
35·3
(33·0 to 37·5)*
7·6
(6·0 to 9·1)*
111·4
(78·2–152·6)
35·2
(31·6 to 38·6)*
7·6
(5·0 to 10·3)*
Cirrhosis and other 
chronic liver diseases due 
to alcohol use
815·6
(758·7 to 877·2)
37·3
(35·4 to 39·3)*
9·8
(8·5 to 11·2)*
133·9
(92·5–185·1)
37·2
(33·9 to 40·5)*
9·9
(7·5 to 12·4)*
Cirrhosis and other 
chronic liver diseases due 
to other causes
750·3
(714·3 to 785·9)
23·8
(22·5 to 25·1)*
6·8
(5·9 to 7·6)*
125·0
(87·5–172·2)
23·3
(20·1 to 26·8)*
6·8
(4·2 to 9·5)*
Digestive diseases 258 248·2
(255 386·4 to 
260 843·9)
12·3
(10·9 to 13·7)*
–9·4
(–10·4 to –8·3)*
12 142·8
(8 492·0–16 592·5)
11·4
(9·8 to 13·2)*
–9·3
(–10·6 to –7·9)*
Peptic ulcer disease 72 044·2
(71 302·7 to 72 763·7)
4·8
(3·7 to 6·0)*
–17·0
(–17·8 to –16·0)*
2341·7
(1605·6–3293·6)
1·1
(–0·2 to 2·5)
–19·5
(–20·6 to –18·4)*
Peptic ulcer disease 
symptomatic episodes
4977·7
(4577·6 to 5379·5)
4·7
(2·4 to 6·9)*
–16·7
(–18·4 to –15·0)*
518·7
(357·9–703·2)
4·5
(2·2 to 6·8)*
–16·7
(–18·5 to –14·9)*
Anaemia due to peptic 
ulcer disease aggregate
67 066·6
(66 465·4 to 67 616·9)
4·8
(3·7 to 6·1)*
–17·0
(–17·9 to –16·0)*
1823·1
(1225·8–2621·2)
0·2
(–1·4 to 1·9)
–20·3
(–21·6 to –19·0)*
Gastritis and duodenitis 161 001·1
(157 928·3 to 164 071·1)
15·5
(13·0 to 17·9)*
–6·9
(–8·8 to –5·0)*
4913·0
(3347·3–6967·1)
11·2
(8·0 to 14·6)*
–9·5
(–11·9 to –6·9)*
Gastritis and duodenitis, 
symptomatic episodes
3941·0
(3547·0 to 4358·9)
15·4
(10·9 to 17·3)*
–6·9
(–10·8 to –5·7)*
416·0
(277·1–567·9)
15·4
(11·2 to 17·5)*
–6·7
(–10·6 to –5·2)*
Anaemia due to gastritis 
and duodenitis 
aggregate
157 060·1
(154 055·1 to 160 141·0)
15·5
(12·9 to 17·9)*
–6·9
(–8·9 to –5·0)*
4497·1
(3050·6–6393·0)
10·8
(7·4 to 14·5)*
–9·8
(–12·4 to –7·0)*
Appendicitis 442·1
(414·6 to 472·3)
14·3
(13·4 to 15·2)*
2·8
(2·1 to 3·4)*
136·0
(92·0–184·6)
14·4
(10·6 to 18·0)*
3·0
(–0·2 to 6·1)
Paralytic ileus and 
intestinal obstruction
119·7
(110·7 to 130·4)
18·9
(16·9 to 20·7)*
–1·3
(–2·8 to –0·0)*
37·3
(25·1–51·1)
18·6
(15·9 to 21·2)*
–1·1
(–3·4 to 1·2)
Inguinal, femoral, and 
abdominal hernia
 18 476·7
(16 577·2 to 20 339·8)
6·5
(4·2 to 8·6)*
–10·6
(–12·4 to –9·0)*
195·8
(97·0–363·1)
6·5
(4·3 to 8·7)*
–10·4
(–12·2 to –8·8)*
Inﬂ ammatory bowel 
disease
11 223·5
(10 396·8 to 12 000·4)
15·7
(15·0 to 16·3)*
–3·7
(–4·1 to –3·4)*
2387·1
(1653·2–3 263·5)
15·6
(14·7 to 16·4)*
–3·6
(–4·2 to –3·0)*
Vascular intestinal 
disorders
35·1
(32·4 to 38·1)
23·3
(21·0 to 25·8)*
–2·4
(–4·1 to –0·6)*
11·0
(7·4–14·8)
23·4
(19·7 to 27·2)*
–2·0
(–5·2 to 1·2)
Gallbladder and biliary 
diseases
5656·5
(5199·3 to 6168·1)
16·9
(14·5 to 19·2)*
–4·1
(–5·9 to –2·2)*
601·0
(409·4–826·4)
16·8
(14·2 to 19·3)*
–3·9
(–5·9 to –1·9)*
Pancreatitis 1018·2
(941·6 to 1 097·4)
24·2
(21·7 to 26·5)*
1·9
(–0·0 to 3·7)
300·0
(203·4–406·7)
24·0
(20·3 to 27·4)*
2·0
(–0·8 to 4·6)
Other digestive diseases ·· ·· ·· 1219·9
(838·5–1677·5)
21·9
(14·4 to 32·4)*
–1·0
(–7·1 to 7·4)
Neurological disorders 2 261 316·4
(2 204 366·6 to 
2 316 282·6)
15·5
(14·6 to 16·4)*
0·5
(–0·3 to 1·2)
59 325·6
(40 845·0–81 083·3)
15·6
(14·3 to 16·9)*
–1·4
(–2·4 to –0·4)*
Alzheimer’s disease and 
other dementias
45 956·3
(40 178·5 to 52 655·9)
37·7
(36·2 to 39·0)*
1·1
(0·3 to 1·8)*
6851·2
(4883·9–9062·8)
38·8
(37·1 to 40·5)*
1·1
(0·2 to 1·8)*
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Parkinson’s disease 6193·3
(5725·7 to 6777·2)
31·6
(28·2 to 35·5)*
0·6
(–1·9 to 3·5)
737·8
(516·1–990·1)
31·4
(27·8 to 35·3)*
0·7
(–2·1 to 3·7)
Epilepsy 23 414·5
(21 549·6 to 25 419·4)
11·3
(7·0 to 15·5)*
–1·1
(–5·0 to 2·7)
6286·9
(4315·8–8250·2)
–6·4
(–11·5 to –1·2)*
–16·3
(–20·9 to –11·6)*
Multiple sclerosis 2012·0
(1865·7 to 2166·9)
19·1
(17·0 to 21·3)*
–2·0
(–3·9 to –0·3)*
667·5
(472·0–855·6)
18·8
(16·2 to 21·5)*
–2·0
(–4·2 to 0·1)
Motor neuron disease 202·4
(189·7 to 216·0)
22·3
(19·9 to 24·8)*
–1·3
(–3·3 to 0·7)
42·3
(30·5–55·1)
22·1
(19·5 to 24·8)*
–1·4
(–3·5 to 0·8)
Migraine 958 789·2
(872 109·0 to 
1 055 630·6)
15·3
(14·0 to 16·6)*
0·6
(–0·3 to 1·5)
32 898·8
(20 303·6–48 883·2)
15·3
(14·0 to 16·6)*
0·8
(–0·1 to 1·8)
Tension-type headache 1 505 892·3
(1 337 310·0 to 
1 681 575·0)
15·3
(14·0 to 16·6)*
0·5
(–0·1 to 1·1)
2260·5
(1058·1–4169·7)
15·3
(14·0 to 16·7)*
0·6
(–0·1 to 1·3)
Medication overuse 
headache
58 454·5
(50 834·9 to 67 363·9)
19·0
(15·4 to 22·7)*
0·4
(–2·4 to 3·3)
9164·7
(6094·5–13 078·0)
18·9
(15·4 to 22·8)*
0·6
(–2·3 to 3·5)
Other neurological 
disorders
11·5
(9·1 to 14·6)
17·0
(14·8 to 19·6)*
–0·2
(–0·9 to 0·4)
415·9
(301·2–547·5)
32·2
(27·5 to 36·3)*
–2·1
(–5·3 to 0·9)
Mental and substance use 
disorders
1 058 903·8
(1 038 544·9 to 
1 080 413·8)
14·3
(13·6 to 14·9)*
0·3
(–0·3 to 0·9)
149 977·9
(108 716·1–193 130·8)
16·1
(15·5 to 16·8)*
1·1
(0·7 to 1·4)*
Schizophrenia 23 383·0
(20 608·0 to 26 418·4)
19·5
(18·6 to 20·4)*
0·1
(–0·4 to 0·6)
15 020·5
(10 816·1–18 623·2)
19·5
(18·5 to 20·4)*
0·3
(–0·4 to 0·9)
Alcohol use disorders 63 469·5
(57 507·8 to 69 863·5)
11·1
(8·9 to 13·5)*
–4·6
(–6·5 to –2·4)*
6321·3
(4205·6–8985·8)*
11·1
(9·0 to 13·6)*
–4·5
(–6·4 to –2·3)*
Alcohol dependence 
aggregate
62 575·3
(56 621·7 to 68 944·3)
11·1
(8·9 to 13·5)*
–4·6
(–6·6 to –2·5)*
6276·2
(4167·7–8929·7)
11·1
(8·9 to 13·6)*
–4·5
(–6·5 to –2·3)*
Fetal alcohol syndrome 
aggregate
894·2
(833·3 to 951·9)
11·1
(10·3 to 11·7)*
–0·5
(–1·1 to 0·2)
45·1
(29·2–65·1)
10·7
(8·2 to 13·1)*
–0·6
(–2·7 to 1·6)
Drug use disorders 46 388·6
(45 252·4 to 47 446·6)
16·3
(15·0 to 17·6)*
3·9
(2·8 to 5·0)*
9849·4
(6959·0–12775·2)
23·6
(21·5 to 25·9)*
8·2
(6·2 to 10·2)*
Opioid use disorders 16 746·5
(14 659·3 to 19 107·5)
23·3
(20·7 to 26·0)*
6·4
(4·2 to 8·6)*
6969·6
(4842·5–8999·8)
23·3
(20·6 to 26·2)*
6·5
(4·2 to 9·0)*
Asymptomatic opioid 
dependence
2716·8
(1979·9 to 3704·4)
23·3
(20·7 to 26·0)*
6·4
(4·2 to 8·6)*
0·0
(0·0–0·0)
0·0
(0·0 to 0·0)
0·0
(0·0 to 0·0)*
Symptomatic opioid 
dependence 
aggregate
14 029·7
(12 042·2 to 16 122·8)
23·3
(20·7 to 26·0)*
6·4
(4·2 to 8·6)*
6969·6
(4842·5–8999·8)
23·3
(20·6 to 26·2)*
6·5
(4·2 to 9·0)
Cocaine use disorders 3846·3
(3401·6 to 4309·8)
31·1
(28·0 to 34·3)*
14·1
(12·0 to 16·4)*
521·5
(329·0–733·9)
30·6
(27·2 to 34·4)*
14·0
(11·4 to 17·0)*
Asymptomatic 
cocaine dependence
1927·8
(1544·3 to 2357·8)
31·1
(28·0 to 34·3)*
14·1
(12·0 to 16·4)*
0·0
(0·0–0·0)
0·0
(0·0 to 0·0)
0·0
(0·0 to 0·0)
Symptomatic cocaine 
dependence 
aggregate
1918·5
(1542·1 to 2341·9)
31·1
(28·0 to 34·3)*
14·1
(12·0 to 16·4)*
521·5
(329·0–733·9)
30·6
(27·2 to 34·4)*
14·0
(11·4 to 17·0)*
Amphetamine use 
disorders
6599·8
(5295·7 to 8024·4)
30·4
(27·0 to 34·2)*
19·2
(16·1 to 22·5)*
874·7
(513·4–1308·7)
30·3
(26·1 to 34·8)*
19·1
(15·5 to 23·0)*
Asymptomatic 
amphetamine 
dependence
3613·7
(2722·6 to 4630·7)
30·4
(27·0 to 34·2)*
19·2
(16·1 to 22·5)*
0·0
(0·0–0·0)
0·0
(0·0 to 0·0)
0·0
(0·0 to 0·0)
Symptomatic 
amphetamine 
dependence 
aggregate
2986·1
(2186·5 to 3 893·0)
30·4
(27·0 to 34·2)*
19·2
(16·1 to 22·5)*
874·7
(513·4–1 308·7)
30·3
(26·1 to 34·8)*
19·1
(15·5 to 23·0)*
Cannabis use disorders 19 762·5
(17 982·4 to 21 770·2)
5·3
(4·0 to 6·5)*
–3·8
(–4·7 to –2·9)*
577·2
(371·8–816·2)
5·3
(3·7 to 7·1)*
–3·7
(–5·0 to –2·3)*
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Asymptomatic 
cannabis dependence
11 430·9
(10 159·4 to 12 892·9)
5·3
(4·0 to 6·5)*
–3·8
(–4·7 to –2·9)*
0·0
(0·0–0·0)
0·0
(0·0 to 0·0)
0·0
(0·0 to 0·0)
Symptomatic 
cannabis dependence 
aggregate
8331·6
(7244·3 to 9593·1)
5·3
(4·0 to 6·5)*
–3·8
(–4·7 to –2·9)*
577·2
(371·8–816·2)
5·3
(3·7 to 7·1)*
–3·7
(–5·0 to –2·3)*
Other drug use disorders  ·· ·· ·· 906·4
(550·1–1 312·1)
30·5
(25·7 to 35·6)*
17·2
(12·9 to 21·7)*
Depressive disorders 311 147·6
(300 016·8 to 320 544·3)
18·4
(17·2 to 19·5)*
0·7
(–0·3 to 1·6)
54 255·4
(37 569·9–72 943·3)
18·2
(17·2 to 19·2)*
1·0
(0·5 to 1·5)*
Major depressive 
disorder
216 047·0
(192 863·4 to 243 319·4)
17·8
(16·6 to 19·0)*
0·8
(0·2 to 1·4)*
44 224·4
(29 672·5–60 297·0)
17·8
(16·6 to 19·0)*
1·1
(0·5 to 1·7)*
Dysthymia 104 106·3
(90 398·1 to 118 968·9)
19·9
(18·4 to 21·5)*
0·6
(–0·3 to 1·4)
10 031·0
(6 605·9–14 267·1)
19·8
(18·3 to 21·5)*
0·7
(–0·2 to 1·6)
Bipolar disorder 44 015·8
(38 150·4 to 50 912·5)
14·9
(14·1 to 15·8)*
0·3
(0·1 to 0·5)*
9004·7
(5501·7–13 388·0)
14·9
(13·9 to 15·9)*
0·5
(–0·0 to 0·9)
Anxiety disorders 267 202·4
(234 064·3 to 306 318·0)
14·9
(13·0 to 16·8)*
0·8
(–0·5 to 2·1)
24 643·0
(16 813·7–33 647·8)
14·8
(12·8 to 16·6)*
1·0
(–0·4 to 2·3)
Eating disorders 6468·4
(6170·6 to 6753·6)
19·1
(16·5 to 21·8)*
9·9
(7·5 to 12·4)*
1386·1
(915·9–1941·2)
19·0
(16·9 to 21·2)*
10·0
(8·1 to 11·9)*
Anorexia nervosa 2912·1
(2357·7 to 3596·2)
12·0
(9·3 to 14·8)*
5·1
(2·6 to 7·6)*
620·5
(411·3–897·7)
12·1
(9·0 to 15·1)*
5·2
(2·3 to 8·0)*
Bulimia nervosa 3629·4
(2937·5 to 4406·8)
25·3
(23·6 to 27·1)*
14·2
(12·5 to 15·8)*
765·6
(490·0–1108·5)
25·3
(23·2 to 27·6)*
14·2
(12·2 to 16·2)*
Autistic spectrum 
disorders
62 212·4
(58 979·0 to 64 744·3)
12·3
(10·5 to 14·1)*
0·3
(–1·2 to 1·9)
10 051·5
(6740·1–13800·3)
12·3
(11·9 to 12·8)*
0·6
(0·2 to 0·9)*
Autism 24 790·1
(20 957·6 to 29 393·1)
12·6
(12·2 to 12·9)*
0·5
(0·3 to 0·7)*
6335·9
(4112·0–8916·1)
12·5
(11·9 to 13·1)*
0·7
(0·2 to 1·2)*
Asperger syndrome and 
other autistic spectrum 
disorders
37 245·4
(31 510·5 to 44 883·1)
12·1
(11·8 to 12·4)*
0·2
(0·1 to 0·3)*
3715·6
(2479·6–5424·6)
12·0
(11·5 to 12·5)*
0·3
(–0·1 to 0·7)
Attention-deﬁ cit or 
hyperactivity disorder
51 094·3
(46 162·4 to 57 267·7)
0·3
(–0·4 to 1·0)
–3·6
(–4·2 to –3·0)*
620·1
(370·1–947·7)
0·4
(–0·6 to 1·2)
–3·5
(–4·4 to –2·8)*
Conduct disorder 48 135·5
(39 315·2 to 58 151·6)
0·4
(–0·1 to 1·1)
1·3
(0·9 to 1·6)*
5770·5
(3485·2–8955·7)
0·5
(–0·3 to 1·4)
1·4
(0·7 to 2·0)*
Idiopathic developmental 
intellectual disability
92 074·0
(52 280·1 to 130 411·2)
10·9
(9·5 to 11·9)*
1·0
(0·0 to 1·8)*
3442·1
(1506·4–5996·9)
10·3
(8·2 to 11·4)*
0·2
(–1·5 to 1·2)
Other mental and 
substance use disorders
128 178·3
(127 512·5 to 128 877·2)
18·8
(17·9 to 19·7)*
0·2
(–0·6 to 0·9)
9613·4
(6699·7–12 951·9)
18·7
(17·7 to 19·8)*
0·3
(–0·6 to 1·1)
Diabetes, urogenital, 
blood, and endocrine 
diseases
2 944 626·8
(2 925 016·2 to 
2 968 511·3)
15·5
(14·7 to 16·1)*
–0·3
(–0·9 to 0·3)
66 092·7
(46 781·5–88 865·8)
22·3
(20·8 to 24·0)*
1·2
(0·1 to 2·3)*
Diabetes 435 328·4
(404 736·1 to 468 562·4)
30·6
(28·0 to 33·0)*
4·5
(2·4 to 6·4)*
33 360·8
(23 043·5–45 530·8)
32·5
(29·7 to 35·3)*
5·4
(3·2 to 7·5)*
Uncomplicated diabetes 271 713·6
(241 414·2 to 302 381·7)
27·8
(24·9 to 30·4)*
3·2
(1·1 to 5·3)*
12 599·0
(7979·9–18 394·2)
27·7
(24·8 to 30·3)*
3·3
(1·2 to 5·4)*
Neuropathy and other 
complications of 
diabetes aggregate
159 067·7
(134 666·7 to 187 174·0)
35·6
(32·2 to 38·8)*
6·6
(4·1 to 9·0)*
20 459·6
(13 572·0–28 749·6)
35·6
(32·3 to 38·8)*
6·7
(4·2 to 9·0)*
Vision loss due to 
diabetes aggregate
4547·1
(3823·8 to 5416·0)
34·7
(32·4 to 36·9)*
5·0
(3·6 to 6·3)*
302·3
(210·1–415·5)
36·1
(33·6 to 38·7)*
5·7
(4·1 to 7·4)*
Acute glomerulonephritis 100·5
(92·1 to 110·1)
–0·9
(–4·4 to 1·9)
–14·5
(–17·3 to –12·6)*
5·0
(3·2–7·5)
–0·6
(–4·6 to 2·8)
–14·1
(–17·4 to –11·4)*
Chronic kidney disease 322 510·6
(312 718·2 to 330 351·1)
26·9
(25·8 to 28·0)*
0·9
(–0·0 to 1·8)
8172·8
(6118·6–10 229·3)
23·8
(22·9 to 24·8)*
0·1
(–0·4 to 0·6)
Chronic kidney disease 
due to diabetes 
100 823·9
(86 922·7 to 115 652·3)
27·3
(24·9 to 29·9)*
2·1
(0·5 to 3·7)*
2456·1
(1780·4–3151·2)
23·0
(20·7 to 25·4)*
0·6
(–0·7 to 2·0)
(Table 3 continues on next page)
Articles
www.thelancet.com   Vol 388   October 8, 2016 1569
Prevalence (thousands) YLDs (thousands)
2015 Percentage change in 
counts between 2005 
and 2015
Percentage change in 
ASR between 2005 and 
2015
2015 Percentage change in 
counts between 2005 
and 2015
Percentage change in 
ASR between 2005 
and 2015
(Continued from previous page)
Stage 3 chronic kidney 
disease due to 
diabetes aggregate
90 937·7
(77 906·5 to 104 617·0)
27·9
(25·4 to 30·5)*
2·3
(0·6 to 4·0)*
119·6
(79·7–175·5)
11·8
(6·5 to 16·7)*
–6·3
(–10·0 to –2·8)*
Stage 4 chronic 
kidney disease due to 
diabetes aggregate
6441·3
(5521·3 to 7401·3)
21·6
(19·1 to 24·2)*
0·9
(–0·4 to 2·2)
787·7
(541·8–1 106·1)
20·2
(17·6 to 22·7)*
0·4
(–1·0 to 1·8)
Stage 5 chronic kidney 
disease untreated due 
to diabetes 
2694·4
(2331·9 to 3091·5)
25·6
(23·0 to 28·2)*
1·3
(–0·0 to 2·8)
1359·3
(920·5–1791·4)
25·3
(22·4 to 28·4)*
1·4
(–0·3 to 3·2)
End-stage chronic 
kidney disease due to 
diabetes aggregate
750·5
(643·3 to 864·2)
19·8
(16·4 to 23·4)*
–3·0
(–5·2 to –0·7)*
189·5
(130·5–252·0)
26·6
(22·3 to 30·9)*
0·7
(–2·1 to 3·7)
Chronic kidney disease 
due to hypertension
78 962·3
(67 846·7 to 91 021·2)
26·0
(23·6 to 28·6)*
0·2
(–1·4 to 1·9)
1508·0
(1108·7–1938·1)
28·5
(25·8 to 31·5)*
1·2
(–0·6 to 3·3)
Stage 3 chronic kidney 
disease due to 
hypertension 
aggregate
72 772·4
(61 662·5 to 84 498·2)
25·9
(23·3 to 28·6)*
0·2
(–1·6 to 2·0)
80·8
(54·2–120·1)
22·1
(17·5 to 26·6)*
–4·4
(–8·0 to –0·9)*
Stage 4 chronic 
kidney disease due to 
hypertension 
aggregate
4102·2
(3503·5 to 4772·6)
25·9
(22·4 to 29·5)*
0·7
(–1·6 to 2·8)
489·8
(341·4–696·7)
25·2
(22·1 to 28·7)*
0·5
(–1·5 to 2·5)
Stage 5 chronic kidney 
disease untreated due 
to hypertension
1652·2
(1404·5 to 1913·7)
30·7
(27·5 to 34·2)*
1·8
(–0·5 to 4·1)
816·8
(565·2–1060·3)
30·5
(27·0 to 34·5)*
2·0
(–0·5 to 4·7)
  End-stage chronic    
kidney disease due to   
hypertension 
aggregate
435·5
(363·3 to 509·1)
27·5
(22·0 to 33·6)*
0·6
(–3·1 to 4·9)
120·6
(83·1–162·3)
33·2
(27·4 to 39·8)*
3·8
(–0·3 to 8·9)
Chronic kidney disease 
due to 
glomerulonephritis
67 348·7
(58 198·9 to 77 439·5)
28·9
(25·8 to 32·3)*
1·1
(–1·1 to 3·6)
1951·4
(1432·2–2479·2)
22·2
(20·1 to 24·4)*
–0·7
(–2·1 to 0·7)
Stage 3 chronic kidney 
disease due to 
glomerulonephritis 
aggregate
59 790·8
(50 844·6 to 69 692·7)
29·9
(26·4 to 33·6)*
1·3
(–1·1 to 4·1)
111·3
(73·5–165·2)
17·1
(13·1 to 20·7)*
–5·6
(–8·8 to –2·7)*
Stage 4 chronic 
kidney disease due to 
glomerulonephritis 
aggregate
4872·4
(4297·2 to 5506·6)
21·3
(18·8 to 23·9)*
–0·5
(–2·2 to 1·6)
602·5
(418·4–845·6)
20·2
(17·7 to 22·9)*
–0·5
(–2·3 to 1·5)
Stage 5 chronic kidney 
disease untreated due 
to glomerulonephritis
2228·1
(1895·7 to 2596·9)
23·6
(21·3 to 25·9)*
–0·6
(–2·0 to 0·7)
1122·6
(773·7–1461·3)
23·5
(20·5 to 26·3)*
–0·4
(–2·4 to 1·5)
End-stage chronic 
kidney disease due to 
glomerulonephritis 
aggregate
457·4
(377·1 to 543·0)
20·5
(16·7 to 24·5)*
–2·6
(–5·1 to –0·0)*
115·0
(80·2–152·9)
26·0
(21·1 to 31·2)*
0·4
(–3·2 to 4·1)
Chronic kidney disease 
due to other causes
94 553·5
(81 141·8 to 109 371·3)
26·2
(24·2 to 28·3)*
0·1
(–1·1 to 1·5)
2257·2
(1663·4–2892·2)
23·0
(21·1 to 25·1)*
–0·5
(–1·6 to 0·6)
Stage 3 chronic kidney 
disease due to other 
causes aggregate
85 459·8
(72 471·6 to 99 605·4)
26·6
(24·6 to 28·8)*
0·1
(–1·2 to 1·6)*
132·2
(88·0–194·5)
17·6
(14·0 to 20·8)*
–6·2
(–8·8 to –3·8)*
Stage 4 chronic 
kidney disease due to 
other causes 
aggregate
6058·4
(5257·9 to 6938·4)
21·3
(18·9 to 23·5)*
–0·2
(–1·1 to 0·8)
739·7
(513·5–1 029·6)
19·4
(17·0 to 21·6)*
–1·0
(–2·2 to 0·2)
Stage 5 chronic kidney 
disease untreated due 
to other causes
2464·6
(2115·1 to 2835·9)
25·7
(23·8 to 27·5)*
0·1
(–0·9 to 1·1)
1233·0
(855·9–1604·1)
25·5
(23·0 to 28·0)*
0·3
(–1·1 to 1·8)
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(Continued from previous page)
End-stage chronic 
kidney disease due to 
other causes 
aggregate
570·6
(485·6 to 668·1)
21·6
(18·0 to 25·0)*
–2·2
(–4·2 to –0·2)*
152·4
(107·3–200·8)
26·3
(21·8 to 30·7)*
0·1
(–3·0 to 3·2)
Urinary diseases and male 
infertility
436 081·7
(425 577·7 to 446 450·5)
24·2
(22·8 to 25·4)*
0·9
(–0·1 to 1·9)
4220·9
(2699·9–6045·2)
28·9
(26·8 to 31·0)*
–0·7
(–2·1 to 0·7)
Interstitial nephritis and 
urinary tract infections
2901·2
(2831·9 to 2980·4)
19·3
(19·0 to 19·7)*
3·1
(2·9 to 3·3)
96·6
(59·9–144·0)
19·2
(17·5 to 20·9)*
3·3
(1·8 to 4·7)*
Urolithiasis 319 600·2
(291 519·2 to 349 966·1)
22·8
(20·8 to 24·9)*
0·9
(–0·7 to 2·5)
89·7
(60·9–122·5)
23·4
(20·0 to 27·0)*
2·8
(0·1 to 5·5)*
Benign prostatic 
hyperplasia
104 625·3
(90 729·8 to 118 244·0)
29·7
(27·5 to 32·0)*
–1·3
(–2·8 to 0·2)
3792·7
(2423·8–5437·3)
29·8
(27·6 to 32·2)*
–1·3
(–2·8 to 0·3)
Male infertility 29 033·2
(23 972·5 to 34 766·8)
22·6
(19·3 to 25·6)*
9·6
(6·8 to 12·1)*
173·9
(70·1–365·3)*
22·7
(19·3 to 25·9)*
9·8
(6·9 to 12·5)*
Other urinary diseases ·· ·· ·· 67·9
(45·5–96·5)
17·2
(9·1 to 27·2)*
–0·6
(–7·3 to 7·7)*
Gynaecological diseases 794 303·2
(786 497·9 to 801 169·7)
13·8
(13·2 to 14·5)*
–1·8
(–2·4 to –1·2)*
10 001·2
(6807·0–14 312·3)
10·7
(9·4 to 11·9)*
–3·3
(–4·3 to –2·5)*
Uterine ﬁ broids 151 115·0
(144 146·9 to 158 477·5)
19·2
(18·8 to 19·5)*
–0·4
(–0·6 to –0·2)*
2383·5
(1450·2–3834·4)
11·1
(8·6 to 13·2)*
–5·8
(–7·7 to –4·2)*
Uterine ﬁ broids cases 
aggregate
108 335·0
(101 618·4 to 115 233·6)
23·0
(22·3 to 23·7)*
1·7
(1·2 to 2·1)*
645·9
(314·9–1193·3)
26·1
(25·0 to 27·3)*
3·4
(2·7 to 4·3)*
Mild abdominal pain 
with anaemia due to 
uterine ﬁ broids 
aggregate
42 780·0
(41 634·5 to 43 881·4)
10·5
(9·5 to 11·5)*
–5·5
(–6·3 to –4·6)*
1737·5
(1125·7–2625·4)
6·4
(4·5 to 8·1)*
–8·9
(–10·5 to –7·4)*
Polycystic ovarian 
syndrome
60 106·4
(46 139·3 to 75 963·4)
10·7
(10·1 to 11·4)*
–0·5
(–0·9 to –0·0)*
532·6
(238·9–1 044·6)
10·8
(9·9 to 11·5)*
–0·5
(–1·1 to 0·0)
Polycystic ovarian 
syndrome cases 
aggregate
47 116·8
(35 880·1 to 60 919·9)
10·4
(9·8 to 11·1)*
–0·8
(–1·2 to –0·3)*
408·0
(181·1–797·7)
10·5
(9·7 to 11·3)*
–0·7
(–1·2 to –0·1)*
Hirsutism and 
infertility due to 
polycystic ovarian 
syndrome aggregate
12 989·6
(8 635·6 to 18 975·6)
11·9
(10·9 to 12·7)*
0·4
(–0·4 to 1·1)
124·6
(47·2–278·0)
11·5
(9·6 to 12·9)*
0·1
(–1·5 to 1·3)
Female infertility 61 300·1
(45 889·9 to 79 647·1)
24·6
(19·2 to 30·0)*
11·2
(6·5 to 15·8)*
344·5
(134·3–746·7)
25·0
(19·7 to 30·0)*
11·7
(7·2 to 16·2)*
Endometriosis 10 758·2
(9 165·5 to 12 485·9)
11·6
(10·9 to 12·2)*
–2·6
(–3·0 to –2·2)*
996·4
(647·1–1 384·7)
11·7
(10·4 to 12·9)*
–2·4
(–3·5 to –1·5)*
Endometriosis cases 
aggregate
10 167·5
(8 652·4 to 11 828·8)
11·5
(10·9 to 12·2)*
–2·7
(–3·1 to –2·3)*
937·3
(610·7–1 312·6)
11·6
(10·3 to 12·9)*
–2·5
(–3·6 to –1·6)*
Abdominal pain and 
infertility due to 
endometriosis 
aggregate
590·7
(415·2 to 787·2)
12·3
(11·2 to 13·3)*
–1·0
(–1·8 to –0·3)*
59·1
(34·2–90·8)
12·3
(9·5 to 15·2)*
–0·9
(–3·4 to 1·5)
Genital prolapse 161 679·1
(142 334·7 to 182 566·5)
17·7
(15·2 to 20·0)*
–6·6
(–8·5 to –4·8)*
503·0
(242·5–904·3)
17·8
(15·4 to 20·3)*
–6·5
(–8·4 to –4·6)*
Premenstrual syndrome 430 696·9
(410 840·7 to 450 494·4)
10·1
(7·9 to 11·8)*
–2·1
(–3·9 to –0·7)*
3621·6
(2249·5–5428·5)
10·2
(8·0 to 12·0)*
–2·0
(–3·8 to –0·4)*
Other gynaecological 
diseases
45 018·8
(44 057·3 to 46 031·2)
8·0
(7·3 to 8·6)*
–4·2
(–4·8 to –3·7)*
1619·8
(1129·8–2210·0)
6·2
(4·9 to 7·6)*
–5·7
(–6·8 to –4·6)*
Other gynaecological 
diseases cases 
aggregate
23 908·1
(22 975·7 to 24 918·0)
13·8
(13·5 to 14·0)*
–0·4
(–0·5 to –0·2)*
936·8
(635·4–1 305·9)
13·8
(12·6 to 15·1)*
–0·2
(–1·2 to 0·8)
Anaemia due to other 
gynaecological 
diseases aggregate
21 110·8
(20 900·6 to 21 328·2)
2·1
(0·9 to 3·4)*
–8·2
(–9·3 to –7·1)*
682·9
(461·0–978·0)
–2·7
(–4·6 to –0·7)*
–12·3
(–14·0 to –10·6)*
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Haemoglobinopathies and 
haemolytic anaemias
1 571 610·0
(1 545 204·5 to 
1 605 099·8)
11·1
(9·5 to 12·6)*
–1·1
(–2·5 to 0·3)
8221·5
(5528·6–11 766·6)
4·3
(2·9 to 5·5)*
–4·9
(–6·0 to –3·9)*
Thalassaemias 439·0
(405·7 to 496·3)
1·4
(–0·1 to 3·4)
–6·5
(–7·8 to –4·6)*
31·3
(21·2–44·4)
1·0
(–3·8 to 6·1)
–7·0
(–11·4 to –2·5)*
β-thalassaemia major 
cases aggregate
229·2
(222·7 to 238·2)
4·4
(3·6 to 5·2)*
–4·2
(–4·9 to –3·4)*
16·1
(11·0–22·9)
4·1
(–2·5 to 11·5)
–4·7
(–10·6 to 1·9)
Haemoglobin E or 
β-thalassaemia cases 
aggregate
67·4
(60·1 to 75·2)
5·4
(2·9 to 8·1)*
–2·5
(–4·8 to 0·1)
5·1
(3·4–7·3)
1·8
(–10·0 to 14·2)
–5·9
(–16·7 to 4·9)
Haemoglobin H 
disease cases 
aggregate
139·0
(107·5 to 196·4)
–5·3
(–10·0 to 0·8)
–11·8
(–16·2 to –6·3)*
9·7
(6·4–14·1)
–4·9
(–12·3 to 4·9)
–11·4
(–18·2 to –2·4)*
Heart failure due to 
thalassaemias 
aggregate
3·4
(3·2 to 3·6)
26·3
(24·3 to 28·4)*
0·1
(–1·1 to 1·4)*
0·4
(0·3–0·6)
26·4
(16·0 to 38·3)*
0·6
(–9·3 to 11·8)
Thalassaemias trait 279 451·4
(272 818·9 to 287 357·4)
10·5
(10·1 to 11·0)*
–2·1
(–2·5 to –1·7)*
3922·2
(2607·9–5653·6)
6·1
(4·8 to 7·4)*
–3·6
(–4·6 to –2·6)*
β-thalassaemia trait 
cases aggregate
226 029·6
(220 111·5 to 233 332·0)
10·1
(9·6 to 10·5)*
–2·5
(–3·0 to –2·1)*
3661·7
(2437·6–5270·8)
5·9
(4·7 to 7·2)*
–3·8
(–4·9 to –2·8)*
Haemoglobin E trait 
cases aggregate
53 421·8
(51 122·3 to 55 882·5)
12·6
(11·5 to 13·7)*
–0·1
(–1·0 to 0·8)
260·5
(174·7–382·8)
8·4
(5·2 to 11·3)*
–0·5
(–3·2 to 2·1)
Sickle-cell disorders 4449·9
(4293·7 to 4600·7)
8·2
(5·2 to 11·9)*
2·8
(–0·2 to 6·2)
371·4
(259·0–518·0)
7·7
(3·3 to 12·3)*
2·3
(–1·8 to 6·6)
Homozygous sickle-
cell and severe sickle-
cell/β-thalassaemia 
cases aggregate
4035·1
(3876·0 to 4173·7)
6·5
(3·3 to 10·3)*
1·2
(–1·8 to 4·8)
339·4
(237·7–472·1)
6·5
(2·0 to 11·4)*
1·3
(–2·9 to 5·9)
Haemoglobin SC 
disease cases 
aggregate
397·6
(368·2 to 427·4)
29·6
(18·3 to 45·6)*
21·5
(11·0 to 36·5)*
30·1
(21·1–42·1)
22·9
(9·6 to 37·4)*
15·2
(2·8 to 28·9)*
Mild 
sickle-cell/β-
thalassaemia cases 
aggregate
17·2
(15·9 to 18·6)
16·1
(10·1 to 21·8)*
6·4
(0·8 to 11·5)*
1·9
(1·3–2·6)
13·2
(4·7 to 21·9)*
2·7
(–4·9 to 10·5)
Sickle-cell trait 404 565·9
(381 223·4 to 448 154·6)
19·4
(18·3 to 20·3)*
7·5
(6·5 to 8·3)*
1720·3
(1156·5–2459·0)
10·8
(7·3 to 13·4)*
1·4
(–1·8 to 3·6)
G6PD deﬁ ciency 247 073·7
(209 306·7 to 286 712·7)
6·9
(1·4 to 11·9)*
–4·4
(–9·3 to 0·1)
28·4
(19·3–39·6)
1·8
(–2·1 to 6·0)
–7·7
(–11·2 to –4·0)*
G6PD cases aggregate 247 068·5
(209 301·6 to 286 707·7)
6·9
(1·4 to 11·9)*
–4·4
(–9·3 to 0·1)
27·7
(18·9–38·7)
1·2
(–2·8 to 5·5)
–8·1
(–11·6 to –4·3)*
Heart failure due to 
G6PD deﬁ ciency 
aggregate
5·2
(4·7 to 5·7)
38·1
(36·6 to 39·8)*
7·9
(6·8 to 9·1)*
0·6
(0·4–0·9)
38·1
(34·6 to 41·5)*
7·8
(5·0 to 10·6)*
G6PD trait 728 549·2
(676 734·8 to 781 533·8)
9·8
(7·9 to 11·4)*
–2·7
(–4·3 to –1·2)*
28·0
(19·3–38·9)
4·3
(0·1 to 8·8)*
–5·3
(–9·0 to –1·2)*
Other 
haemoglobinopathies 
and haemolytic 
anaemias
74 385·1
(73 897·6 to 74 861·6)
1·8
(0·9 to 2·7)*
–9·0
(–9·7 to –8·2)*
2119·8
(1423·9–3029·9)
–3·8
(–5·5 to –2·2)*
–12·3
(–13·8 to –11·0)*
Other 
haemoglobinopathies 
and haemolytic 
anaemias cases 
aggregate
74 273·3
(73 786·0 to 74 751·1)
1·8
(0·9 to 2·7)*
–9·0
(–9·8 to –8·2)*
2067·4
(1384·3–2963·9)
–4·1
(–5·8 to –2·4)*
–12·6
(–14·1 to –11·2)*
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Heart failure due to 
other 
haemoglobinopathies 
and haemolytic 
anaemias aggregate
111·8
(103·8 to 119·6)
34·9
(33·9 to 36·0)*
2·0
(1·3 to 2·7)*
13·1
(8·9–18·2)
34·9
(31·2 to 38·7)*
2·1
(–0·8 to 5·0)
Endocrine, metabolic, 
blood, and immune 
disorders
66 128·9
(65 597·1 to 66 663·8)
4·0
(2·2 to 5·9)*
–7·2
(–8·7 to –5·5)*
2110·5
(1431·5–2993·7)
1·3
(–1·1 to 3·8)
–8·3
(–10·4 to –6·1)*
Endocrine metabolic 
blood and immune 
disorders cases 
aggregate
7577·2
(7382·6 to 7766·6)
19·8
(19·0 to 20·6)*
–0·6
(–1·2 to 0·0)
292·4
(200·2–401·8)
19·5
(18·1 to 21·0)*
–0·5
(–1·6 to 0·6)
58 430·4
(57 936·0–58 946·7)
2·2
(0·3–4·3)*
–8·0
(–9·7––6·2)*
1804·4
(1216·0–2582·3)
–1·3
(–3·9–1·5)
–9·5
(–11·9––7·0)*
Anaemia due to 
endocrine metabolic 
blood and immune 
disorders aggregate
58 430·4
(57 936·0 to 58 946·7)
2·2
(0·3 to 4·3)*
–8·0
(–9·7 to –6·2)*
1804·4
(1216·0–2582·3)
–1·3
(–3·9 to 1·5)
–9·5
(–11·9 to –7·0)*
Heart failure due to 
endocrine metabolic blood 
and immune disorders 
aggregate
121·4
(113·3 to 130·0)
30·7
(29·6 to 31·9)*
–1·9
(–2·6 to –1·2)*
13·6
(9·4–19·1)
30·7
(27·4 to 34·0)*
–1·7
(–4·3 to 0·8)
Musculoskeletal disorders 1 304 100·4
(1 288 602·8 to 
1 316 641·4)
20·7
(20·2 to 21·2)*
–0·7
(–1·1 to –0·3)*
146 783·8
(106 764·7–194 473·5)
20·5
(19·6 to 21·5)*
–0·7
(–1·3 to –0·0)*
Rheumatoid arthritis 24 491·2
(22 552·0 to 26 750·7)
23·8
(21·1 to 26·7)*
0·6
(–1·5 to 2·9)
5777·8
(4016·1–7769·6)
23·6
(20·9 to 26·7)*
0·7
(–1·4 to 3·1)*
Osteoarthritis 237 368·6
(230 335·9 to 244 648·1)
32·9
(31·9 to 33·8)*
2·2
(1·6 to 2·9)*
12 886·2
(8 999·7–17 540·0)
34·8
(33·6 to 36·0)*
3·9
(3·0 to 4·8)*
Osteoarthritis of the hip 
cases aggregate
35 629·2
(32 482·6 to 38 970·1)
33·5
(32·4 to 34·6)*
1·8
(1·0 to 2·6)*
1776·2
(1224·9–2477·0)
35·8
(34·4 to 37·3)*
3·7
(2·6 to 5·0)*
Osteoarthritis of the knee 
cases aggregate
201 739·4
(195 205·3 to 208 276·6)
32·7
(31·7 to 33·9)*
2·3
(1·5 to 3·1)*
11 110·0
(7742·1–15 123·2)
34·6
(33·3 to 35·9)*
3·9
(3·0 to 4·9)*
Low back and neck pain 820 689·8
(803 467·4 to 837 808·9)
18·7
(17·9 to 19·4)*
–2·0
(–2·6 to –1·4)*
94 941·5
(67 825·3–128 035·0)
18·6
(17·6 to 19·6)*
–2·1
(–2·7 to –1·4)*
Low back pain 539 907·4
(521 448·6 to 559 556·0)
17·3
(16·5 to 18·2)*
–2·8
(–3·4 to –2·2)*
60 074·8
(42 721·9–82 343·7)
17·2
(16·4 to 18·1)*
–2·6
(–3·2 to –2·0)*
Neck pain 358 006·6
(313 408·4 to 409 411·0)
21·1
(19·0 to 23·3)*
–1·1
(–2·4 to 0·0)
34 866·7
(23 362·1–47 636·9)
21·0
(18·9 to 23·2)*
–1·1
(–2·3 to 0·1)
Gout 42 214·2
(37 688·2 to 47 495·5)
26·4
(25·2 to 27·7)*
0·5
(0·1 to 1·0)*
1342·8
(910·0–1843·8)
26·3
(24·6 to 27·9)*
0·6
(–0·3 to 1·5)
Asymptomatic gout 37 712·9
(33 598·4 to 42 467·0)
26·4
(25·2 to 27·7)*
0·5
(0·1 to 1·0)*
0·0
(0·0–0·0)
0·0
(0·0 to 0·0)
0·0
(0·0 to 0·0)
Other musculoskeletal 
disorders
342 067·7
(305 430·7 to 385 146·7)
20·7
(17·5 to 24·0)*
1·2
(–1·2 to 3·7)
31 835·4
(21 489·1–44 268·4)
20·5
(17·2 to 23·7)*
1·3
(–1·1 to 3·8)
Other non-communicable 
diseases
5 316 342·1
(5 283 701·8 to 
5 355 928·3)
14·6
(14·3 to 14·8)*
0·4
(0·2 to 0·6)*
139 001·8
(95 459·0–197 704·3)
20·4
(19·5 to 21·5)*
1·2
(0·6 to 2·0)*
Congenital anomalies 95 706·4
(88 133·4 to 102 483·4)
22·5
(18·5 to 26·3)*
9·3
(5·8 to 12·8)*
8621·0
(5389·1–12 950·2)
28·5
(20·0 to 37·6)*
14·7
(7·1 to 22·7)*
Neural tube defects 1449·6
(988·4 to 2091·8)
17·7
(14·5 to 20·3)*
7·2
(4·3 to 9·7)*
499·1
(285·3–823·7)
18·4
(14·1 to 22·2)*
8·1
(4·1 to 11·6)*
Congenital heart 
anomalies
48 869·1
(34 325·7 to 72 829·2)
29·8
(25·3 to 34·1)*
15·4
(11·4 to 19·2)*
1688·2
(659·4–3116·9)
29·7
(25·6 to 33·7)*
15·6
(11·7 to 19·1)*
Less severe heart 
anomalies cases 
aggregate
44 599·5
(29 800·6 to 68 498·5)
29·4
(24·5 to 34·0)*
15·2
(10·7 to 19·1)*
1431·0
(532·7–2747·7)
29·3
(24·2 to 34·0)*
15·2
(10·7 to 19·2)*
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Severe congenital 
heart anomalies
4008·6
(2671·1 to 6011·2)
33·7
(27·4 to 39·0)*
18·5
(12·9 to 23·3)*
235·0
(93·2–467·8)
33·5
(27·4 to 38·7)*
18·5
(13·2 to 23·2)*
Critical congenital 
heart anomalies
155·8
(90·3 to 252·4)
42·0
(27·5 to 52·9)*
28·6
(15·5 to 38·5)*
9·2
(3·2–18·7)
42·0
(26·4 to 54·2)*
28·9
(14·9 to 40·1)*
Heart failure due to 
congenital heart 
anomalies aggregate
105·2
(99·2 to 111·4)
11·6
(10·9 to 12·4)*
–1·0
(–1·5 to –0·5)*
12·9
(8·8–18·2)
11·6
(8·3 to 15·1)*
–1·0
(–3·9 to 2·0)
Cleft lip and cleft palate 6882·6
(4029·2 to 11 483·5)
19·5
(7·7 to 27·5)*
6·6
(–3·9 to 13·9)
79·6
(39·5–143·1)
12·2
(2·6 to 19·9)*
0·9
(–7·9 to 7·7)
Down syndrome 5361·8
(3424·6 to 8192·1)
17·9
(13·7 to 21·8)*
6·4
(2·3 to 10·0)*
507·0
(286·2–837·2)
20·3
(15·8 to 24·2)*
6·5
(2·2 to 10·2)*
Turner syndrome 372·4
(174·6 to 677·1)
11·9
(9·8 to 13·9)*
0·1
(–1·7 to 1·9)
6·6
(2·4–14·4)
11·4
(8·7 to 14·0)*
–0·1
(–2·4 to 2·2)
Klinefelter syndrome 220·5
(115·5 to 395·5)
12·8
(10·9 to 14·2)*
0·5
(–1·2 to 1·9)
1·3
(0·5–3·1)
13·5
(10·6 to 15·6)*
0·2
(–2·2 to 2·0)
Other chromosomal 
abnormalities
4728·6
(2628·9 to 8303·2)
16·2
(11·8 to 19·8)*
4·3
(0·1 to 7·7)*
454·1
(233·5–852·1)
18·5
(13·6 to 22·3)*
4·2
(–0·5 to 7·9)
Other congenital 
anomalies
32 363·0
(17 788·1 to 59 394·1)
14·5
(12·3 to 16·8)*
2·0
(–0·1 to 4·1)
5385·0
(3209·4–8562·1)
31·3
(18·8 to 45·9)*
17·1
(6·1 to 30·3)*
Skin and subcutaneous 
diseases
2 239 493·4
(2 222 716·3 to 
2 258 252·8)
12·5
(12·1 to 12·8)*
0·7
(0·4 to 1·1)*
44 896·0
(28 943·3–67 159·6)
11·7
(11·0 to 12·3)*
0·4
(0·1 to 0·7)*
Dermatitis 245 290·6
(227 283·4 to 262 752·2)
14·0
(13·2 to 14·8)*
0·3
(0·1 to 0·7)*
8788·0
(5963·4–12 273·5)
13·6
(12·9 to 14·4)*
1·6
(1·0 to 2·2)*
Eczema cases 
aggregate
85 585·6                 
(75 115·2 to 97 031·7)
13·0
(12·4 to 13·6)*
3·3
(2·8 to 3·8)*
5239·2
(3515·1 to 7348·6)
13·0
(12·2 13·9)*
3·4
(2·7 to 4·2)*
Contact dermatitis 
cases aggregate
98 015·1
(85 097·0 to 110 396·7)
15·2
(13·3 to 16·9)*
–1·0
(–1·2 to –0·9)*
2632·0
(1625·8–3852·4)
15·0
(13·1 to 16·8)*
–0·9
(–1·4 to –0·5)*
Seborrhoeic 
dermatitis cases 
aggregate
61 690·0
(54 642·8 to 68 788·8)
13·3
(12·0 to 14·7)*
–1·3
(–1·7 to –1·0)*
916·8
(521·6–1454·1)
13·2
(11·8 to 14·7)*
–1·3
(–1·8 to –0·8)*
Psoriasis 79 699·7
(76 690·9 to 82 804·5)
17·6
(17·0 to 18·3)*
0·4
(–0·1 to 0·9)
6438·3
(4495·6–8734·5)
17·5
(16·6 to 18·4)*
0·6
(–0·0 to 1·2)
Cellulitis 959·9
(887·6 to 1033·6)
24·0
(22·1 to 25·7)*
5·8
(4·3 to 7·2)*
69·0
(45·0–97·8)
23·6
(20·7 to 26·1)*
5·8
(3·5 to 8·1)*
Pyoderma 5812·7
(5581·7 to 6019·0)
15·5
(14·7 to 16·3)*
1·4
(0·7 to 2·1)*
32·7
(13·2–68·4)
15·4
(14·0 to 16·8)*
1·5
(0·3 to 2·7)*
Scabies 204 151·7
(177 533·7 to 237 466·2)
6·6
(4·0 to 9·5)*
–2·6
(–4·5 to –0·6)*
5268·9
(2966·9–8605·6)
6·6
(3·8 to 9·5)*
–2·5
(–4·5 to –0·5)*
Fungal skin diseases 492 372·6
(448 950·9 to 538 232·5)
13·3
(12·5 to 14·1)*
1·6
(1·3 to 1·9)*
2783·3
(1105·6–5905·3)
13·3
(12·4 to 14·1)*
1·7
(1·4 to 2·0)*
Viral skin diseases 174 843·1
(165 156·3 to 185 072·0)
8·5
(8·0 to 9·0)*
–1·1
(–1·4 to –0·8)*
5396·9
(3417·1–7959·9)
8·4
(7·9 to 9·0)*
–1·0
(–1·4 to –0·6)*
Molluscum 
contagiosum cases 
aggregate
40 464·2
(35 685·6 to 46 233·4)
5·2
(4·7 to 5·8)*
–0·9
(–1·3 to –0·5)*
1263·0
(783·0–1932·3)
5·3
(4·6 to 6·1)*
–0·8
(–1·5 to –0·2)*
Viral warts cases 
aggregate
134 378·9
(125 683·9 to 143 028·0)
9·5
(8·9 to 10·1)*
–1·1
(–1·4 to –0·7)*
4133·9
(2628·4–6153·4)
9·4
(8·8 to 10·1)*
–1·0
(–1·5 to –0·6)*
Acne vulgaris 632 741·0
(595 241·9 to 671 248·9)
4·6
(3·5 to 5·6)*
0·8
(–0·1 to 1·7)
6854·0
(3275·1–12 713·9)
4·6
(3·5 to 5·6)*
0·8
(–0·1 to 1·8)
Alopecia areata 20 594·9
(19 607·8 to 21 617·0)
14·0
(13·5 to 14·4)*
–1·1
(–1·3 to –1·0)*
695·6
(428·5–1035·6)
13·9
(13·1 to 14·7)*
–1·0
(–1·7 to –0·4)*
Pruritus 69 582·5
(62 063·2 to 78 152·6)
17·6
(15·7 to 19·5)*
0·4
(–0·7 to 1·6)
741·6
(360·0–1348·6)
17·5
(15·6 to 19·4)*
0·5
(–0·7 to 1·7)
Urticaria 67 749·8
(58 743·2 to 77 086·4)
10·7
(9·6 to 12·0)*
–0·1
(–0·3 to 0·0)
4115·7
(2567·2–5833·6)
10·7
(9·6 to 12·0)*
–0·0
(–0·5 to 0·4)
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Prevalence (thousands) YLDs (thousands)
2015 Percentage change in 
counts between 2005 
and 2015
Percentage change in 
ASR between 2005 and 
2015
2015 Percentage change in 
counts between 2005 
and 2015
Percentage change in 
ASR between 2005 
and 2015
(Continued from previous page)
Decubitus ulcer 1087·5
(991·2 to 1189·7)
35·4
(33·4 to 37·4)*
4·7
(3·3 to 6·0)*
161·3
(112·0–218·7)
34·5
(31·9 to 37·3)*
4·7
(2·6 to 6·9)*
Other skin and 
subcutaneous diseases
605 036·3
(589 500·0 to 619 675·6)
22·8
(22·1 to 23·4)*
2·4
(1·9 to 2·9)*
3550·5
(1706·2–6514·4)
22·6
(22·0 to 23·3)*
2·5
(2·0 to 2·9)*
Sense organ diseases 1 788 125·6
(1 771 367·0 to 
1 808 438·8)
23·7
(23·3 to 24·1)*
0·6
(0·3 to 0·9)*
68 515·2
(47 798·2–93 894·8)
25·2
(24·2 to 26·4)*
0·6
(–0·0 to 1·3)
Glaucoma 5954·5
(5077·5 to 6905·8)
39·1
(36·9 to 41·4)*
4·2
(2·8 to 5·5)*
541·3
(370·0–747·9)
39·4
(37·0 to 41·9)*
4·3
(2·6 to 5·8)*
Cataract 59 727·0
(53 633·2 to 66 879·2)
26·9
(25·2 to 28·5)*
–3·2
(–4·5 to –2·0)*
3879·7
(2766·9–5229·2)
25·5
(24·1 to 26·9)*
–4·2
(–5·2 to –3·2)*
Macular degeneration 6188·4
(5250·3 to 7273·2)
48·5
(46·1 to 50·8)*
8·2
(6·9 to 9·8)*
462·4
(327·4–633·0)
47·7
(45·2 to 49·9)*
6·9
(5·3 to 8·6)*
Refraction and 
accommodation 
disorders
819 307·4
(789 917·4 to 848 059·2)
21·9
(20·5 to 23·2)*
–0·4
(–1·3 to 0·6)
14 593·8
(9392·9–22 901·1)
21·1
(20·2 to 22·1)*
–0·3
(–0·9 to 0·4)
Age-related and other 
hearing loss
1 210 055·2
(1 140 224·2 to 
1 274 664·8)
28·3
(27·4 to 29·2)*
1·4
(1·0 to 1·8)*
40 596·8
(27 898·4–56 075·0)
26·4
(24·6 to 28·3)*
1·1
(0·0 to 2·1)*
Other vision loss 25 797·4
(22 675·6 to 28 504·6)
27·1
(24·6 to 29·5)*
5·5
(4·2 to 6·7)*
1 756·4
(1248·9–2392·7)
29·9
(27·8 to 32·0)*
5·6
(4·3 to 6·7)*
Other sense organ 
diseases
267 689·7
(258 379·8 to 277 711·4)
24·0
(23·1 to 24·9)*
0·8
(0·1 to 1·4)*
6684·7
(4185·0–9714·7)
23·8
(22·9 to 24·8)*
0·9
(0·2 to 1·5)*
Acute other sense 
organ diseases
1343·8
(1303·5 to 1385·9)
14·9
(14·2 to 15·7)*
0·9
(0·4 to 1·4)*
35·4
(21·6–51·6)
14·8
(12·7 to 16·9)*
0·9
(–0·9 to 2·7)
Chronic other sense 
organ diseases
266 345·9
(257 047·4 to 276 383·0)
24·0
(23·1 to 24·9)*
0·8
(0·1 to 1·4)*
6649·3
(4162·3–9662·4)
23·9
(23·0 to 24·9)*
0·9
(0·2 to 1·5)*
Oral disorders 3 521 901·1
(3 468 088·2 to 3 575 
854·4)
14·5
(13·8 to 15·0)*
0·4
(–0·1 to 0·9)
16 969·6
(10 296·5–26 044·5)
22·4
(21·6 to 23·2)*
–0·2
(–0·5 to 0·1)
Deciduous caries 572 694·1
(475 089·8 to 686 991·2)
4·5
(2·3 to 6·1)*
–2·3
(–4·2 to –0·7)*
147·2
(63·0–292·1)
4·1
(1·6 to 5·9)*
–2·7
(–4·9 to –0·8)*
Permanent caries 2 521 197·8
(2 361 418·3 to 
2 679 668·7)
14·5
(13·7 to 15·4)*
0·8
(0·3 to 1·4)*
1743·4
(776·7–3320·9)
13·5
(12·6 to 14·4)*
–0·4
(–1·2 to 0·4)
Periodontal diseases 537 506·0
(465 113·9 to 625 888·8)
25·4
(24·1 to 26·5)*
1·1
(0·5 to 1·7)*
3520·7
(1359·3–7253·7)
25·4
(24·1 to 26·5)*
1·2
(0·6 to 1·8)*
Edentulism and severe 
tooth loss
275 619·1
(264 200·8 to 288 252·3)
27·3
(26·9 to 27·7)*
–0·9
(–1·1 to –0·7)*
7640·3
(5096·6–10 562·3)
27·3
(26·9 to 27·7)*
–0·8
(–1·1 to –0·6)*
Other oral disorders 133 719·0
(127 499·7 to 139 776·2)
15·9
(15·4 to 16·4)*
–0·1
(–0·2 to 0·1)
3918·1
(2432·7–5879·4)
15·8
(15·3 to 16·4)*
0·0
(–0·2 to 0·3)
Injuries 1 019 157·4
(977 405·7 to 
1 064 704·2)
16·4
(15·5 to 17·4)*
–3·4
(–4·1 to –2·6)*
41 022·0
(29 290·4–55 288·4)
8·0
(4·6 to 11·1)*
–9·9
(–12·5 to –7·5)*
Transport injuries 115 981·0
(110 575·9 to 123 047·1)
23·1
(22·5 to 23·7)*
–0·0
(–0·4 to 0·4)
6444·8
(4500·6–8733·0)
12·2
(8·7 to 15·8)*
–8·0
(–10·7 to –5·3)*
Road injuries 107 722·4
(102 214·5 to 114 850·0)
23·4
(22·8 to 24·1)*
0·3
(–0·1 to 0·7)
5956·1
(4130·8–8076·3)
13·3
(9·9 to 16·7)*
–7·1
(–9·7 to –4·6)*
Pedestrian road injuries 14 157·8
(12 664·5 to 16 095·9)
22·9
(21·7 to 24·1)*
–0·7
(–1·4 to 0·0)
770·8
(532·9–1060·8)
9·6
(5·5 to 13·6)*
–10·6
(–13·7 to –7·6)*
Cyclist road injuries 18 700·6
(16 545·4 to 20 951·1)
21·4
(19·9 to 22·7)*
–0·4
(–1·2 to 0·4)
968·2
(655·2–1348·5)
9·9
(5·5 to 14·2)*
–9·0
(–12·5 to –5·9)*
Motorcyclist road 
injuries
26 417·2
(23 496·7 to 29 722·0)
31·7
(30·3 to 33·0)*
7·3
(6·5 to 8·1)*
1397·9
(962·0–1919·8)
17·6
(13·0 to 22·1)*
–3·3
(–7·0 to 0·2)
Motor vehicle road 
injuries
44 311·4
(40 212·6 to 49 496·3)
18·7
(17·7 to 19·8)*
–4·1
(–4·7 to –3·4)*
2585·4
(1811·2–3556·8)
12·2
(9·6 to 14·8)*
–8·4
(–10·4 to –6·6)*
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Prevalence (thousands) YLDs (thousands)
2015 Percentage change in 
counts between 2005 
and 2015
Percentage change in 
ASR between 2005 and 
2015
2015 Percentage change in 
counts between 2005 
and 2015
Percentage change in 
ASR between 2005 
and 2015
(Continued from previous page)
Other road injuries 4135·3
(3603·7 to 4692·7)
40·2
(38·6 to 42·1)*
15·2
(14·4 to 16·1)*
233·7
(158·3–320·9)
32·1
(28·3 to 35·5)*
9·5
(6·8 to 11·9)*
Other transport injuries 8258·5
(7469·0 to 9141·6)
18·8
(17·9 to 19·7)*
–3·2
(–3·6 to –2·7)*
488·7
(348·6–660·5)
0·3
(–4·0 to 5·2)
–17·1
(–20·5 to –13·3)*
Unintentional injuries 790 101·8
(759 587·4 to 
824 995·0)
14·3
(13·8 to 14·8)*
–5·2
(–5·5 to –4·9)*
30 679·5
(21 602·9–41 953·7)
6·2
(3·1 to 9·0)*
–11·4
(–13·6 to –9·2)*
Falls 225 736·9
(207 914·3 to 245 787·2)
25·1
(24·4 to 25·8)*
1·7
(1·3 to 2·1)*
11 770·2
(8257·6–16 166·4)
11·3
(6·7 to 15·7)*
–8·6
(–12·1 to –5·2)*
Drowning 4455·5
(4041·2 to 4919·4)
7·0
(5·8 to 8·1)*
–13·1
(–13·5 to –12·7)*
247·3
(173·4–335·8)
–6·7
(–10·3 to –2·4)*
–23·4
(–26·2 to –20·2)*
Fire, heat, and hot 
substances
69 666·6
(60 988·1 to 78 550·1)
10·8
(10·1 to 11·7)*
–8·3
(–8·8 to –7·9)*
2269·4
(1571·4–3131·8)
1·9
(–1·8 to 5·5)
–13·5
(–16·1 to –11·2)*
Poisonings 5722·4
(4829·3 to 6854·1)
13·8
(12·7 to 14·9)*
–2·0
(–3·2 to –0·6)*
549·4
(367·8–791·1)
8·8
(6·7 to 10·8)*
–4·5
(–6·6 to –2·6)*
Exposure to mechanical 
forces
183 582·4
(169 658·6 to 197 859·6)
13·9
(13·0 to 14·7)*
–3·5
(–4·0 to –2·9)*
3580·8
(2485·7–4922·9)
5·9
(2·9 to 8·9)*
–9·9
(–12·1 to –7·6)*
Unintentional ﬁ rearm 
injuries
2333·0
(2074·5 to 2625·1)
13·4
(12·4 to 14·4)*
–6·3
(–7·1 to –5·6)*
93·2
(65·4–126·2)
4·1
(0·6 to 7·4)*
–12·6
(–15·0 to –10·1)*
Unintentional 
suﬀ ocation
9759·3
(8142·5 to 11 916·9)
9·7
(5·5 to 13·9)*
–7·7
(–10·3 to –5·1)*
353·7
(245·8–480·3)
11·4
(8·6 to 14·0)*
–6·8
(–8·6 to –5·1)*
Other exposure to 
mechanical forces
171 490·1
(157 821·0 to 185 364·4)
14·1
(13·2 to 14·9)*
–3·2
(–3·7 to –2·6)*
3133·9
(2172·1–4356·6)
5·4
(2·2 to 8·5)*
–10·1
(–12·6 to –7·7)*
Adverse eﬀ ects of medical 
treatment
11 158·6
(8773·5 to 13 610·2)
3·1
(1·3 to 4·9)*
–13·9
(–15·4 to –12·4)*
1487·4
(926·9–2223·0)
3·1
(1·3 to 4·9)*
–13·9
(–15·4 to –12·4)*
Animal contact 34 049·7
(30 774·2 to 37 569·0)
9·4
(8·0 to 10·6)*
–6·6
(–7·5 to –5·9)*
1100·9
(763·8–1486·9)
4·6
(3·0 to 6·2)*
–8·8
(–10·0 to –7·5)*
Venomous animal 
contact
14 680·7
(13 173·4 to 16 375·1)
13·2
(12·2 to 14·2)*
–3·6
(–4·4 to –2·8)*
820·7
(558·1–1117·5)
5·3
(3·7 to 7·1)*
–7·8
(–9·2 to –6·2)*
Non-venomous animal 
contact
19 369·1
(16  794·5 to 22 306·5)
6·7
(4·8 to 8·2)*
–8·8
(–10·1 to –7·7)*
280·3
(187·2–410·5)
2·5
(0·2 to 4·7)*
–11·4
(–13·1 to –9·8)*
Foreign body 32 345·9
(28 877·3 to 36 026·4)
15·7
(14·1 to 17·1)*
–1·9
(–2·9 to –1·1)*
1263·3
(899·4–1722·5)
3·7
(0·2 to 7·5)*
–10·9
(–13·6 to –8·1)*
Pulmonary aspiration 
and foreign body in 
airway
13 351·2
(11 069·0 to 16 798·7)
15·5
(12·5 to 18·4)*
–1·6
(–3·6 to 0·2)
690·2
(477·9–973·1)
–0·2
(–4·1 to 4·5)
–14·0
(–17·2 to –10·4)*
Foreign body in eyes 1007·2
(444·0 to 1 593·4)
16·3
(15·0 to 18·2)*
1·4
(0·8 to 1·9)*
56·2
(24·0–100·6)
15·2
(13·8 to 16·7)*
0·5
(–0·9 to 1·3)
 Foreign body in other 
body part
17 987·4
(15 874·1 to 20 237·9)
15·9
(14·9 to 17·0)*
–2·3
(–3·0 to –1·6)*
517·0
(364·4–713·3)
8·0
(5·5 to 10·6)*
–7·7
(–9·6 to –5·8)*
Environmental heat and 
cold exposure
61 942·3
(56 211·9 to 68 761·8)
15·9
(15·4 to 16·5)*
–4·2
(–4·6 to –3·8)*
2657·1
(1861·7–3636·2)
6·4
(3·7 to 9·4)*
–11·0
(–13·0 to –8·9)*
Other unintentional 
injuries
161 441·6
(147 971·3 to 176 204·3)
4·7
(4·0 to 5·3)*
–13·7
(–14·1 to –13·3)*
5753·6
(3913·1–8024·1)
0·4
(–1·4 to 2·1)
–16·7
(–17·8 to –15·7)*
Self-harm and 
interpersonal violence
24 083·0
(22 279·7 to 25 744·4)
15·2
(14·6 to 15·7)*
–5·5
(–5·9 to –5·2)*
1077·5
(762·7–1 448·2)
1·9
(–1·6 to 5·8)
–15·1
(–17·8 to –12·1)*
Self-harm 6358·6
(5682·1 to 7154·5)
15·2
(14·5 to 15·8)*
–6·2
(–6·7 to –5·8)*
332·7
(232·4–446·9)
0·9
(–2·1 to 4·5)
–15·9
(–18·4 to –13·2)*
Interpersonal violence 17 724·4
(16 186·6 to 19 268·4)
15·2
(14·5 to 15·9)*
–5·3
(–5·7 to –4·8)*
744·8
(521·9–1007·3)
2·4
(–1·4 to 6·4)
–14·6
(–17·5 to –11·6)*
Assault by ﬁ rearm 1043·6
(900·8 to 1213·2)
16·1
(14·9 to 17·3)*
–4·9
(–5·8 to –4·2)*
46·5
(32·4–64·9)
4·6
(0·7 to 8·1)*
–13·2
(–16·1 to –10·5)*
Assault by sharp object 4019·5
(3330·4 to 4668·1)
12·5
(11·5 to 13·6)*
–7·0
(–7·7 to –6·3)*
123·4
(84·8–168·7)
–6·4
(–11·4 to –0·9)*
–21·1
(–24·8 to –16·8)*
Assault by other means 12 661·3
(11 425·5 to 14 018·9)
16·0
(15·2 to 16·8)*
–4·7
(–5·3 to –4·3)*
574·8
(404·0–782·2)
4·3
(0·8 to 8·0)*
–13·3
(–15·9 to –10·4)*
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disability in Nepal, Bangladesh, and Bhutan, respectively. 
YLDs due to anxiety were lower than expected in all 
countries in the region except for Bangladesh.
In the GBD super-region of central Europe, eastern 
Europe, and central Asia, lower back and neck pain was the 
leading cause of disability in every geographical region in 
2015; Although all countries in eastern and central Europe 
recorded higher than expected YLD ratios for most of their 
top ten causes, central Asia mostly had lower than expected 
or as expected YLD ratios. Sense organ diseases were the 
second leading causes of disability and depressive disorders 
were the third leading causes in this super-region.
Sizeable discrepancies occurred for observed and 
expected YLDs based on SDI throughout north Africa 
and the Middle East, probably reﬂ ecting the uneven 
achievements in development found in this region. 
Lower back and neck pain was the primary driver of 
YLDs in the region. Exceptions to this were Lebanon and 
Syria, for which war caused the most disability in 2015, 
and Afghanistan for which iron-deﬁ ciency was the 
leading cause. Depression, sense organ diseases, diabetes 
ranked second, third, and fourth, respectively, for the 
region. Observed YLDs due to diabetes consistently 
exceeded expected levels, with two countries posting 
ratios higher than 3·00 (ie, Qatar [3·12], and the United 
Arab Emirates [3·52]). Iran and Morocco recorded much 
higher disability due to drug use disorders than expected 
based on SDI.
In comparison with the rest of the world, ranks of cause-
speciﬁ c disability, and their ratios of observed to expected 
values, were vastly diﬀ erent in sub-Saharan Africa. Of the 
46 countries within the super-regions, nine had lower back 
and neck pain as the leading cause of YLDs in 2015. In 
southern Sub-Saharan Africa, HIV/AIDS was the leading 
cause of disability for all countries. Iron-deﬁ ciency anaemia 
ranked as the leading cause of YLDs for 11 countries in 
western sub-Saharan Africa. For the remaining countries, 
lower back and neck pain were primarily the leading cause 
of YLDs; Liberia, the exception, had onchocerciasis as its 
leading cause of disability. Malaria and various neglected 
tropical diseases caused more YLDs than expected in most 
west African countries. For eastern sub-Saharan Africa, 
sense organ diseases, iron deﬁ ciency, depressive disorders, 
and lower back and neck pain were leading causes of YLDs 
Prevalence (thousands) YLDs (thousands)
2015 Percentage change in 
counts between 2005 
and 2015
Percentage change in 
ASR between 2005 and 
2015
2015 Percentage change in 
counts between 2005 
and 2015
Percentage change in 
ASR between 2005 
and 2015
(Continued from previous page)
Forces of nature, war, and 
legal intervention
88 991·7
(65 131·0 to 116 786·1)
28·8
(18·4 to 40·5)*
11·7
(2·9 to 21·7)*
2820·2
(1921·3 to 3850·1)
23·4
(1·7 to 47·8)*
7·2
(–11·4 to 28·3)
Exposure to forces of 
nature
25 293·7
(16 193·6 to 37 658·7)
13·5
(–2·1 to 32·2)
–1·3
(–14·5 to 14·1)
796·9
(541·4 to 1091·4)
–27·4
(–43·2 to –6·2)*
–35·9
(–49·6 to –17·8)*
Collective violence and 
legal intervention
63 697·9
(45 248·7–83 186·4)
36·1
(20·9–54·9)*
18·1
(5·1–34·4)*
2023·3
(1303·8–2903·0)
70·5
(33·0–118·3)*
47·1
(15·3–88·8)*
Impairments ·· ·· ·· ·· ·· ··
Anaemia 2 359 107·9
(2 349 938·3 to 
2 369 065·8)
4·0
(3·5 to 4·5)*
–7·1
(–7·6 to –6·7)*
77 876·7
(52 436·9 to 111 360·0)
–0·7
(–2·0 to 0·4)
–10·2
(–11·2 to –9·2)*
Developmental 
intellectual disability
152 664·0
(113 511·5 to 190 764·1)
12·6
(12·2 to 13·0)*
2·0
(1·6 to 2·4)*
16 875·1
(12 072·6 to 22 373·1)
15·0
(13·4 to 17·0)*
3·8
(2·2 to 5·7)*
Epilepsy 39 160·5
(34 270·8 to 43 685·8)
15·8
(12·6 to 18·9)*
3·5
(0·5 to 6·4)*
11 770·0
(8 578·8 to 15 276·3)
5·8
(0·5 to 11·0)*
–4·9
(–9·8 to –0·1)*
Guillain-Barré syndrome 35·0
(28·6 to 42·1)
17·0
(14·7 to 19·5)*
–0·2
(–0·9 to 0·4)
10·4
(6·6 to 15·0)
17·0
(14·7 to 19·5)
–0·2
(–0·9 to 0·4)
Hearing loss 1 330 902·9
(1 261 401·0 to 
1 397 100·6)
26·0
(25·2 to 26·7)*
0·9
(0·5 to 1·3)*
46 183·1
(31 566·7 to 63 209·9)
23·6
(22·1 to 25·1)*
0·6
(–0·4 to 1·5)
Heart failure 40 048·6
(38 613·2 to 41 418·2)
32·3
(31·6 to 33·1)*
0·3
(–0·2 to 0·8)
6199·4
(4700·7 to 7785·5)
33·2
(31·7 to 34·6)*
1·1
(0·1 to 2·0)*
Infertility 113 113·8
(93 429·4–136 497·5)
21·1
(17·6–24·5)*
8·0
(4·9–10·9)*
752·4
(327·7–1543·8)
19·9
(16·8–22·7)*
7·0
(4·3–9·4)*
Pelvic inﬂ ammatory 
disease
754·1
(652·8 to 878·7)
1·1
(0·1 to 2·1)*
–12·0
(–12·7 to –11·2)*
99·9
(67·8 to 138·6)
1·3
(–0·7 to 3·4)
–11·7
(–13·4 to –10·0)*
Vision loss 939 580·2
(905 009·5 to 974 112·3)
22·4
(21·2 to 23·6)*
–0·4
(–1·3 to 0·4)
24 462·7
(16 954·9 to 34 455·1)
22·4
(21·6 to 23·3)*
–0·2
(–0·8 to 0·3)
Data in parentheses are 95% UIs. *Percentage changes that are statistically signiﬁ cant. 
Table 3: Global prevalence and YLDs for 2015, percentage change of counts, and percentage change of age-standardised rates between 2005 and 2015 for all causes, Level 5 sequelae, and 
nine impairments
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in 2015. In central sub-Saharan Africa, skin diseases were 
consistently among the leading three-to-four causes of 
disability in this region. HIV/AIDS resulted in far more 
YLDs than expected based on SDI, with Equatorial Guinea, 
and Central African Republic recording ratios of observed 
versus expected YLDs higher than 2·00.
Discussion
We used 60 900 data sources to estimate the incidence 
and prevalence of 2619 sequelae of 310 causes for 
591 geographical regions for the years 1990, 1995, 2000, 
2005, 2010, and 2015. After accounting for variation over 
time and across regions in case deﬁ nitions, disease assays, 
survey instruments, and coding practice, and using 
standardised modelling approaches to deal with missing 
data, conﬂ icting data, and a range of sampling and non-
sampling errors, we characterised the global and national 
patterns in non-fatal health outcomes. We found that global 
age-standardised YLDs per capita decreased slightly in the 
last 25 years from 0·114 (0·085–0·147) in 1990 to 0·110 
(0·082–0·141) per capita in 2015, a total decrease of 3·69% 
(3·12–4·25%) over a generation (appendix pp 714–16). The 
ageing of the world’s population and the general increase 
in YLDs per capita with age resulted in an increase in 
global YLDs per capita. Within this overall pattern, 133 out 
of 310 causes had statistically signiﬁ cant decreases in YLDs 
per capita between 2005 and 2015 compared with 82 causes 
with statistically signiﬁ cant increases in YLDs per capita 
over the same time period. The most important 
contributors to global YLDs were musculoskeletal disorders 
(18·5% [16·4–20·9%] of all YLDs in 2015), mental and 
substance use disorders (18·4% [15·6–21·2%]), and the 
category of other NCDs (17·9% [15·0–21·7%]), dominated 
by hearing loss, vision loss, and skin diseases. 
Typology of diseases based on YLDs and YLLs
The comparison of trends in age-standardised YLDs and 
YLLs provides insight into the drivers of diﬀ erences in 
rates of increases and decreases for diseases and injuries. 
Diseases and injuries can be parsed into four groups. The 
ﬁ rst of these are a small set of disorders including causes 
such as drug use disorders and skin cancer for which age-
standardised rates of both YLDs and YLLs increased at a 
rate of more than 0·4% per year from 2005 to 2015. 
A second category of diseases includes those in which 
YLDs are increasing but YLLs are decreasing, including 
disorders such as thyroid cancer, cirrhosis, and neonatal 
encephalopathy. One explanation for this pattern is that 
risk factors, broadly deﬁ ned, are causing an increase in 
incidence, whereas access to eﬀ ective treatment has 
improved enough to continue reducing mortality. For a 
third category of disorders, YLDs are essentially constant, 
but YLLs are decreasing. This grouping is quite large and 
includes many of the major causes of disability such as 
musculoskeletal disorders, various neurological disorders, 
and a number of cancers. For many infectious causes, 
decreased are occurring for both YLLs and YLDs but are 
much faster for YLLs; this pattern is to be expected if access 
to eﬀ ective treatment is decreasing the number of deaths 
but not reducing prevalence or incidence. The last category 
includes disorders where decreases are equal, if not slightly 
higher, for YLDs including ischaemic heart disease, falls, 
cervical cancer, and other injuries. Examination of 
diﬀ erential trends by region or country might provide 
insights into the role of access to treatment in reducing 
YLLs and, conversely, the role of increasing or decreasing 
risks and social determinants in driving changes in disease 
incidence and prevalence. More detailed exploration of 
these diﬀ erential trends is warranted in future work.
Disability and retirement age
As life expectancy has steadily increased in most countries, 
there have been calls in some high SDI countries to extend 
retirement ages to reﬂ ect these changes in survival.28–30 
A crucial factor in these debates is whether individuals are 
living for longer and have higher average levels of 
functional health at each age or not. In this study, we 
found that age-standardised YLDs per capita decreased, 
but rather slowly, over the period 2005 to 2015. Comparison 
of trends in age-standardised YLDs and YLLs by cause 
shows that the main causes of YLDs are not decreasing 
and in some settings might be increasing. Other than a 
somewhat slower rate of improvement for YLDs at oldest 
age (≥80 years), age discontinuities are not observable in 
these patterns. Ultimately, the debate on retirement age 
will hinge on the skill sets required for diﬀ erent types 
of work, whether work contributes to diminished 
or improved functional health status, and societal 
expectations for retirement. Our ﬁ ndings suggest that the 
burden from mental and substance use disorders, and 
musculoskeletal disorders, which are frequent causes of 
early retirement31,32 in terms of age-speciﬁ c prevalence, has 
not declined much over time; the continued prevalence of 
these and other disorders associated with increasing age 
might limit the capacities of an older workforce. 
Epidemiological transition 
The analysis of YLD rates by Level 2 causes as a function of 
SDI shows a very diﬀ erent picture than that reported for 
YLLs. At the lower end of the SDI spectrum, incremental 
increases in SDI are associated with reductions in both 
age-standardised YLDs and all-age YLD rates spurred by 
decreases in disability from neglected tropical diseases and 
anaemia as well as decreases in tuberculosis, diarrhoea, 
pneumonia, meningitis, and other infectious diseases. 
At SDI levels above 0·8 (see methods appendix pp 698–711 
for SDI values for each country), age-standardised rates of 
health loss increase slightly, attributable to higher rates of 
mental and substance use disorders, musculoskeletal 
disorders, and neurological disorders. In this phase of the 
epidemiological transition, this increase in rates, although 
small, combined with population ageing, results in 
increases in YLDs per 100 000. The rising average YLD per 
capita rates have implications for health systems; a larger 
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fraction of the population is likely to need care for many 
disorders. Some of these disorders are currently costly to 
manage.33 The increase in health-care costs per individual 
in the population that occurs once an SDI of 0·8 is exceeded 
is a predictable component of the epidemiological 
transition; these costs should be anticipated during the 
health planning processes of countries in that stage of the 
transition.
Disease-speciﬁ c issues
Musculoskeletal disorders
Musculoskeletal disorders continue to be a leading cause 
of disability worldwide and more so when taking into 
account that additional musculoskeletal burden from 
long-term sequelae of fractures and dislocations is 
classiﬁ ed under injuries in GBD. A key component of 
healthy ageing is to maintain mobility, and a key public 
health intervention recommended for improving health 
outcomes for all chronic diseases is physical activity. 
Painful musculoskeletal disorders increase with age and 
are a great threat to mobility, compromising health more 
broadly.34–36 Even if cures for musculoskeletal disorders 
are not yet available, the clinical goal of preventing 
disability is attainable.37,38
Mental and substance use disorders
Consistent with the ﬁ ndings of earlier GBD studies, 
GBD 2015 conﬁ rms the large contribution of mental and 
substance use disorders to global disability. For the ﬁ rst 
time, in GBD 2015 we found a positive association 
between conﬂ ict and depression and anxiety, albeit with 
wide uncertainty. This uncertainty is due to sparse and 
low-quality data for these disorders in post-conﬂ ict 
countries. Going forward, we plan to make separate 
estimates for post-traumatic stress disorder in GBD, 
which might add considerably more data from conﬂ ict 
settings and show a stronger association. GBD results 
have provided an evidence base to support global action 
such as a stated commitment by the World Bank and 
WHO to make mental health a global development 
priority39 and the consideration of mental health and 
substance use disorders in shaping the Sustainable 
Development Goals.40 Cost-eﬀ ective interventions are 
able to reduce the burden imposed by mental and 
substance use disorders, including in low-income and 
middle-income countries.41
Increases in deaths attributable to drug use in the 
USA have resulted in considerable policy and media 
attention. In our assessment, the ten countries with the 
% change
number
of YLDs
1990–2005
% change
all-age
YLD rate
1990–2005
% change age-
standardised
YLD rate
1990–2005
% change
number
of YLDs
2005–15
% change
all-age
YLD rate
2005–15
% change age-
standardised
YLD rate
2005–15
 34·5 9·4 –1·8
 39·4 13·4 2·1
 14·8 –6·6 –0·6
 32·9 8·0 0·6
 21·9 –0·8 0·5
 29·7 5·5 –0·3
 51·8 23·4 13·5
 69·2 37·6 20·7
 26·1 2·6 –1·5
 2·6 –16·5 –15·5
 33·9 8·9 –1·6
 36·1 10·7 0·7
 13·4 –7·8 –13·9
 22·2 –0·6 –9·8
 53·0 24·4 6·3
 29·1 5·0 –3·4
 23·2 0·2 0·5
 32·5 7·8 0·2
 42·1 15·6 11·6
 10·8 –9·9 –5·3
 29·4 5·2 0·1
 32·6 7·9 –1·5
 10·9 –9·8 –7·9
 48·9 21·1 22·4
 35·3 10·1 –2·4
 15·8 –5·8 0·7
 0·7 –18·1 –23·6
 28·2 4·2 –2·5
 40·7 14·4 –2·7
 –2·2 –20·5 –9·9
 18·6 4·9 –2·1
 25·2 10·8 0·6
 18·2 4·5 1·0
 –3·8 –14·9 –11·6
 11·7 –1·2 0·4
 32·5 17·2 5·4
 15·3 2·0 0·8
 20·5 6·6 1·3
 14·8 1·5 1·0
 22·4 8·2 –0·2
 9·4 –3·3 –2·3
 19·5 5·7 0·3
 34·8 19·2 3·9
 16·2 2·8 –5·9
 11·3 –1·5 –8·6
 12·3 –0·7 0·6
 10·7 –2·1 –3·3
 23·6 9·4 8·2
 18·7 5·0 0·3
 18·9 5·2 0·6
 14·9 1·6 0·5
 28·5 13·7 14·7
 4·3 –7·7 –4·9
 23·8 9·5 0·1
 30·2 15·2 –0·3
 38·8 22·8 1·1
 20·7 6·8 –4·2
 11·1 –1·7 –4·5
 –6·4 –17·2 –16·3
 23·9 9·6 0·5
Leading causes 2005
1 Lower back and neck pain
2 Sense organ diseases
3 Iron-deﬁciency anaemia
4 Depressive disorders
5 Skin diseases
6 Migraine
7 Other musculoskeletal disorders
8 Diabetes
9 Anxiety disorders
10 Asthma
11 Oral disorders
12 Schizophrenia
13 Falls
14 COPD
15 Osteoarthritis
16 Gynaecological diseases
17 Autistic spectrum
18 Other mental and substance
19 Drug use disorders
20 Haemoglobinopathies
21 Bipolar disorder
22 Medication overuse headache
23 Epilepsy
24 Congenital anomalies
25 Chronic kidney disease
26 Conduct disorder
27 Other unintentional
28 Alcohol use disorders
29 Ischaemic heart disease
30 Diarrhoeal diseases
31 Cerebrovascular disease
33 Alzheimer’s disease
34 Other cardiovascular
39 Intestinal nematode
Leading causes 1990
1 Lower back and neck pain
2 Iron-deﬁciency anaemia
3 Sense organ diseases
4 Depressive disorders
5 Skin diseases
6 Migraine
7 Other musculoskeletal disorders
8 Anxiety disorders
9 Diabetes
10 Asthma
11 Oral disorders
12 Falls
13 Schizophrenia
14 COPD
15 Autistic spectrum
16 Haemoglobinopathies
17 Gynaecological diseases
18 Intestinal nematode
19 Osteoarthritis
20 Other mental and substance
21 Bipolar disorder
22 Epilepsy
23 Medication overuse headache 
24 Other unintentional
25 Drug use disorders
26 Diarrhoeal diseases
27 Conduct disorder
28 Chronic kidney disease
29 Congenital anomalies
30 Alcohol use disorders
33 Cerebrovascular disease
34 Ischaemic heart disease
36 Other cardiovascular
40 Alzheimer’s disease
Leading causes 2015
1 Lower back and neck pain
2 Sense organ diseases
3 Depressive disorders
4 Iron-deﬁciency anaemia
5 Skin diseases
6 Diabetes
7 Migraine
8 Other musculoskeletal disorders
9 Anxiety disorders
10 Oral disorders
11 Asthma
12 Schizophrenia
13 Osteoarthritis
14 COPD
15 Falls
16 Autistic spectrum
17 Gynaecological diseases
18 Drug use disorders
19 Other mental and substance
20 Medication overuse headache
21 Bipolar disorder
22 Congenital anomalies
23 Haemoglobinopathies
24 Chronic kidney disease
25 Ischaemic heart disease
26 Alzheimer’s disease
27 Cerebrovascular disease
28 Alcohol use disorders
29 Epilepsy
30 Other cardiovascular
33 Conduct disorder
34 Other unintentional
35 Diarrhoeal diseases
46 Intestinal nematode
Communicable, maternal, 
neonatal, and nutritional
Non-communicable
Injuries
Figure 2: Leading 30 Level 3 causes of global YLDs for both sexes combined, 1990, 2005, and 2015, with percentage change in number of YLDs, and all-age and age-standardised rates
Causes are connected by lines between time periods. For the time period of 1990 to 2005 and for 2005 to 2015, three measures of change are shown: percent change in the number of YLDs, percent 
change in the all-age YLD rate, and percent change in the age-standardised YLD rate. YLD=years lived with disability. COPD=chronic obstructive pulmonary disease.
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highest prevalence of opioid dependence in decreasing 
order in 2015 were Iran, United Arab Emirates, Russia, 
Morocco, the USA, Australia, Ukraine, Tunisia, Belarus, 
Canada, and Iraq. Among these countries, we estimated 
the highest excess mortality from opioid dependence in 
the eastern European countries at about twice the level 
of that in the USA, Canada, and the north African and 
Middle Eastern countries; the lowest rate among these 
highly prevalent countries was in Australia. Within the 
USA, prescription opioids have been estimated to 
account for 37% of drug overdose deaths in 2013.42,43 
The availability of overdose response treatments in 
the form of naloxone kits to laypersons has also 
accelerated.44 An alternative approach is opioid 
substitution treatment to reduce the risk of overdose. 
The intensity at which countries use harm-reduction 
strategies such as needle exchange and opioid 
substitution programmes follows an inverse pattern,45 
with the most intense programmes in Australia, but 
very rare use of such strategies in eastern Europe, 
suggesting that embracing harm reduction is an 
eﬀ ective means of reducing drug deaths.  
Diabetes
To obtain standard estimates for health loss due to diabetes 
for GBD 2015 using both fasting plasma glucose (FPG) 
means and standard deviations as well as diabetes 
prevalence, we re-extracted all available data from 1990 to 
2015. Across studies, we found 20 diﬀ erent case deﬁ nitions 
for diabetes. We also included, wherever possible, studies 
reporting on mean FPG but not diabetes prevalence, using 
a regression between mean FPG and diabetes prevalence 
from studies reporting on both. We have also made the 
assessment of diabetes prevalence more consistent with 
cause of death data for diabetes. Our improved eﬀ orts at 
measuring the prevalence of diabetes conﬁ rms the 
increase in global age-standardised incidence, prevalence, 
and YLDs. Of note, the increase in YLDs at the global scale 
is greater than the increase in YLLs, which reﬂ ects 
improved access to treatments that lower case fatality. The 
rise of diabetes prevalence, related to the global increase in 
body-mass index,46 given the costs of treating the disease47 
and the related increases in cardiovascular risks, poses one 
of the more important challenges to health systems in the 
coming years. This is particularly the case in regions with 
high prevalence of diabetes such as central America, 
north Africa and the Middle East, and Oceania.  
Ezzati and colleagues48 and the International Diabetes 
Federation (IDF)49 have estimated diabetes prevalence for 
many countries; the intra-class correlation coeﬃ  cient for 
the estimates from Ezzati and colleagues and the GBD 
for 2015 is 0·74, and for the IDF estimates is 0·65. These 
large diﬀ erences appear to stem from the inclusion of 
cause of death data in the modelling for GBD and also 
from the inclusion of self-reported diabetes prevalence in 
the study by Ezzati and colleagues.48 In GBD, these 
sources were excluded from our analyses because of 
changing patterns in the prevalence of known and 
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Figure 3: Leading ten Level 3 causes of global age-speciﬁ c years lived with disability in 2015
Each cause is coloured by the percentage change in age-speciﬁ c years lived with disability from 2005 to 2015. Alzheimer’s=Alzheimer disease and other dementias. 
ASD=autism. Back & neck=low back and neck pain. Conduct=conduct disorders. Congenital=congenital anomalies. COPD=chronic obstructive pulmonary disease. 
Drugs=drug use disorders. Endocrine=endocrine, metabolic, blood, and immune disorders. Gyne=gynaecological disorders. Haemog=haemoglobinopathies and haemolytic 
anaemias. IHD=ischaemic heart disease. Iron=iron-deﬁ ciency anaemia. NN enceph=neonatal encephalopathy due to birth asphyxia and trauma. NN preterm=neonatal 
preterm birth complications. NN sepsis=neonatal sepsis and other neonatal infections. Other NTD=other neglected tropical diseases. Oral=oral disorders. 
Osteoarth=osteoarthritis. Other inf=other infectious diseases. Other mental=other mental and substance use disorders. Other MSK=other musculoskeletal disorders. 
Other nutr=other nutritional deﬁ ciencies. PEM=protein-energy malnutrition. Schiz=schizophrenia. Sense=sense organ disease. Skin=skin and subcutaneous diseases.
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Figure 4: Global annualised rate of change in age-standardised years of life lost (YLLs) and years lived with disability (YLDs) for Level 3 causes between 
1990 and 2015
TB=tuberculosis. HIV=HIV/AIDS. Diarrhoea=diarrhoeal diseases. Intest Inf=intestinal infectious diseases. LRI=lower respiratory infections. URI=upper respiratory 
infections. Otitis=otitis media. Whooping=whooping cough. Varicella=varicella and herpes zoster. Chagas=chagas disease. Cysticer=cysticercosis. LF=lymphatic 
ﬁ lariasis. Oncho=onchocerciasis. Trachoma=trachoma. Dengue=dengue. Yellow Fev=yellow fever.Nematode=intestinal nematode infections. Mat hem=maternal 
haemorrhage. Mat sepsis=maternal sepsis and other maternal infections. Mat HTN=maternal hypertensive disorders. Obst labour=maternal obstructed labour and 
uterine rupture. Comp abort=maternal abortion, miscarriage, and ectopic pregnancy. Oth mat=other maternal disorders. NN preterm=neonatal preterm birth 
complications. NN enceph=neonatal encephalopathy due to birth asphyxia and trauma. NN sepsis=neonatal sepsis and other neonatal infections. 
NN haemol=haemolytic disease and other neonatal jaundice. Oth NN=other neonatal disorders. PEM=protein-energy malnutrition. Iodine=iodine deﬁ ciency. 
Oth nutr=other nutritional deﬁ ciencies. STD=sexually transmitted diseases excluding HIV. Hep=hepatitis. Stomach C=stomach cancer. Melanoma=malignant skin 
melanoma. Skin C=non-melanoma skin cancer. Cervix C=cervical cancer. Uterus C=uterine cancer. Prostate C=prostate cancer. Testis C=testicular cancer. Kidney 
C=kidney cancer. Thyroid C=thyroid cancer. Hodgkin=Hodgkin lymphoma. Lymphoma=non-Hodgkin lymphoma. Myeloma=multiple myeloma. Oth neopla=Other 
neoplasms. RHD=rheumatic heart disease. Stroke=cerebrovascular disease. HTN HD=hypertensive heart disease. PVD=peripheral vascular disease. COPD=chronic 
obstructive pulmonary disease. Asthma=asthma. ILD=interstitial lung disease and pulmonary sarcoidosis. Oth resp=other chronic respiratory diseases. PUD=peptic 
ulcer disease. Gastritis=gastritis and duodenitis. Hernia=inguinal, femoral, and abdominal hernia. Oth digest=other digestive diseases. Parkinson=Parkinson’s disease. 
Schiz=schizophrenia. Drugs=drug use disorders. AGN=acute glomerulonephritis. Congenital=congenital anomalies. Skin=skin and subcutaneous diseases. 
Road inj=road injuries. Oth trans=other transport injuries. Drown=drowning. Fire=ﬁ re, heat, and hot substances. Poison=poisonings. Mech=exposure to mechanical 
forces. Med treat=adverse eﬀ ects of medical treatment. Animal=animal contact. F body=foreign body. Heat & cold=environmental heat and cold exposure. 
Oth unint=other unintentional injuries. Violence=interpersonal violence. War=collective violence and legal intervention.
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unknown diabetes in surveys that vary with geography, 
making it diﬃ  cult to crosswalk these studies.
Dementia
Brayne and colleagues50,51 reported that age-speciﬁ c 
prevalence of Alzheimer’s was decreasing in the UK. Of 
the four studies in the USA with similar measurements 
over time that were reviewed, one showed a decrease, 
whereas no change in prevalence was seen 
in the remaining studies.52,53 Our assessment of 
age-standardised prevalence showed that Alzheimer’s 
and other dementias decreased slowly in the UK, by 
3·69% (2·53–4·85%) from 2005 to 2015, but remained 
constant in the rest of the world. The decrease might be 
due to reductions in vascular dementias rather than 
reductions in Alzheimer’s and other dementias. Our 
assessment also suggests that the number of individuals 
with Alzheimer’s disease increased from 21·7 million 
(18·9–24·8 million) worldwide in 1990 to 46·0 million 
(40·2–52·7 million) in 2015. Although it is useful to 
know that age-standardised rates might be starting to 
decrease, if only slightly, the rapid increase in the 
absolute number of cases points to the major challenge 
that dementia presents to societies with increasing life 
expectancy. This number is similar to the most recent 
estimates from the World Alzheimer Report 2015 that 
estimated 46·8 million people living with dementia in 
2015. However, there is less agreement about new cases 
per year: The World Alzheimer Report estimated 
9·9 million new cases of dementia per year in 2015 
compared with 6·44 million (5·52–7·45 million) new 
cases in 2015 estimated in GBD 2015. The World 
Alzheimer Report separately analysed prevalence and 
incidence whereas we use DisMod-MR 2.1 to produce 
internally consistent prevalence and incidence estimates. 
We observed a fundamental disagreement in the 
underlying incidence and prevalence data in many 
countries and decided to exclude incidence data from 
our modelling approach, putting greater trust in 
prevalence studies than incidence studies, arguing that 
the point of incidence in dementia is more diﬃ  cult to 
establish than prevalence when the diagnosis over time 
becomes more established.
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Figure 5: Population pyramids with the number of individuals, by age and 
sex, grouped by severity of their disability weight (DW) for all comorbid 
conditions combined into no disability, very mild disability (DW 0–0·01), 
mild disability (DW 0·01–0·05), moderate disability (DW 0·05–0·1), severe 
disability (DW 0·1–0·3), and very severe disability (DW >0·3) for geographies 
of high (A) and low (B) quintiles of Socio-demographic Index in 2015
Disability weights are combined multiplicatively as 1−(1−DW1)(1− DW2)...
(1−DWn) for n comorbid sequelae. Socio-demographic Index (SDI) is calculated 
for each geography as a function of lag-dependent income per capita, average 
educational attainment in the population aged over 15 years, and the total 
fertility rate. SDI units are interpretable; a zero represents the lowest level of 
income per capita, educational attainment, and highest total fertility rate (TFR) 
observed from 1980 to 2015 and a one represents the highest income per 
capita, educational attainment, and lowest TFR observed in the same period. 
Cutoﬀ s on the SDI scale for the quintiles have been selected based on 
examination of the entire distribution of geographies between 1980 and 2015.
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Hepatitis C
The availability of new medical treatments for chronic 
hepatitis C has driven considerable interest in the 
prevalence data  for this disease. Available treatments are 
highly eﬀ ective but costly.54 Some programmes have been 
launched in Egypt and other lower-SDI countries that 
oﬀ er treatment at lower cost. Good data on the number 
of courses of treatment that have been delivered are not 
widely available. Given the number of individuals with 
chronic infection and the potential to be cured, tracking 
the fraction of people treated each year should be 
undertaken. Even in high-income countries such as the 
USA, the fraction of those treated among those who 
would beneﬁ t from treatment is not yet available.
Malaria
Our assessment of malaria prevalence and incidence in 
high burden sub-Saharan Africa was based on the Malaria 
Atlas Project spatial analysis of prevalence surveys done 
across Africa between 2000 and 2015.55,56 The dynamic 
map of malaria prevalence was updated for GBD 2015 and 
extended back to 1980. Children younger than 5 years 
in sub-Saharan Africa showed a remarkable 33·5% 
(24·8–46·0%) decrease in incidence from the 2005 peak 
of 0·78 (0·56–0·96) cases per person per year to 0·52 
(0·33–0·71) in 2015. Yet there were 81·7 million 
(52·0–111·7 million) incident cases in this age group in 
2015. The decrease in children was more rapid than that 
recorded for older age groups. In adolescents and adults, 
incidence dropped by 30·0% (17·2–39·2%) and 
21·1% (15·3–26·9%), respectively, and resulted in 
58·7 million (37·7–91·5 million) and 53·3 million 
(40·7–67·5 million) incident cases, respectively, in 2015. 
The observed decreases in malaria incidence underscore 
the remarkable eﬀ ect of the scale-up of antimalarial 
interventions57 across Africa in the past decade.55 
Sustaining the levels of these interventions is crucial to 
continue to reduce malaria morbidity on the continent, 
avoid resurgence, and improve on these levels that are 
vital to global aspirations for malaria eradication.58 Overall, 
we estimate there were 286·9 million (219·7–377·3 million) 
cases of malaria worldwide in 2015, whereas the World 
Malaria Report (WMR) 2015 reports 214 million 
(149–303 million) cases in 2015.59 Of these cases, the WMR 
estimates that 88% of cases occurred in the WHO African 
region (188 million) whereas we estimate 189·4 million 
(151·7–239·4 million; 66·1%) cases for GBD 2015. Outside 
of Africa, the WMR reports 26 million cases versus our 
estimate of 97·3 million (50·2–181·8 million), but both 
sets of estimates feature identical regional rankings 
among the six WHO regions with malaria. Increasing 
convergence in estimates is expected as dynamic maps of 
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Figure 6: Expected relationship between age-standardised years lived with 
disability (YLD) rates per 100 000 people for the 21 GBD Level 2 causes and SDI 
(A) and the expected relationship between all-age years lived with disability 
(YLD) rates per 100 000 people for the 21 GBD Level 2 causes and SDI (B) by sex
These stacked curves represent the average relationship between SDI and each 
cause of YLDs  observed across all geographies over the time period 1990 to 2015. 
In each ﬁ gure, the y-axis spans from lowest SDI up to highest SDI. To the left of the 
midline are male rates, and the female rates are to the right; higher rates are 
further from the midline. SDI=Socio-demographic Index.
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malaria prevalence and incidence become available for all 
malaria-endemic countries outside of Africa.
Tuberculosis 
We added new data from tuberculosis prevalence surveys 
done in Indonesia, Ghana, and several subnational 
locations in India. Our analysis of tuberculosis relied on 
prevalence surveys, case notiﬁ cations and cause-speciﬁ c 
mortality estimates. We used the expert judgment values 
for the case-detection rates (CDRs) from WHO as an initial 
guide of how much notiﬁ cations need to be increased to 
reﬂ ect incidence of all tuberculosis, but relied on 
DisMod-MR 2.1 to ﬁ nd an estimate that is consistent with 
available prevalence and cause-speciﬁ c mortality rates. We 
found that, particularly in older age groups, our estimated 
CDR often falls below the all-age CDR of WHO. In 
GBD 2013, we used a relative risk approach to predict the 
proportion of HIV-infected individuals with tuberculosis. 
In GBD 2015, we improved our modelling strategy by 
making use of more abundantly available data on the 
proportions of HIV infected cases among all tuberculosis 
cases from the WHO case notiﬁ cations to separate out 
combined HIV and tuberculosis from all forms of 
tuberculosis. In our modelling of tuberculosis, we have not 
separately estimated the incidence and prevalence related 
to multidrug-resistant tuberculosis. Given the policy 
interest in multidrug-resistant tuberculosis, we plan to 
include estimates for multidrug-resistant tuberculosis in 
future rounds of the GBD. Our global tuberculosis (all-
forms) incidence estimate (10·2 million [9·2–11·5 million] 
cases in 2015) is slightly higher than that of WHO 
(9·6 million cases in 2014), and we estimate a slightly 
larger fraction of combined HIV and tuberculosis (13·0%) 
than WHO (12·0%). Our list of countries with high burden 
of tuberculosis is consistent with that of WHO, with a few 
exceptions. Afghanistan and Cambodia are lower in our 
estimates, and surpassed by Ukraine and Angola.
Cardiovascular diseases
Ageing and population growth have led to a growing 
number of people living with atherosclerotic vascular 
disease worldwide, despite the decrease in incident 
myocardial infarction and ischaemic stroke in high-
income regions. Rising levels of obesity and diabetes in 
many countries makes this an area of major concern for 
global health. Increased attention will need to be directed 
toward this highly treatable set of disorders. Health 
systems will need to improve the delivery of cost-eﬀ ective 
treatments such as blood pressure and cholesterol-
lowering drugs while eﬀ orts continue to focus on 
decreasing tobacco smoking, improving diet, and 
increasing physical activity. Investments in universal 
primary care and public health campaigns need to be 
balanced against the need to improve access to emergency 
care, including the strengthening of pre-hospital systems 
and expanded access to revascularisation treatments.
Cancer
The International Agency for Research on Cancer last 
produced cancer estimates by country, age, sex, and 
cancer site for 2012 for the GLOBOCAN project.60 The 
total estimated cancer incidence from GLOBOCAN for 
2012 was 14·1 million individuals. By comparison, GBD 
2015 estimated 18·6 million (18·0–19·4 million) new 
cases of cancer in 2015, which includes cases of non-
melanoma skin cancer. GLOBOCAN used nine diﬀ erent 
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methods to estimate incidence, which precludes the 
calculation of uncertainty for those estimates. The GBD 
relies on the strength of the mortality estimates and 
transformation of the mortality estimates to incidence, 
taking into account uncertainty associated with both the 
mortality estimates and with the mortality to incidence 
ratios. Until high-quality cancer incidence is available in 
all countries, the GBD approach, which maximises the 
amount of data used to determine incidence estimates, is 
highly beneﬁ cial.
Vision loss
Globally, 34·3 million (30·7–38·0 million) people are 
blind, an additional 24·3 million (21·6–27·6 million) 
have severe vision impairment, 214 million 
(193–237 million) have moderate vision impairment, and 
663 million (638–690 million) have near vision 
impairment in 2015. Combined, vision loss accounts for 
24·5 million (17·0–34·5 million) YLDs and is the third 
largest impairment after anaemia (77·9 million 
[52·4–111·4 million] YLDs) and hearing loss (46·2 million 
[31·6–63·2 million] YLDs). YLDs from vision loss are 
slightly lower than those for anxiety disorders, 
which rank ninth worldwide. Largely due to ageing, 
substantial increases occurred from 2005 to 2015 in the 
number of people with blindness (increasing by 
23·3% [21·9–24·6%]), severe visual impairment 
(24·3% [22·4–26·0%]), moderate visual impairment 
(22·0% [20·1–23·7%]), and near vision impairment 
(22·5% [20·9–24·0%]). Most causes of vision loss can be 
prevented or cured using cost-eﬀ ective interventions.61,62 
Chronic kidney disease 
Compared with our GBD 2013 estimates, we estimated 
global prevalence of chronic kidney disease to be lower 
by a third. Data for chronic kidney disease at younger 
ages are sparse. We increased the number of datapoints 
below the age of 30 years from 20 to 51, and that led to 
considerably lower prevalence estimates for these ages. 
We have used diﬀ erent strategies for estimating deaths 
versus YLDs secondary to chronic kidney disease due to 
other causes. In our cause of death analysis, deaths 
secondary to many of the causes typically categorised 
within the chronic kidney disease other category, such as 
cystic disease and other congenital renal diseases, were 
already counted under the primary disease following the 
principles of the ICD, and thus could not be recounted 
within the chronic kidney disease other category. In 
comparison, for the YLD analysis we counted chronic 
kidney disease from these causes in the chronic kidney 
disease other category. This diﬀ erence in the classiﬁ cation 
of morbidity and mortality from chronic kidney disease 
other is driven by the underlying nature of the data on 
causes of death and prevalence. In future GBD versions, 
we plan to make explicit estimates of death and YLDs for 
polycystic kidney disease, an important component of 
the other category.
Emerging infectious diseases 
Emerging and re-emerging infectious diseases pose a 
persistent yet dynamic challenge to global health63 and to 
the GBD study. GBD 2015 has included Ebola virus 
disease in response to the devastating outbreak in west 
Africa starting in 2013,64 whereas we have not captured the 
recent expansions of chikungunya65 and Zika virus across 
the Americas,66 for instance. Quantifying the eﬀ ect of 
newly emerging epidemic diseases is diﬃ  cult because the 
formal reporting of the disease events might considerably 
lag the ﬁ rst presentation of cases. As a result, contemporary 
events such as the substantial deviation from baseline 
levels in reported congenital abnormalities in Brazil in 
2015,67 now established to be associated with Zika virus,68 
will need to be incorporated into GBD 2016.
Advances in data and analysis
DisMod-MR
For GBD 2015, we improved the estimation for subnational 
units in DisMod-MR 2.1 compared to GBD 2013 and made 
substantive eﬀ orts to standardise the modelling approach 
across diseases. Three changes had an important eﬀ ect on 
our estimates. First, the cascade was implemented such 
that national estimates were used to inform subnational 
estimation (in GBD 2013, each subnational unit was 
treated as a country within a GBD region). Second, 
wherever possible, we improved the linkage in the 
estimation between cause-speciﬁ c mortality and disease 
incidence and prevalence by the systematic inclusion of 
estimated excess mortality data to provide more 
informative priors for each location in the geographical 
hierarchy. Third, in GBD 2010, and to a lesser degree in 
GBD 2013, many DisMod-MR models did not include 
ﬁ xed eﬀ ects of country covariates for incidence or 
prevalence. Spatial heterogeneity was largely estimated 
from the random eﬀ ects. For GBD 2015, we systematically 
tested the inclusion of more ﬁ xed eﬀ ects in DisMod-MR 2.1 
models including, where appropriate, variables related to 
the risk factor exposures we estimate for each disease. 
Disability weights
For GBD 2015, we have not incorporated any new 
population-based data on disability weights; we have used 
the same disability weights as for GBD 2013. The present 
set of disability weights were based on population surveys 
in nine countries and an open internet survey. So far, 
these studies have not found systematic variation in 
disability weights across populations or within populations 
as a function of education, income per capita, or other 
variables. In future, we hope that more population surveys 
on disability weights will continue to be done to enrich the 
database for disability weight estimation. Given that we 
have not been able to collect disability weights in every 
location included in the GBD, it is possible that disability 
weights might vary systematically across communities. 
Even if this were to be conﬁ rmed empirically, for global 
standardised comparisons we would still use the global 
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average disability weights; however, country analyses 
might use local disability weights. Until there is evidence 
of systematic variation across communities, this remains 
a theoretical and not a practical consideration. Given the 
close correlation between the internet survey and the 
population-based surveys, we are considering the 
implementation of an open rolling internet survey to 
collect more data for disability weights including new or 
revised health-state descriptions.
GATHER compliance
Providing all documentation for data sources, establishing 
access to the datasets used in modelling, and posting the 
code has been a labour-intensive activity; GBD 2015 is 
compliant with the new GATHER guidelines as a result.17 
Posting code, we believe, will stimulate other researchers 
to explore the methods used in GBD estimation of non-
fatal outcomes and hopefully lead to suggestions for 
improved estimation. With a steadily growing set of co-
investigators and a widening community interested in 
global health estimation, the enhanced transparency of 
GBD will improve the eﬃ  cacy of the overall eﬀ ort.
Using claims data
For the USA we used claims data for selected disorders. 
These data were particularly useful in the estimation of 
state-by-state prevalence for some disorders. Claims data, 
however, have important potential biases. Because of 
exclusion of some disadvantaged groups from health 
insurance, disease rates might be diﬀ erent for individuals 
that are covered compared with those from the general 
population.69,70 As the claims dataset included information 
from Medicaid and Medicare, the coverage schemes for 
low-income citizens and older adults (older than 65 years) 
in the USA, the bias toward underestimation might not 
be so great. Indeed, we found that for many diseases, 
such as asthma, diabetes, or rheumatoid arthritis, the 
claims data were consistent with high-quality survey 
estimates. A potential problem of overestimation exists 
because visits to rule out a diagnosis can be coded to the 
diagnosis. Others working with claims have counted 
diagnoses only if they had appeared at least twice during 
a year. Applying such a restriction would have led to 
rejection of 44–68% of skin disorders, such as acne, 
psoriasis, or scabies, where one would expect that even 
after a single visit a diagnosis can be reliably made. As we 
tend to adjust the claims data used in DisMod-MR 2.1 if a 
systematic bias is detected from population-based 
sources, such as the National Health and Nutrition 
Examination Survey or other quality surveys, we believe 
our estimates have not been inﬂ uenced much by this 
problem. The potential for greater inclusion of claims 
data in the GBD analysis is large; in countries with 
universal health access, claims data might overcome the 
problems of non-responder bias in survey data, which 
tend to lead to underestimates of the true population 
prevalence or incidence.
Self-reported functional health status
We found only modest progress in high-SDI countries 
in reducing age-standardised YLDs per capita over the 
last 25 years. There are, however, reports in the literature 
of substantial improvements based on self-rated 
health.71,72 In the USA, these improvements seem to be 
survey programme-speciﬁ c and have not been reported 
in all data systems.71 Nevertheless, more work is needed 
to understand the diﬀ erent trends between our 
assessment of YLDs per capita and self-rated health. 
Item response theory has been used in some ﬁ elds to 
identify changing response patterns for single items 
compared with the pool of all items.73 Item response 
theory cannot capture systematic changes that aﬀ ect a 
set of items, and anchoring vignettes have been 
proposed as a strategy to deal with these challenges.72,74 
In the era of increased interest in measuring functional 
health status, more exploration of the reasons for 
the divergence from a sequelae-based approach to 
measuring functional health status used in GBD versus 
an overall self-rating will be an important avenue of 
future research.
Crosswalks
Because of the diversity of data sources available, 
we estimated the statistical association between 
measurements taken using diﬀ erent case deﬁ nitions, 
diﬀ erent assays, diﬀ erent survey items, or diﬀ erent 
ascertainment methods to a reference category. We used 
these statistical associations to crosswalk each type of data 
to the reference category. Crosswalks are a crucial 
dimension in the GBD analysis; in most cases we estimate 
these crosswalks from within DisMod-MR 2.1. If 
crosswalks were believed to vary substantially by age, sex, 
or location, these crosswalks were estimated outside of 
DisMod-MR 2.1 and adjusted data were used as inputs. 
Where data are sparse, the estimated crosswalks can shift 
substantially when new studies are identiﬁ ed that inform 
the crosswalk. With each iteration of the GBD, we have 
recognised the crucial nature of the crosswalk analysis for 
data processing. We believe that more research is needed 
in future iterations of GBD to standardise the approaches 
used for estimating crosswalks across disorders and risk 
factors, and for propagating uncertainty in crosswalks into 
the ﬁ nal results.
Data gaps
We have described the availability of data by cause and 
geography over diﬀ erent time periods, highlighting very 
large gaps in information availability. The data availability 
by country ranged from 6·1% in North Korea to 91·3% in 
the USA (methods appendix p 606). Among the top ﬁ ve 
causes of YLDs, data availability was rather poor. Lower 
back pain, iron-deﬁ ciency anaemia, major depressive 
disorder, other hearing loss, and neck pain all have data 
representativeness indices below 50%. Because of the 
broad overview provided of major data sources for disease 
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incidence and prevalence, GBD provides a framework to 
assist countries in prioritising the collection of new data 
to inform better monitoring of functional health status. 
By setting clear reference case deﬁ nitions and data 
collection methods (methods appendix pp 4–7), GBD can 
also provide guidance on how to collect information most 
relevant to population health measurement.
Future directions for GBD
With each cycle of the GBD we expect, given the present 
interest in subnational assessments, to report increasingly 
granular results. These subnational ﬁ ndings will be of 
important national policy interest, but the discipline of 
examining the evidence for each community and modelling 
at the more granular level will, we believe, improve the 
quality of the national estimation as well. Additions to the 
cause list will continue to be driven by policy interest, such 
as the need to incorporate Zika virus, to split diabetes into 
separate estimates for type 1 and type 2, and by adding 
diseases to our cause list that are main contributors to large 
residual categories, such as other cardiovascular disease, 
other musculoskeletal disorders, and other neurological 
disorders. We plan to continue to expand our networks of 
topic-speciﬁ c and country collaborators to enhance the 
quality of our estimates through their feedback and by 
enhancing the amount of data we can bring to bear on 
GBD estimation. Our country collaborations to generate 
subnational estimates have shown us that these eﬀ orts 
greatly enhance access to valuable data sources, particularly 
administrative datasets on inpatient and outpatient 
episodes and unpublished surveys.
Limitations
The GBD 2015 study has some key limitations. First, 
although we have sought to capture and include in our 
estimations many sources of uncertainty, we have not 
captured all sources. We have not been able to routinely 
capture uncertainty due to diﬀ erent model speciﬁ cations 
in our results. We do not have the ability to reﬂ ect the 
uncertainty of data sources that exist but of which we are 
not aware. Subnational collaborations in China and 
Mexico revealed many data sources not captured in 
previous iterations of the GBD study. Inclusion of these 
data sources can lead to shifts in estimates that are 
outside the previously estimated 95% UIs.
Second, within DisMod-MR 2.1 we estimate the average 
association between diﬀ erent types of studies for reporting 
on a speciﬁ c outcome such as the diﬀ erence between 
12-month recall and point prevalence in a survey. These 
estimated associations from within the DisMod-MR 2.1 
likelihood estimation are used to adjust the data to a 
reference case deﬁ nition or study design. These estimated 
adjustment factors are themselves uncertain, which 
increases the overall uncertainty in our estimation. More 
standardisation in data collection would be highly desirable 
and would reduce our dependence on the relatively 
challenging estimation process involved in crosswalks.
Third, for some disorders the data available to estimate 
excess mortality by age and sex and to capture how excess 
mortality changes with development status are very 
limited. There are probably many unpublished sources 
of information in some countries that could be usefully 
brought to bear on the challenge of estimating the 
age–sex–year–location levels of excess mortality.
Fourth, the microsimulation step of this study assumes 
that prevalence within an age–sex–location–year group of 
diﬀ erent sequelae is independent. Although this is clearly 
known not to be the case for some pairs of disorders, the 
independence assumption provides reasonable overall 
adjustments for comorbidity. Progress in incorporating 
dependent comorbidity has been diﬃ  cult because 
information on the correlation structure of prevalence is 
extremely limited and only available for a minor fraction 
of all possible pairs of conditions in the GBD study.
Fifth, we estimated separate DisMod-MR 2.1 models for 
1990, 1995, 2000, 2005, 2010, and 2015. Independent 
estimation of each time period implies that the uncertainty 
intervals for each period are also independent. Furthermore, 
compositional bias in the data available in diﬀ erent time 
periods might lead to spurious time trends. A more 
appealing strategy would be to simultaneously estimate the 
trends in incidence, excess mortality, and remission by age 
and sex consistent with all the available data for a geography 
on prevalence, incidence, remission, excess mortality, and 
cause-speciﬁ c mortality by age and sex. DisMod-MR 2.1 
does not allow for time-varying trends in incidence, excess 
mortality, and remission, but a prototype DisMod-MR AT 
(age and time) has been developed and is being tested. 
Allowing for all rates to change at diﬀ erent paces over age 
and time increases the number of parameters that need to 
be estimated by orders of magnitude.
Sixth, we have emphasised in the reporting of results 
the changes from calendar year 2005 to calendar 
year 2015, although we have estimated results for 1990, 
1995, 2000, 2005, 2010, and 2015 and interpolated for the 
years in between. For some disorders, reporting the 
change from 2005 to 2015 (such as for Ebola virus 
disease) does not capture the major epidemic in west 
Africa in 2014. Likewise, disasters and wars are often 
concentrated in a single year; comparisons of any two 
years can provide misleading inferences about trends.
Seventh, for a few disorders (eg, tetanus, neonatal sepsis, 
rabies, and diphtheria) we estimate disease incidence from 
estimates of mortality and the inverse of the case-fatality 
rate estimated from available studies. When the case-
fatality rate is very low, these estimates of incidence are 
highly sensitive to very small changes in the estimated 
case-fatality rate and have large uncertainty intervals.
Finally, although extraordinary eﬀ orts have gone into 
vetting the results by GBD researchers and the 
collaborator network, there are probably some ﬁ ndings 
that have not been scrutinised carefully enough. Making 
all results and underlying data available and having an 
increasing number of visualisation tools are eﬀ ective 
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strategies that we will keep expanding to meet our goal of 
producing the highest quality global health data to our 
growing audience of policy makers, researchers, the 
media, and the general population.
Conclusion
The GBD studies seek to quantify the prevalence and 
incidence of the major sequelae for a comprehensive list 
of diseases and injuries; given the diversity of data 
sources, the range of biases in these sources, and the 
gaps in availability, this is a challenging task. Despite 
the limitations, the standardised and comprehensive 
approach of the GBD studies  study provides useful 
insights. We believe users of the ﬁ ndings, including the 
wealth of country-speciﬁ c and cause-speciﬁ c detail 
available in the appendix, can usefully examine the broad 
trends for their country or subnational geography, 
benchmark against geographies at a similar level of 
development, and understand the strength or weakness 
of these estimates. Regular quantiﬁ cation of health is 
particularly important as the new health-related targets 
of the Sustainable Development Goals have broadened 
the health agenda throughout the world. At the same 
time, development and transformations in the risks to 
health experienced by diﬀ erent groups in the world are 
leading to some broad transformations in health. 
Everyone needs to have access to the timeliest, valid, 
reliable, and local information possible to enrich debates 
on how to accelerate health progress in all communities.
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